

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 6
JUNE 2016**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2016

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Cumulative Supplement 6

June 2016

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend	x
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

**CUMULATIVE SUPPLEMENT 06
June 2016**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 36th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

BD RX INC
(BD RX)

CITRON PHARMA LLC
(CITRON PHARMA LLC)

PROSAM LABS LLC
(PROSAM LABS)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

FRESENIUS KABI USA LLC
(FRESENIUS KABI USA)

CASPER PHARMA LLC
(CASPER PHARMA LLC)

OXFORD PHARMACEUTICALS LLC
(OXFORD PHARMS)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies

to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been

available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2015</u>	<u>MAR 2016</u>	<u>JUN 2016</u>	<u>SEP 2016</u>	<u>DEC 2016</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	17151 2664 (15.5%)	17251 2693 (15.6%)	17528 2664 (15.2%)		
MULTISOURCE	14487 (84.5%)	14558 (84.4%)	14864 (84.8%)		
THERAPEUTICALLY EQUIVALENT	14366 (83.8%)	14434 (83.7%)	14731 (84%)		
NOT THERAPEUTICALLY EQUIVALENT	121 (0.7%)	124 (0.7%)	133 (0.8%)		
EXCEPTIONS ¹	73 (0.4%)	73 (0.4%)	73 (0.4%)		
NEW MOLECULAR ENTITIES APPROVED	28	9	20		
NUMBER OF APPLICANTS	1011	1007	1023		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL
ACAMPROSATE CALCIUM

AB	+	GLENMARK GENERICS	333MG	A202229	001	Jul 16, 2013	May	CRLD
----	---	-------------------	-------	---------	-----	--------------	-----	------

ACETAMINOPHEN

SOLUTION; IV (INFUSION)
ACETAMINOPHEN

AP		PADDOCK LLC	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	May	NEWA
AP		SANDOZ INC	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Mar	NEWA
		OFIRMEV						
AP	+	MALLINCKRODT IP	1GM/100ML (10MG/ML)	N022450	001	Nov 02, 2010	Mar	CFTG

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>A>	+	METRIC	325MG; 50MG; 40MG	A089007	001	Mar 17, 1986	Jun	CAHN
>D>	+	MIKART	325MG; 50MG; 40MG	A089007	001	Mar 17, 1986	Jun	CAHN

TABLET; ORAL
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

	@	INGENUS PHARMS NJ	325MG; 50MG; 40MG	A040864	001	Dec 01, 2008	Jan	CAHN
	@	SUN PHARM INDS	325MG; 50MG; 40MG	A040601	001	Jul 29, 2005	Jan	CAHN
		FIORICET						
AA		ACTAVIS LABS UT INC	325MG; 50MG; 40MG	A088616	001	Nov 09, 1984	May	CMFD

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
FIORICET W/ CODEINE

AB	+	ALLERGAN SALES LLC	325MG; 50MG; 40MG; 30MG	N020232	001	Jul 30, 1992	Apr	CAHN
----	---	--------------------	-------------------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
@ SUN PHARM INDS 300MG; 60MG

A089673	001	Feb 10, 1988	Mar	CAHN
---------	-----	--------------	-----	------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL
ZYFREL

AA		CYPRESS PHARM INC	325MG/15ML; 7.5MG/15ML	A090468	001	Apr 14, 2016	Apr	NEWA
----	--	-------------------	------------------------	---------	-----	--------------	-----	------

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		ACTAVIS LABS FL INC	300MG; 5MG	A206470	001	Jun 02, 2016	May	NEWA
AA			300MG; 7.5MG	A206470	002	Jun 02, 2016	May	NEWA
AA			300MG; 10MG	A206470	003	Jun 02, 2016	May	NEWA
>D>	@		500MG; 10MG	A040148	002	Feb 14, 1997	Jun	CAHN
>A>	@	ALLERGAN SALES LLC	500MG; 10MG	A040148	002	Feb 14, 1997	Jun	CAHN
AA		AMNEAL PHARMS NY	325MG; 7.5MG	A040746	002	May 10, 2016	Apr	NEWA
>A>	AA	LARKEN LABS INC	325MG; 5MG	A202935	002	Jun 15, 2016	Jun	NEWA
>A>	AA		325MG; 7.5MG	A202935	003	Jun 15, 2016	Jun	NEWA
>A>	AA		325MG; 10MG	A202935	004	Jun 15, 2016	Jun	NEWA
>A>	AA	PAR PHARM	300MG; 5MG	A205001	001	Jul 05, 2016	Jun	NEWA
>A>	AA		300MG; 7.5MG	A205001	002	Jul 05, 2016	Jun	NEWA
>A>	AA		300MG; 10MG	A205001	003	Jul 05, 2016	Jun	NEWA
AA		RHODES PHARMS	325MG; 5MG	A202991	001	Apr 12, 2016	Mar	NEWA
AA			325MG; 7.5MG	A202991	002	Apr 12, 2016	Mar	NEWA
AA			325MG; 10MG	A202991	003	Apr 12, 2016	Mar	NEWA
>A>	AA	TRIS PHARMA INC	300MG; 5MG	A202214	004	Mar 15, 2016	Jun	NEWA
>A>	AA		300MG; 7.5MG	A202214	005	Mar 15, 2016	Jun	NEWA
>A>	AA		300MG; 10MG	A202214	006	Mar 15, 2016	Jun	NEWA

NORCO

>D>	AA	ACTAVIS LABS FL INC	325MG; 2.5MG	A040148	004	Jul 07, 2014	Jun	CAHN
>D>	AA		325MG; 5MG	A040148	005	Jul 07, 2014	Jun	CAHN
>D>	AA	+	325MG; 7.5MG	A040148	003	Sep 12, 2000	Jun	CAHN
>D>	AA	+	325MG; 10MG	A040148	001	Feb 14, 1997	Jun	CAHN
>A>	AA	ALLERGAN SALES LLC	325MG; 2.5MG	A040148	004	Jul 07, 2014	Jun	CAHN
>A>	AA	+	325MG; 5MG	A040099	001	Jun 25, 1997	Jun	CAHN
>A>	AA		325MG; 5MG	A040148	005	Jul 07, 2014	Jun	CAHN
>A>	AA	+	325MG; 7.5MG	A040148	003	Sep 12, 2000	Jun	CAHN
>A>	AA	+	325MG; 10MG	A040148	001	Feb 14, 1997	Jun	CAHN
>D>	AA	+	325MG; 5MG	A040099	001	Jun 25, 1997	Jun	CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL					
OXYCODONE AND ACETAMINOPHEN					
AA	MALLINCKRODT INC	325MG/5ML; 5MG/5ML	A040680	001	Sep 29, 2006 May CMFD
TABLET; ORAL					
OXYCODONE AND ACETAMINOPHEN					
AA	ALVOGEN MALTA	325MG; 5MG	A202677	003	Mar 08, 2016 Feb NEWA
AA		325MG; 7.5MG	A202677	001	Jul 26, 2012 Jan CAHN
AA		325MG; 10MG	A202677	002	Jul 26, 2012 Jan CAHN
AA	AMNEAL PHARMS NY	325MG; 7.5MG	A040778	002	Jun 27, 2014 Apr NEWA
AA	MAYNE PHARMA INC	325MG; 2.5MG	A090177	001	Oct 20, 2008 Feb CAHN
AA		325MG; 5MG	A090177	002	Oct 20, 2008 Feb CAHN
AA		325MG; 7.5MG	A090177	003	Oct 20, 2008 Feb CAHN
AA		325MG; 10MG	A090177	004	Oct 20, 2008 Feb CAHN
	@	500MG; 7.5MG	A090177	005	Oct 20, 2008 Feb CAHN
	@	650MG; 10MG	A090177	006	Oct 20, 2008 Feb CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL					
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN					
AB	ATLAS PHARMS LLC	325MG; 37.5MG	A202076	001	Mar 30, 2012 May CAHN

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL					
ACETAZOLAMIDE					
AB	NOSTRUM LABS INC	500MG	A204691	001	Mar 29, 2016 Mar NEWA

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS					
ACETYLCYSTEINE					
AP	AUROBINDO PHARMA LTD	6GM/30ML (200MG/ML)	A207358	001	Feb 29, 2016 Feb NEWA
TABLET, EFFERVESCENT; ORAL					
CETYLEV					
	ARBOR PHARMS LLC	500MG	N207916	001	Jan 29, 2016 Jan NEWA
+		2.5GM	N207916	002	Jan 29, 2016 Jan NEWA

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL					
SEMPREX-D					
+	AUXILIUM PHARMS INC	8MG; 60MG	N019806	001	Mar 25, 1994 Mar CAHN

ACYCLOVIR

CAPSULE; ORAL					
ACYCLOVIR					
	@ RANBAXY	200MG	A074975	001	Sep 30, 1998 Feb DISC
AB	ZYDUS PHARMS USA INC	200MG	A204313	001	Mar 25, 2016 Mar NEWA
OINTMENT; TOPICAL					
ACYCLOVIR					
AB	FOUGERA PHARMS INC	5%	A206633	001	May 11, 2016 Apr NEWA
TABLET; BUCCAL					
SITAVIG					
+	CIPHER PHARMS US	50MG	N203791	001	Apr 12, 2013 Jan CAHN
TABLET; ORAL					
ACYCLOVIR					
	@ SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998 Feb DISC
	@	800MG	A074980	002	Sep 30, 1998 Feb DISC

ACYCLOVIR SODIUM

INJECTABLE; INJECTION					
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE					
	@ HIKMA MAPLE	EQ 500MG BASE/VIAL	A074885	001	Dec 19, 1997 Feb DISC
	@	EQ 1GM BASE/VIAL	A074885	002	Dec 19, 1997 Feb DISC
ACYCLOVIR SODIUM					
>A>	@ AMPHASTAR PHARMS INC	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997 Jun CAHN
>A>	@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997 Jun CAHN
	@ BEDFORD	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997 Feb DISC
	@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997 Feb DISC
AP	+	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997 Feb CTEC
>D>	@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997 Jun CAHN
	@	EQ 500MG BASE/VIAL	A074596	002	Apr 22, 1997 Apr CAHN
>D>	@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997 Jun CAHN

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

	@	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Apr CAHN
AP	HIKMA PHARMS LLC	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016	Feb NEWA
	+	EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb CRLD
AP		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb NEWA

ADAPALENE

GEL; TOPICAL
ADAPALENE

>A>	AB	TARO	0.3%	A208322	001	Jun 23, 2016	Jun NEWA
-----	----	------	------	---------	-----	--------------	----------

ADENOSINE

INJECTABLE; INJECTION
ADENOSINE

AP	EUROHLTH INTL SARL	3MG/ML	A076404	001	Jun 16, 2004	Apr CAHN
	SOLUTION; IV (INFUSION)					
	ADENOSCAN					
	@ ASTELLAS	60MG/20ML (3MG/ML)	N020059	001	May 18, 1995	Apr DISC
	@	90MG/30ML (3MG/ML)	N020059	002	May 18, 1995	Apr DISC
	ADENOSINE					
AP	+ TEVA PHARMS USA	60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013	Apr CRLD
AP	+	90MG/30ML (3MG/ML)	A077425	002	Aug 29, 2013	Apr CRLD

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE

	@ HI TECH PHARMA	EQ 0.083% BASE	A075063	001	Feb 09, 1999	Mar DISC
	@ LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006	Mar DISC
	@ MYLAN SPECLT	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Mar DISC
AN	+ NEPHRON	EQ 0.083% BASE	A074880	001	Sep 17, 1997	Mar CRLD
	@ TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999	Mar DISC
	@ WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003	Mar DISC
	TABLET; ORAL					
	ALBUTEROL SULFATE					
AB	SUN PHARM INDS	EQ 2MG BASE	A072637	002	Dec 05, 1989	Mar CAHN
AB		EQ 4MG BASE	A072637	001	Dec 05, 1989	Mar CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

>D>	DUONEB							
>D>	AN	+	MYLAN SPECLT	EQ 0.083% BASE;0.017%	N020950	001	Mar 21, 2001	Jun DISC
>A>		@		EQ 0.083% BASE;0.017%	N020950	001	Mar 21, 2001	Jun DISC

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

>D>	AB	CADISTA PHARMS	EQ 5MG BASE	A090557	001	Feb 18, 2010	Jun CAHN
>D>	AB		EQ 10MG BASE	A090557	002	Feb 18, 2010	Jun CAHN
>D>	AB		EQ 35MG BASE	A090557	003	Feb 18, 2010	Jun CAHN
>D>	AB		EQ 70MG BASE	A090557	004	Feb 18, 2010	Jun CAHN
>A>	AB	JUBILANT CADISTA	EQ 5MG BASE	A090557	001	Feb 18, 2010	Jun CAHN
>A>	AB		EQ 10MG BASE	A090557	002	Feb 18, 2010	Jun CAHN
>A>	AB		EQ 35MG BASE	A090557	003	Feb 18, 2010	Jun CAHN
>A>	AB		EQ 70MG BASE	A090557	004	Feb 18, 2010	Jun CAHN

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALFUZOSIN HYDROCHLORIDE

AB	UNICHEM LABS LTD	10MG	A203192	001	Jan 28, 2016	Jan NEWA
----	------------------	------	---------	-----	--------------	----------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	SUN PHARM INDS	300MG	A071450	001	Jan 09, 1987	Mar CAHN
	ZYLOPRIM					
AB	SEBELA IRELAND LTD	100MG	N016084	001		Jan CAHN
AB	+	300MG	N016084	002		Jan CAHN

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

AB	AJANTA PHARMA LTD	EQ 6.25MG BASE	A205523	001	Mar 03, 2016	Feb NEWA
AB		EQ 12.5MG BASE	A205523	002	Mar 03, 2016	Feb NEWA

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

LOTRONEX

AB	SEBELA IRELAND LTD	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Feb CAHN
AB	+	EQ 1MG BASE	N021107	001	Feb 09, 2000	Feb CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@	ACTAVIS LABS FL INC	0.5MG
@		1MG
@		2MG
@		3MG
@	COREPHARMA	0.5MG
@		1MG
@		2MG
@		3MG
@	IMPAX LABS	0.5MG
@		1MG
@		2MG
@		3MG

A077198	001	May 13, 2010	Jan DISC
A077198	002	May 13, 2010	Jan DISC
A077198	003	May 13, 2010	Jan DISC
A077198	004	May 13, 2010	Jan DISC
A077996	001	Jan 31, 2007	Mar DISC
A077996	002	Jan 31, 2007	Mar DISC
A077996	003	Jan 31, 2007	Mar DISC
A077996	004	Jan 31, 2007	Mar DISC
A077968	004	May 24, 2007	Jan DISC
A077968	003	May 24, 2007	Jan DISC
A077968	002	May 24, 2007	Jan DISC
A077968	001	May 24, 2007	Jan DISC

ALPROSTADIL

INJECTABLE; INJECTION

EDEX

	@ AUXILIUM PHARMS INC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Mar CAHN
AP		0.01MG/VIAL	N020649	002	Jun 12, 1997	Mar CAHN
	+	0.01MG/VIAL	N020649	005	Jul 30, 1998	Mar CAHN
AP		0.02MG/VIAL	N020649	003	Jun 12, 1997	Mar CAHN
	+	0.02MG/VIAL	N020649	006	Jul 30, 1998	Mar CAHN
AP		0.04MG/VIAL	N020649	004	Jun 12, 1997	Mar CAHN
	+	0.04MG/VIAL	N020649	007	Jul 30, 1998	Mar CAHN

SUPPOSITORY; URETHRAL

MUSE

	+ MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	Jan CRLD
	+	0.25MG	N020700	002	Nov 19, 1996	Jan CRLD
	+	0.5MG	N020700	003	Nov 19, 1996	Jan CRLD

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB	BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jan CAHN
AB	ZYDUS PHARMS USA INC	100MG	A208278	001	May 31, 2016	May NEWA

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

AP	+	EMCURE PHARMS LTD	EQ 250MG BASE/ML	A204040	001	Dec 12, 2013	May CRLD
AP		EUROHLTH INTL SARL	EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	May CRLD
AP		SAGENT PHARMS	EQ 250MG BASE/ML	A203323	001	May 12, 2016	Apr NEWA

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	002	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	005	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	001	Mar 26, 1997	Mar CMS1
---	-----------------	---	---------	-----	--------------	----------

INJECTABLE; INJECTION

CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	009	Mar 26, 1997	Mar CMS1
---	-----------------	---	---------	-----	--------------	----------

CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	011	Mar 26, 1997	Mar CMS1
---	-----------------	---	---------	-----	--------------	----------

CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997	Mar CMS1
---	-----------------	---	---------	-----	--------------	----------

CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	008	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	016	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	017	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	018	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	019	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	021	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

AMINOLEVULINIC ACID HYDROCHLORIDE

GEL; TOPICAL

AMELUZ

+	BIOFRONTERA	10%	N208081	001	May 10, 2016	May NEWA
---	-------------	-----	---------	-----	--------------	----------

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

@	IDT AUSTRALIA LTD	100MG	A085261	003		May CAHN
@		100MG	A085262	002		May CAHN
@		200MG	A085261	002		May CAHN

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	200MG	A204742	001	Jun 03, 2016	May NEWA
----	----------------------	-------	---------	-----	--------------	----------

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

@	SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008	Mar DISC
@		10MG	A089399	002	Jul 14, 1987	Mar DISC
AB		10MG	A089399	002	Jul 14, 1987	Mar CAHN
@		25MG	A040816	001	Jun 27, 2008	Mar DISC
@		25MG	A089399	001	Jul 14, 1987	Mar DISC
AB		25MG	A089399	001	Jul 14, 1987	Mar CAHN
@		50MG	A040816	003	Jun 27, 2008	Mar DISC
@		50MG	A089399	003	Jul 14, 1987	Mar DISC
AB		50MG	A089399	003	Jul 14, 1987	Mar CAHN
@		75MG	A040816	004	Jun 27, 2008	Mar DISC
@		75MG	A089399	004	Jul 14, 1987	Mar DISC
AB		75MG	A089399	004	Jul 14, 1987	Mar CAHN
@		100MG	A040816	005	Jun 27, 2008	Mar DISC
@		100MG	A089399	005	Jul 14, 1987	Mar DISC
AB		100MG	A089399	005	Jul 14, 1987	Mar CAHN
@		150MG	A040816	006	Jun 27, 2008	Mar DISC
@		150MG	A089399	006	Jul 14, 1987	Mar DISC

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB		150MG		A089399	006	Jul 14, 1987	Mar CAHN
----	--	-------	--	---------	-----	--------------	----------

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

@	SUN PHARM INDS	EQ 12.5MG BASE;5MG		A070765	001	Dec 10, 1986	Mar CAHN
---	----------------	--------------------	--	---------	-----	--------------	----------

@		EQ 25MG BASE;10MG		A070766	001	Dec 10, 1986	Mar CAHN
---	--	-------------------	--	---------	-----	--------------	----------

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@	SUN PHARM INDS	10MG;2MG		A071077	001	Nov 12, 1986	Mar CAHN
---	----------------	----------	--	---------	-----	--------------	----------

@		10MG;4MG		A071078	001	Nov 12, 1986	Mar CAHN
---	--	----------	--	---------	-----	--------------	----------

@		25MG;2MG		A070297	001	Nov 12, 1986	Mar CAHN
---	--	----------	--	---------	-----	--------------	----------

@		25MG;4MG		A071079	001	Nov 12, 1986	Mar CAHN
---	--	----------	--	---------	-----	--------------	----------

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB	CHINA RESOURCES	EQ 2.5MG BASE		A090752	003	May 16, 2016	May NEWA
----	-----------------	---------------	--	---------	-----	--------------	----------

AB	INVAGEN PHARMS	EQ 2.5MG BASE		A206367	001	Dec 10, 2015	Feb CAHN
----	----------------	---------------	--	---------	-----	--------------	----------

AB		EQ 5MG BASE		A206367	002	Dec 10, 2015	Feb CAHN
----	--	-------------	--	---------	-----	--------------	----------

AB		EQ 10MG BASE		A206367	003	Dec 10, 2015	Feb CAHN
----	--	--------------	--	---------	-----	--------------	----------

>A>	AB	POLYGEN PHARMS	EQ 2.5MG BASE	A207821	001	Jul 11, 2016	Jun NEWA
-----	----	----------------	---------------	---------	-----	--------------	----------

>A>	AB		EQ 5MG BASE	A207821	002	Jul 11, 2016	Jun NEWA
-----	----	--	-------------	---------	-----	--------------	----------

>A>	AB		EQ 10MG BASE	A207821	003	Jul 11, 2016	Jun NEWA
-----	----	--	--------------	---------	-----	--------------	----------

@	SUN PHARM INDS	EQ 2.5MG BASE		A078081	001	Jan 31, 2008	Mar CAHN
---	----------------	---------------	--	---------	-----	--------------	----------

@		EQ 5MG BASE		A078081	002	Jan 31, 2008	Mar CAHN
---	--	-------------	--	---------	-----	--------------	----------

@		EQ 10MG BASE		A078081	003	Jan 31, 2008	Mar CAHN
---	--	--------------	--	---------	-----	--------------	----------

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;160MG		A206512	001	Apr 22, 2016	Apr NEWA
----	----------------------	-------------------	--	---------	-----	--------------	----------

AB		EQ 5MG BASE;320MG		A206512	002	Apr 22, 2016	Apr NEWA
----	--	-------------------	--	---------	-----	--------------	----------

AB		EQ 10MG BASE;160MG		A206512	003	Apr 22, 2016	Apr NEWA
----	--	--------------------	--	---------	-----	--------------	----------

AB		EQ 10MG BASE;320MG		A206512	004	Apr 22, 2016	Apr NEWA
----	--	--------------------	--	---------	-----	--------------	----------

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	MA GENERAL HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)		A207025	001	Feb 03, 2016	Jan NEWA
----	-----------------	------------------------------------	--	---------	-----	--------------	----------

AP	MIDWEST MEDCL	30mCi-300mCi/8ML (3.75-37.5mCi/ML)		A204457	001	Nov 18, 2015	Jan NEWA
----	---------------	------------------------------------	--	---------	-----	--------------	----------

AMMONIUM LACTATE

CREAM;TOPICAL

AMMONIUM LACTATE

AB	+	PERRIGO NEW YORK	EQ 12% BASE	A075774	001	May 01, 2002	Apr CRLD
----	---	------------------	-------------	---------	-----	--------------	----------

LAC-HYDRIN

@	RANBAXY	EQ 12% BASE		N020508	001	Aug 29, 1996	Apr DISC
---	---------	-------------	--	---------	-----	--------------	----------

LOTION;TOPICAL

AMMONIUM LACTATE

AB	+	PERRIGO NEW YORK	EQ 12% BASE	A075570	001	Jun 23, 2004	Apr CRLD
----	---	------------------	-------------	---------	-----	--------------	----------

LAC-HYDRIN

@	RANBAXY	EQ 12% BASE		N019155	001	Apr 24, 1985	Apr DISC
---	---------	-------------	--	---------	-----	--------------	----------

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

@	SUN PHARM INDS LTD	250MG		A065016	001	Apr 08, 1999	Feb DISC
---	--------------------	-------	--	---------	-----	--------------	----------

@		500MG		A065016	002	Apr 08, 1999	Feb DISC
---	--	-------	--	---------	-----	--------------	----------

TABLET;ORAL

AMOXICILLIN

@	SUN PHARM INDS LTD	500MG		A065059	001	Nov 24, 2000	Feb DISC
---	--------------------	-------	--	---------	-----	--------------	----------

@		875MG		A065059	002	Nov 24, 2000	Feb DISC
---	--	-------	--	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL

AMOXICILLIN

@	SUN PHARM INDS LTD	125MG		A065021	001	Dec 23, 1999	Feb DISC
---	--------------------	-------	--	---------	-----	--------------	----------

@		250MG		A065021	002	Dec 23, 1999	Feb DISC
---	--	-------	--	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL
MOXATAG

+ VERNALIS R AND D LTD 775MG N050813 001 Jan 23, 2008 Jan CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A201090	001	Dec 20, 2011	Feb CDFR
AB		400MG/5ML;EQ 57MG BASE/5ML	A201090	002	Dec 20, 2011	Feb CDFR
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A201091	001	Dec 20, 2011	Feb CDFR
	@ SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Feb DISC
	@	400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Feb DISC
	@	600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Feb DISC

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SUN PHARM INDS LTD 875MG;EQ 125MG BASE A065102 001 Sep 17, 2002 Feb DISC

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Feb DISC
@		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Feb DISC

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL
ADZENYS XR-ODT

	NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jan NEWA
		EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jan NEWA
		EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jan NEWA
		EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jan NEWA
		EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jan NEWA
+		EQ 18.8MG BASE	N204326	006	Jan 27, 2016	May CRLD
		EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016	Feb NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016	Feb NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016	Feb NEWA
AB		5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016	Feb NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016	Feb NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016	Feb NEWA
AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Feb CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Feb CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Feb CTNA
AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Feb CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Feb CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Feb CTNA

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016	Jan NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016	Jan NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016	Jan NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016	Jan NEWA
AB		5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016	Jan NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX;INJECTION

AMPHOTEC

@	ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996	Apr DISC
@		100MG/VIAL	N050729	002	Nov 22, 1996	Apr DISC

ARIPIRAZOLE

>D> INJECTABLE;INTRAMUSCULAR

>D> ABILIFY

>D>	+	OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006	Jun DISC
-----	---	--------	-------------------------	---------	-----	--------------	----------

>A>	@		9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006	Jun DISC
-----	---	--	-------------------------	---------	-----	--------------	----------

SOLUTION;ORAL

ARIPIRAZOLE

AA	+	AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Feb CRLD
----	---	---------------	--------	---------	-----	--------------	----------

TABLET;ORAL

ARIPIPIRAZOLE

>A>	AB	AMNEAL PHARMS	2MG	A204838	001	Jun 17, 2016	Jun NEWA
>A>	AB		5MG	A204838	002	Jun 17, 2016	Jun NEWA
>A>	AB		10MG	A204838	003	Jun 17, 2016	Jun NEWA
>A>	AB		15MG	A204838	004	Jun 17, 2016	Jun NEWA
>A>	AB		20MG	A204838	005	Jun 17, 2016	Jun NEWA
>A>	AB		30MG	A204838	006	Jun 17, 2016	Jun NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

ABILIFY

@ OTSUKA

10MG

N021729 002 Jun 07, 2006 May DISC

@

15MG

N021729 003 Jun 07, 2006 May DISC

ARIPIPIRAZOLE

+ ALEMBIC PHARMS LTD

10MG

A202102 001 Apr 28, 2015 May CRLD

15MG

A202102 002 Apr 28, 2015 May CTEC

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

AB MYLAN PHARMS INC

50MG

A200043 001 Jun 01, 2012 Apr CMFD

AB

150MG

A200043 002 Jun 01, 2012 Apr CMFD

AB

250MG

A200043 003 Jun 01, 2012 Apr CMFD

NUVIGIL

AB CEPHALON

50MG

N021875 001 Jun 15, 2007 Apr CTEC

AB

150MG

N021875 003 Jun 15, 2007 Apr CTEC

AB

+

250MG

N021875 004 Jun 15, 2007 Apr CTEC

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

@ TELIGENT PHARMA INC

100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL

N018933 002 Aug 08, 1985 Jan CAHN

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

FOREST LABS LLC

EQ 2.5 BASE

N022117 003 Mar 12, 2015 Mar NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

@ NOSTRUM LABS INC

325MG;50MG;40MG

A078149 001 Jun 13, 2007 Jan CAHN

FIORINAL

AA + ALLERGAN SALES LLC

325MG;50MG;40MG

N017534 005 Apr 16, 1986 Apr CAHN

TABLET;ORAL

FIORINAL

@ ALLERGAN SALES LLC

325MG;50MG;40MG

N017534 003 Apr 16, 1986 Apr CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

FIORINAL W/CODEINE

AB + ALLERGAN SALES LLC

325MG;50MG;40MG;30MG

N019429 003 Oct 26, 1990 Apr CAHN

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

>D> AB HERITAGE PHARMS INC

325MG;200MG

A089594 001 Mar 31, 1989 Jun CRLD

>A> AB

+

325MG;200MG

A089594 001 Mar 31, 1989 Jun CRLD

AB

INGENUS PHARMS NJ

325MG;200MG

A040832 001 Jan 07, 2010 Jan CAHN

>D>

SOMA COMPOUND

>D> AB

+

MEDA PHARMS

325MG;200MG

N012365 005 Jul 11, 1983 Jun DISC

>A>

@

325MG;200MG

N012365 005 Jul 11, 1983 Jun DISC

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar CMFD
	@	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jan CAHN
AB	+ SANDOZ	325MG;200MG;16MG	A040118	001	Apr 16, 1996	Mar CTEC
	+	325MG;200MG;16MG	A040118	001	Apr 16, 1996	Jan CRLD
	SOMA COMPOUND W/ CODEINE					
	@ MEDA PHARMS	325MG;200MG;16MG	N012366	002	Jul 11, 1983	Jan DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

ASPIRIN AND DIPYRIDAMOLE

	@ AMNEAL PHARMS	25MG;200MG	A206392	001	Mar 08, 2016	Apr DISC
AB		25MG;200MG	A206392	001	Mar 08, 2016	Feb NEWA

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

	@ SUN PHARM INDS	325MG;4.5MG;0.38MG	A040260	001	Jul 17, 1998	Mar CAHN
	@	325MG;4.5MG;0.38MG	A087794	001	May 26, 1982	Mar CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	ALVOGEN MALTA	25MG	A073646	001	Jul 31, 1992	Jan CAHN
AB		50MG	A072303	001	Jul 15, 1988	Jan CAHN
AB		100MG	A072304	001	Jul 15, 1988	Jan CAHN
	TENORMIN					
AB	ALVOGEN MALTA	25MG	N018240	004	Apr 09, 1990	Jan CAHN
AB		50MG	N018240	001		Jan CAHN
AB	+	100MG	N018240	002		Jan CAHN

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB	ALVOGEN MALTA	50MG;25MG	A072301	001	May 31, 1990	Jan CAHN
AB		100MG;25MG	A072302	001	May 31, 1990	Jan CAHN
AB	SUN PHARM INDS	100MG;25MG	A073582	001	Apr 29, 1993	Mar CAHN
	TENORETIC 100					
AB	+ ALVOGEN MALTA	100MG;25MG	N018760	001	Jun 08, 1984	Jan CAHN
	TENORETIC 50					
AB	ALVOGEN MALTA	50MG;25MG	N018760	002	Jun 08, 1984	Jan CAHN

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	SCIEGEN PHARMS INC	EQ 10MG BASE	A205519	001	May 19, 2016	May NEWA
AB		EQ 20MG BASE	A205519	002	May 19, 2016	May NEWA
AB		EQ 40MG BASE	A205519	003	May 19, 2016	May NEWA
AB		EQ 80MG BASE	A205519	004	May 19, 2016	May NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

	@ SUN PHARM INDS	0.025MG;2.5MG	A085506	001		Mar CAHN
--	------------------	---------------	---------	-----	--	----------

AURANOFIN

CAPSULE; ORAL

RIDAURA

+	SEBELA IRELAND LTD	3MG	N018689	001	May 24, 1985	Jan CAHN
---	--------------------	-----	---------	-----	--------------	----------

AXITINIB

TABLET; ORAL

INLYTA

	PF PRISM CV	1MG	N202324	001	Jan 27, 2012	Apr CAHN
+		5MG	N202324	002	Jan 27, 2012	Apr CAHN

AZACITIDINE

	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS					
	AZACITIDINE					
AP	MYLAN INSTITUTIONAL	100MG/VIAL	A204949	001	Apr 28, 2016	Apr NEWA
	POWDER;IV (INFUSION), SUBCUTANEOUS					
	AZACITIDINE					
	ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016	Apr NEWA

AZATHIOPRINE

TABLET;ORAL						
IMURAN						
	@	SEBELA IRELAND LTD	25MG	N016324	002	Jan CAHN
AB	+		50MG	N016324	001	Jan CAHN

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION					
IMURAN					
@ SEBELA IRELAND LTD	EQ 100MG BASE/VIAL	N017391	001		Jan CAHN

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL						
EDARBI						
ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Jan CAHN	
+	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Jan CAHN	

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL							
EDARBYCLOR							
ARBOR PHARMS LLC		EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Jan	CAHN
+		EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Jan	CAHN

AZITHROMYCIN

FOR SUSPENSION;ORAL							
AZITHROMYCIN							
BX	LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Apr	CTEC
BX		EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Apr	CTEC

AZTREONAM

INJECTABLE;INJECTION						
AZTREONAM						
@	EUROHLTH INTL SARL	1GM/VIAL	A065286	001	Mar 23, 2011	Mar DISC
@		2GM/VIAL	A065286	002	Mar 23, 2011	Mar DISC

BACLOFEN

INJECTABLE;INTRATHECAL						
BACLOFEN						
AP	SINETICA SA	0.05MG/ML	A091193	001	May 03, 2016	Apr NEWA
AP		0.5MG/ML	A091193	002	May 03, 2016	Apr NEWA
AP		2MG/ML	A091193	003	May 03, 2016	Apr NEWA
LIORESAL						
AP	+ SAOL THERAPS RES LTD	0.05MG/ML	N020075	003	Nov 07, 1996	May CAHN
AP	+	0.5MG/ML	N020075	001	Jun 17, 1992	May CAHN
AP	+	2MG/ML	N020075	002	Jun 17, 1992	May CAHN
TABLET;ORAL						
BACLOFEN						
AB	NORTHSTAR HLTHCARE	10MG	A078401	002	Sep 18, 2009	Jan NEWA

BARIUM SULFATE

FOR SUSPENSION;ORAL						
E-Z-HD						
+	BRACCO	334GM/BOTTLE	N208036	001	Jan 11, 2016	Jan NEWA
SUSPENSION;ORAL						
READI-CAT 2						
+	BRACCO	2% (9GM/450ML)	N208143	001	Jan 15, 2016	Jan NEWA
READI-CAT 2 SMOOTHIES						
	BRACCO	2% (9GM/450ML)	N208143	002	Jan 15, 2016	Jan NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

@ ACTAVIS LABS FL INC	5MG	A076267	001	Feb 11, 2004	Jan DISC
@	10MG	A076267	002	Feb 11, 2004	Jan DISC
@	20MG	A076267	003	Feb 11, 2004	Jan DISC
@	40MG	A076267	004	Feb 11, 2004	Jan DISC

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ ACTAVIS LABS FL INC	5MG; 6.25MG	A076342	001	Feb 11, 2004	Jan DISC
@	10MG; 12.5MG	A076342	002	Feb 11, 2004	Jan DISC
@	20MG; 12.5MG	A076342	003	Feb 11, 2004	Jan DISC
@	20MG; 25MG	A076342	004	Feb 11, 2004	Jan DISC
@ IVAX SUB TEVA PHARMS	5MG; 6.25MG	A076348	001	Feb 11, 2004	Mar DISC
@	10MG; 12.5MG	A076348	002	Feb 11, 2004	Mar DISC
@	20MG; 12.5MG	A076348	003	Feb 11, 2004	Mar DISC
@	20MG; 25MG	A076348	004	Feb 11, 2004	Mar DISC
@ SUN PHARM INDS LTD	5MG; 6.25MG	A077483	001	Sep 08, 2005	Mar DISC
@	10MG; 12.5MG	A077483	002	Sep 08, 2005	Mar DISC
@	20MG; 12.5MG	A077483	003	Sep 08, 2005	Mar DISC
@	20MG; 25MG	A077483	004	Sep 08, 2005	Mar DISC

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	25MG/VIAL	A205574	001	May 19, 2016	May NEWA
AP		100MG/VIAL	A205574	002	May 19, 2016	May NEWA
AP	GLENMARK PHARMS LTD	25MG/VIAL	A204771	001	Mar 24, 2016	Mar NEWA
AP		100MG/VIAL	A204771	002	Mar 24, 2016	Mar NEWA
AP	HOSPIRA INC	25MG/VIAL	A204086	001	May 20, 2016	May NEWA
AP		100MG/VIAL	A204086	002	May 20, 2016	May NEWA
AP	INNOPHARMA LICENSING	25MG/VIAL	A205476	001	Mar 24, 2016	Mar NEWA
AP		100MG/VIAL	A205476	002	Mar 24, 2016	Mar NEWA
	TREANDA					
AP	+ CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Mar CFTG
AP	+	100MG/VIAL	N022249	001	Mar 20, 2008	Mar CFTG

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	BIONPHARMA INC	100MG	A081297	001	Jan 29, 1993	Jan CAHN
AA		200MG	A081297	002	Oct 30, 2007	Jan CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN PAK

+	CUTANEA	5%; 3%	N050769	001	Nov 27, 2000	Feb CAHN
---	---------	--------	---------	-----	--------------	----------

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

@ IMPAX LABS	50MG	A040845	001	Nov 18, 2008	Mar DISC
--------------	------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE

SPRAY; TOPICAL

SERNIVO

+	PROMIUS PHARMA LLC	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Feb NEWA
---	--------------------	---------------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	GLENMARK PHARMS	EQ 0.05% BASE; 1%	A202894	001	Oct 30, 2015	Mar CAHN
----	-----------------	-------------------	---------	-----	--------------	----------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT	TELIGENT PHARMA INC	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Jan CAHN
----	---------------------	--------------	---------	-----	--------------	----------

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

@ IMPAX LABS	5MG	A040739	001	Nov 01, 2006	Mar DISC
@	10MG	A040741	001	Nov 01, 2006	Mar DISC
@	25MG	A040740	001	Nov 01, 2006	Mar DISC
@	50MG	A040721	004	Nov 01, 2006	Mar DISC

BIMATOPROST

SOLUTION/DROPS; TOPICAL

BIMATOPROST

AT	SANDOZ INC	0.03%	A202719	001	Apr 19, 2016	Apr NEWA
----	------------	-------	---------	-----	--------------	----------

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

@ SEBELA IRELAND LTD	262.4MG, N/A, N/A; N/A, 250MG, N/A; N/A, N/A, 500MG	N050719	001	Aug 15, 1996	Jan CAHN
----------------------	---	---------	-----	--------------	----------

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

@ SUN PHARM INDS	5MG	A075474	001	Oct 25, 2002	Mar CAHN
@	10MG	A075474	002	Oct 25, 2002	Mar CAHN

>D> BOCEPREVIR

>D> CAPSULE; ORAL

>D> VICTRELIS

>D>	+	MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011	Jun DISC
>A>	@		200MG	N202258	001	May 13, 2011	Jun DISC

BRIVARACETAM

SOLUTION; INTRAVENOUS

BRIVIACT

+	UBC INC	50MG/5ML (10MG/ML)	N205837	001	Feb 18, 2016	Feb NEWA
+	UCB INC	50MG/5ML (10MG/ML)	N205837	001	May 12, 2016	May CMS1

SOLUTION; ORAL

BRIVIACT

+	UCB INC	10MG/ML	N205838	001	May 12, 2016	May CMS1
+		10MG/ML	N205838	001	Feb 18, 2016	Feb NEWA

TABLET; ORAL

BRIVIACT

	UCB INC	10MG	N205836	001	May 12, 2016	May CMS1
		10MG	N205836	001	Feb 18, 2016	Feb NEWA
		25MG	N205836	002	May 12, 2016	May CMS1
		25MG	N205836	002	Feb 18, 2016	Feb NEWA
		50MG	N205836	003	May 12, 2016	May CMS1
		50MG	N205836	003	Feb 18, 2016	Feb NEWA
		75MG	N205836	004	May 12, 2016	May CMS1
		75MG	N205836	004	Feb 18, 2016	Feb NEWA
+		100MG	N205836	005	May 12, 2016	May CMS1
+		100MG	N205836	005	Feb 18, 2016	Feb NEWA

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMSITE

+	INSITE VISION INC	EQ 0.075% ACID	N206911	001	Apr 08, 2016	Apr NEWA
---	-------------------	----------------	---------	-----	--------------	----------

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

AB	+	MYLAN	EQ 5MG BASE	A077226	001	Apr 04, 2005	Jan CRLD
		PARLODEL					
	@	US PHARMS HOLDINGS I	EQ 5MG BASE	N017962	002	Mar 01, 1982	Jan DISC

TABLET; ORAL

BROMOCRIPTINE MESYLATE

AB	+	PADDOCK LLC	EQ 2.5MG BASE	A077646	001	Oct 01, 2008	Jan CRLD
AB		SANDOZ INC	EQ 2.5MG BASE	A074631	001	Jan 13, 1998	Feb CAHN
		PARLODEL					
AB		US PHARMS HOLDINGS I	EQ 2.5MG BASE	N017962	001		Apr CMFD
	@		EQ 2.5MG BASE	N017962	001		Jan DISC

BUDESONIDECAPSULE; ORAL
BUDESONIDE

AB		ACTAVIS ELIZABETH	3MG	A206623	001	Apr 08, 2016	Mar NEWA
		ENTOCORT EC					

AB	+	ELAN PHARMA INTL LTD	3MG	N021324	001	Oct 02, 2001	Jan CAHN
AB	+	PERRIGO PHARMA INTL	3MG	N021324	001	Oct 02, 2001	May CAHN

SUSPENSION; INHALATION
BUDESONIDE

>D>		@ APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009	Jun CMFD
>A>	AN		0.25MG/2ML	A078202	001	Mar 30, 2009	Jun CMFD
>D>		@	0.5MG/2ML	A078202	002	Mar 30, 2009	Jun CMFD
>A>	AN		0.5MG/2ML	A078202	002	Mar 30, 2009	Jun CMFD
	AN	TEVA PHARMS USA	1MG/2ML	A204548	001	Mar 08, 2016	Feb NEWA

BUMETANIDEINJECTABLE; INJECTION
BUMETANIDE

>A>	AP	+	AMPHASTAR PHARMS INC	0.25MG/ML	A074441	001	Jan 27, 1995	Jun CAHN
>D>	AP	+	EUROHLTH INTL SARL	0.25MG/ML	A074441	001	Jan 27, 1995	Jun CAHN
	AP	+		0.25MG/ML	A074441	001	Jan 27, 1995	Apr CAHN

BUPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION
BUPIVACAINE HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	0.25%	A207183	001	May 13, 2016	May NEWA
AP			0.5%	A207183	002	May 13, 2016	May NEWA

BUPRENORPHINE HYDROCHLORIDEIMPLANT; IMPLANTATION
PROBUPHINE

>A>		+	BRAEBURN PHARMS INC	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Jun CAHN
>D>		+	TITAN PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Jun CAHN
		+		EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	May NEWA

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 2MG BASE	A201760	001	Jan 29, 2016	Jan NEWA
AB			EQ 8MG BASE	A201760	002	Jan 29, 2016	Jan NEWA

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
BUPROPION HYDROCHLORIDE

AB1		INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Jan NEWA
AB1			150MG	A206674	002	Feb 09, 2016	Jan NEWA
AB1			200MG	A206674	003	Feb 09, 2016	Jan NEWA
AB1		SCIEGEN PHARMS INC	100MG	A205794	001	Mar 01, 2016	Feb NEWA
AB1			150MG	A205794	002	Mar 01, 2016	Feb NEWA
AB1			200MG	A205794	003	Mar 01, 2016	Feb NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
CONTRAVE

	+	OREXIGEN	90MG; 8MG	N200063	001	Sep 10, 2014	Apr CAHN
--	---	----------	-----------	---------	-----	--------------	----------

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

>D>	AB		EMCURE PHARMS USA	5MG	A204582	001	Sep 18, 2015	Jun CAHN
>D>	AB			10MG	A204582	002	Sep 18, 2015	Jun CAHN
>D>	AB			15MG	A204582	003	Sep 18, 2015	Jun CAHN
>D>	AB			30MG	A204582	004	Sep 18, 2015	Jun CAHN
>A>	AB		HERITAGE PHARMA	5MG	A204582	001	Sep 18, 2015	Jun CAHN
>A>	AB			10MG	A204582	002	Sep 18, 2015	Jun CAHN
>A>	AB			15MG	A204582	003	Sep 18, 2015	Jun CAHN
>A>	AB			30MG	A204582	004	Sep 18, 2015	Jun CAHN

BUSULFAN

INJECTABLE; INJECTION
BUSULFAN

AP LUITPOLD PHARMS INC 6MG/ML A202259 001 Dec 22, 2015 Mar CAHN

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
BUTOCONAZOLE NITRATE

>D> @ ELAN PHARMA INTL LTD 2% N019881 001 Feb 07, 1997 Jun CAHN
>A> @ PERRIGO PHARMA INTL 2% N019881 001 Feb 07, 1997 Jun CAHN

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE

AP @ CLARIS 2MG/ML A075697 001 Oct 23, 2001 Jan CAHN
EUROHLTH INTL SARL 2MG/ML A075046 001 Aug 12, 1998 Apr CAHN
BUTORPHANOL TARTRATE PRESERVATIVE FREE
@ CLARIS 1MG/ML A075695 001 Oct 23, 2001 Mar CAHN
@ 2MG/ML A075695 002 Oct 23, 2001 Mar CAHN
AP EUROHLTH INTL SARL 1MG/ML A075045 001 Aug 12, 1998 Apr CAHN
AP 2MG/ML A075045 002 Aug 12, 1998 Apr CAHN

CABERGOLINE

TABLET; ORAL
CABERGOLINE

@ IMPAX LABS INC 0.5MG A077843 001 Jul 03, 2007 Mar DISC

CABOZANTINIB S-MALATE

TABLET; ORAL
CABOMETYX

EXELIXIS INC EQ 20MG BASE N208692 001 Apr 25, 2016 Apr NEWA
EQ 40MG BASE N208692 002 Apr 25, 2016 Apr NEWA
+ EQ 60MG BASE N208692 003 Apr 25, 2016 Apr NEWA

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
MIGERGOT

+ HORIZON PHARMA 100MG; 2MG A086557 001 Oct 04, 1983 Jan CAHN

>A> CALCIFEDIOL

>A> CAPSULE, EXTENDED RELEASE; ORAL
>A> RAYALDEE

>A> + OPKO IRELAND GLOBAL 0.03MG N208010 001 Jun 17, 2016 Jun NEWA

CALCIPOTRIENE

CREAM; TOPICAL
CALCIPOTRIENE

AB GLENMARK PHARMS 0.005% A205772 001 Jun 09, 2015 Mar CAHN

CALCITRIOL

CAPSULE; ORAL
CALCITRIOL

AB BIONPHARMA INC 0.25MCG A091174 001 May 24, 2013 Jan CAHN
AB 0.5MCG A091174 002 May 24, 2013 Jan CAHN

INJECTABLE; INJECTION
CALCITRIOL

AKORN 0.001MG/ML A078066 001 Jan 29, 2008 Feb CTEC
@ ROCKWELL MEDCL 0.001MG/ML A076206 001 Sep 17, 2003 Feb DISC

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
@ FRESENIUS MEDCL 25.7MG/100ML; 1.5GM/100ML; 15.2MG/10 N018379 002 Feb DISC
0ML; 567MG/100ML; 392MG/100ML

DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
@ FRESENIUS MEDCL 25.7MG/100ML; 2.5GM/100ML; 15.2MG/10 N018379 003 Feb DISC
0ML; 567MG/100ML; 392MG/100ML

DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
@ FRESENIUS MEDCL 25.7MG/100ML; 3.5GM/100ML; 15.2MG/10 N018379 007 Jun 24, 1988 Feb DISC
0ML; 567MG/100ML; 392MG/100ML

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N018379	001			Feb	DISC
--------------------	--	---------	-----	--	--	-----	------

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	004	Jul 07, 1982		Feb	DISC
--------------------	---	---------	-----	--------------	--	-----	------

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	005	Jul 07, 1982		Feb	DISC
--------------------	---	---------	-----	--------------	--	-----	------

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	008	Jun 24, 1988		Feb	DISC
--------------------	---	---------	-----	--------------	--	-----	------

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N018379	006	Jul 07, 1982		Feb	DISC
--------------------	--	---------	-----	--------------	--	-----	------

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML	N017512	010	Nov 18, 1985		Feb	CTEC
-----------------	---	---------	-----	--------------	--	-----	------

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985		Feb	CTEC
-----------------	---	---------	-----	--------------	--	-----	------

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

@ APOTEX	12.5MG	A074737	001	Oct 28, 1998		Mar	DISC
----------	--------	---------	-----	--------------	--	-----	------

@	25MG	A074737	002	Oct 28, 1998		Mar	DISC
---	------	---------	-----	--------------	--	-----	------

@	50MG	A074737	003	Oct 28, 1998		Mar	DISC
---	------	---------	-----	--------------	--	-----	------

@	100MG	A074737	004	Oct 28, 1998		Mar	DISC
---	-------	---------	-----	--------------	--	-----	------

>A> AB	HIKMA INTL PHARMS	12.5MG	A074505	001	Feb 13, 1996	Jun	CAHN
--------	-------------------	--------	---------	-----	--------------	-----	------

>A> AB		25MG	A074505	002	Feb 13, 1996	Jun	CAHN
--------	--	------	---------	-----	--------------	-----	------

>A> AB		50MG	A074505	003	Feb 13, 1996	Jun	CAHN
--------	--	------	---------	-----	--------------	-----	------

>A> AB		100MG	A074505	004	Feb 13, 1996	Jun	CAHN
--------	--	-------	---------	-----	--------------	-----	------

>D> AB	HIKMA PHARMS	12.5MG	A074505	001	Feb 13, 1996	Jun	CAHN
--------	--------------	--------	---------	-----	--------------	-----	------

>D> AB		25MG	A074505	002	Feb 13, 1996	Jun	CAHN
--------	--	------	---------	-----	--------------	-----	------

>D> AB		50MG	A074505	003	Feb 13, 1996	Jun	CAHN
--------	--	------	---------	-----	--------------	-----	------

>D> AB		100MG	A074505	004	Feb 13, 1996	Jun	CAHN
--------	--	-------	---------	-----	--------------	-----	------

@ SANDOZ	12.5MG	A074363	001	Nov 09, 1995		Jan	DISC
----------	--------	---------	-----	--------------	--	-----	------

@	25MG	A074363	002	Nov 09, 1995		Jan	DISC
---	------	---------	-----	--------------	--	-----	------

@	50MG	A074363	003	Nov 09, 1995		Jan	DISC
---	------	---------	-----	--------------	--	-----	------

@	100MG	A074363	004	Nov 09, 1995		Jan	DISC
---	-------	---------	-----	--------------	--	-----	------

@ STASON	12.5MG	A074677	004	May 30, 1997		Mar	DISC
----------	--------	---------	-----	--------------	--	-----	------

@	25MG	A074677	002	May 30, 1997		Mar	DISC
---	------	---------	-----	--------------	--	-----	------

@	50MG	A074677	001	May 30, 1997		Mar	DISC
---	------	---------	-----	--------------	--	-----	------

@	100MG	A074677	003	May 30, 1997		Mar	DISC
---	-------	---------	-----	--------------	--	-----	------

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB	MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jan	CAHN
----	-------------------	-------	---------	-----	--------------	-----	------

AB		200MG	A076697	002	May 20, 2011	Jan	CAHN
----	--	-------	---------	-----	--------------	-----	------

AB		300MG	A076697	003	May 20, 2011	Jan	CAHN
----	--	-------	---------	-----	--------------	-----	------

CARBIDOPA

TABLET;ORAL

CARBIDOPA

AB	EDENBRIDGE PHARMS	25MG	A205304	001	Feb 17, 2016	Feb	NEWA
----	-------------------	------	---------	-----	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

@ IDT AUSTRALIA LTD	10MG;100MG	A073586	001	Jun 29, 1995		May	CAHN
---------------------	------------	---------	-----	--------------	--	-----	------

@	25MG;100MG	A073587	001	Jun 29, 1995		May	CAHN
---	------------	---------	-----	--------------	--	-----	------

@	25MG;250MG	A073620	001	Jun 29, 1995		May	CAHN
---	------------	---------	-----	--------------	--	-----	------

CARBINOXAMINE MALEATE

TABLET;ORAL

CARBINOXAMINE MALEATE

MIKART INC	6MG	A207484	001	May 31, 2016		May	NEWA
------------	-----	---------	-----	--------------	--	-----	------

CARBOPLATIN

INJECTABLE;IV (INFUSION)
CARBOPLATIN

	@ ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Apr	DISC
	@	150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Apr	DISC
	@	450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Apr	DISC
	@	600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Apr	DISC
AP	SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	Feb	CAHN
AP		150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	Feb	CAHN
AP		450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	Feb	CAHN
AP	SANJA PHARMS CO	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Mar	NEWA
AP		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Mar	NEWA
AP		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Mar	NEWA

CARFILZOMIB

POWDER;INTRAVENOUS
KYPROLIS

>A>	ONYX THERAP	30MG/VIAL	N202714	002	Jun 03, 2016	Jun	NEWA
	+	60MG/VIAL	N202714	001	Jul 20, 2012	Feb	CAHN

CARISOPRODOL

TABLET;ORAL
CARISOPRODOL

AA	INGENUS PHARMS NJ	350MG	A040823	001	Oct 22, 2008	Jan	CAHN
AB	STRIDES PHARMA	250MG	A205513	001	Nov 12, 2015	May	CAHN
AA		350MG	A205513	002	Nov 12, 2015	May	CAHN

CARVEDILOL

TABLET;ORAL
COREG

AB	SMITHKLINE BEECHAM	3.125MG	N020297	004	May 29, 1997	May	CAHN
AB		6.25MG	N020297	003	Sep 14, 1995	May	CAHN
AB	+	12.5MG	N020297	002	Sep 14, 1995	May	CAHN
AB		25MG	N020297	001	Sep 14, 1995	May	CAHN

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL
COREG CR

SMITHKLINE BEECHAM 10MG
20MG
+ 40MG
80MG

N022012	001	Oct 20, 2006	May	CAHN
N022012	002	Oct 20, 2006	May	CAHN
N022012	003	Oct 20, 2006	May	CAHN
N022012	004	Oct 20, 2006	May	CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION;ORAL
CEFADROXIL

@ SUN PHARM INDS LTD EQ 125MG BASE/5ML
@ EQ 250MG BASE/5ML
@ EQ 500MG BASE/5ML

A065115	001	Mar 26, 2003	Feb	DISC
A065115	002	Mar 26, 2003	Feb	DISC
A065115	003	Mar 26, 2003	Feb	DISC

CEFAZOLIN SODIUM

INJECTABLE;INJECTION
CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016	Jan	NEWA
----	-------------	------------------	---------	-----	--------------	-----	------

CEFDITOREN PIVOXIL

TABLET;ORAL
SPECTRACEF

@ VANSER PHARMA 200MG
@ 400MG

N021222	001	Aug 29, 2001	Apr	DISC
N021222	002	Jul 21, 2008	Apr	DISC

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION
CEFEPIME HYDROCHLORIDE

AP	QILU PHARM CO LTD	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan	NEWA
AP		EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan	NEWA
AP		EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan	NEWA

CEFOTAXIME SODIUM

INJECTABLE;INJECTION
CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Feb NEWA
AP		EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Feb NEWA
	CLAFORAN					
AP	+ US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Jan CAHN
AP	+	EQ 1GM BASE/VIAL	N050547	002		Jan CAHN
AP	+	EQ 2GM BASE/VIAL	N050547	003		Jan CAHN
AP	+	EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan CAHN
>D>	CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER					
>D>	+ SANOFI AVENTIS US	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jun DISC
>A>	@ US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jun DISC
>D>	+	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jun DISC
>A>	@	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jun DISC
	+	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan CAHN
	CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	@ US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan CAHN
	@	EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan CAHN

CEFOTETAN DISODIUM

INJECTABLE;INJECTION
CEFOTAN

	@ TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	Jan CAHN
AP		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb CMFD
	@	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Jan CAHN
	@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	Jan CAHN
AP		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb CMFD
	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Jan CAHN
	@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Jan CAHN
	CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER					
>D>	+ B BRAUN	EQ 1GM BASE/VIAL	\$065430	001	Aug 09, 2007	Jun CMS2
>A>	+	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007	Jun CMS2
>D>	+	EQ 2GM BASE/VIAL	A065430	002	Aug 09, 2007	Jun CMS2
>A>	+	EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007	Jun CMS2

CEFOXITIN SODIUM

INJECTABLE;INJECTION
CEFOXITIN

AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	May CAHN
AP		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	May CAHN
AP		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	May CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL
CEFPODOXIME PROXETIL

	@ SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Feb DISC
	@	EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Feb DISC

TABLET;ORAL

	@ SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Feb DISC
	@	EQ 200MG BASE	A065083	002	Aug 20, 2003	Feb DISC

>D> CEFTIBUTEN DIHYDRATE

>D> CAPSULE;ORAL
>D> CEDAX

>D>	+ PERNIX THERAP	EQ 400MG BASE	N050685	002	Dec 20, 1995	Jun DISC
>A>	@	EQ 400MG BASE	N050685	002	Dec 20, 1995	Jun DISC
>D>	FOR SUSPENSION;ORAL					
>D>	CEDAX					
>D>	+ PERNIX THERAP	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jun DISC
>A>	@	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jun DISC
>D>	+	EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jun DISC
>A>	@	EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jun DISC

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION
CEFTRIAXONE

	@ HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005	Apr DISC
	@	EQ 1GM BASE/VIAL	A202563	001	Aug 20, 2012	Apr DISC
	@	EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005	Apr DISC

INJECTABLE; INJECTION

CEFTRIAZONE

@	EQ 2GM BASE/VIAL	A202563	002	Aug 20, 2012	Apr DISC
ROCEPHIN					
@ HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL	A063239	002	Aug 13, 1993	Apr DISC
@	EQ 1GM BASE/VIAL	A063239	003	Aug 13, 1993	Apr DISC

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAZONE

>D> AP	BEDFORD	EQ 250MG BASE/VIAL	A065465	001	Aug 18, 2008	Jun DISC
>A>	@	EQ 250MG BASE/VIAL	A065465	001	Aug 18, 2008	Jun DISC
>D> AP		EQ 500MG BASE/VIAL	A065465	002	Aug 18, 2008	Jun DISC
>A>	@	EQ 500MG BASE/VIAL	A065465	002	Aug 18, 2008	Jun DISC
>D> AP		EQ 1GM BASE/VIAL	A065465	003	Aug 18, 2008	Jun DISC
>A>	@	EQ 1GM BASE/VIAL	A065465	003	Aug 18, 2008	Jun DISC
>D> AP		EQ 2GM BASE/VIAL	A065465	004	Aug 18, 2008	Jun DISC
>A>	@	EQ 2GM BASE/VIAL	A065465	004	Aug 18, 2008	Jun DISC
>A> AP	QILU PHARM CO LTD	EQ 250MG BASE/VIAL	A203702	001	Jun 29, 2016	Jun NEWA
>A> AP		EQ 500MG BASE/VIAL	A203702	002	Jun 29, 2016	Jun NEWA
>A> AP		EQ 1GM BASE/VIAL	A203702	003	Jun 29, 2016	Jun NEWA
>A> AP		EQ 2GM BASE/VIAL	A203702	004	Jun 29, 2016	Jun NEWA

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL

CEFTIN

	GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994	Feb CTEC
+		EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997	Feb CTEC
CEFUROXIME AXETIL						
@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Feb DISC
@		EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Feb DISC

TABLET; ORAL

CEFUROXIME AXETIL

@	SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Feb DISC
@		EQ 250MG BASE	A065118	002	Apr 25, 2003	Feb DISC
@		EQ 500MG BASE	A065118	003	Apr 25, 2003	Feb DISC

CEFUROXIME SODIUM

INJECTABLE; INJECTION

ZINACEF

AP	+	IGI LABS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jan CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jan CAHN
ZINACEF IN PLASTIC CONTAINER							
@		IGI LABS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jan CAHN
+			EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jan CAHN

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

ZINACEF

AB	+	IGI LABS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jan CAHN
----	---	--------------	--------------------	---------	-----	--------------	----------

CELECOXIB

CAPSULE; ORAL

CELECOXIB

AB	AUROBINDO PHARMA LTD	50MG	A206827	001	Feb 01, 2016	Jan NEWA
AB		100MG	A206827	002	Feb 01, 2016	Jan NEWA
AB		200MG	A206827	003	Feb 01, 2016	Jan NEWA
AB		400MG	A206827	004	Feb 01, 2016	Jan NEWA
AB	MACLEODS PHARMS LTD	50MG	A204590	001	Mar 16, 2016	Feb NEWA
AB		100MG	A204590	002	Mar 16, 2016	Feb NEWA
AB		200MG	A204590	003	Mar 16, 2016	Feb NEWA
AB		400MG	A204590	004	Mar 16, 2016	Feb NEWA

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

@	SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Feb DISC
@		EQ 500MG BASE	A065007	002	Sep 16, 1999	Feb DISC

FOR SUSPENSION; ORAL

KEFLEX

@	PRAGMA PHARMS LLC	EQ 100MG BASE/ML	N050406	003		Mar CAHN
@		EQ 125MG BASE/5ML	N050406	001		Mar CAHN
@		EQ 250MG BASE/5ML	N050406	002		Mar CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

AA	NOSTRUM LABS INC	5MG/5ML	A090191	001	Nov 12, 2009	Mar CAHN
	@ WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009	Apr DISC

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

PERIOGARD

AT	COLGATE-PALMOLIVE CO	0.12%	A203212	001	Jan 28, 2016	Jan NEWA
----	----------------------	-------	---------	-----	--------------	----------

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

@ IMPAX LABS

EQ 150MG BASE

A080880 001

Mar DISC

@

EQ 300MG BASE

A040516 001 Aug 29, 2003 Mar DISC

CHLORPHENIRAMINE MALEATE

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

@ AUROLIFE PHARMA LLC

4MG

A080961 001

Mar CAHN

>D>

@ MUTUAL PHARM

4MG

A080700 001

Jun CAHN

>A>

@ SUN PHARM INDS

4MG

A080700 001

Jun CAHN

>D> CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

>D> TABLET, EXTENDED RELEASE; ORAL

>D> CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

>D> SPRIASO LLC

8MG; 54.3MG

N206323 001 Jun 22, 2015

Jun DISC

>A>

@

8MG; 54.3MG

N206323 001 Jun 22, 2015

Jun DISC

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA MAYNE PHARMA INC

4MG/5ML; 5MG/5ML; 60MG/5ML

A205657 001 Aug 03, 2015

Feb CAHN

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ AUROLIFE PHARMA LLC

100MG

A088725 001 Aug 31, 1984

Mar CAHN

@

250MG

A088726 001 Aug 31, 1984 Mar CAHN

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB MYLAN

25MG

A086831 002

Jan CTEC

AB SUN PHARM INDS

25MG

A089286 002 Jul 21, 1986

Jan NEWA

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

@ AUROLIFE PHARMA LLC

250MG

A089852 001 May 04, 1988

Feb CAHN

@

500MG

A089853 001 May 04, 1988 Feb CAHN

+ MIKART

750MG

A040861 002 Jun 01, 2010

Apr CRLD

>A>

+ MIKART INC

250MG

A207483 001 Jun 24, 2016

Jun NEWA

@ SUN PHARM INDS

500MG

A089970 001 Sep 27, 1990

Mar CAHN

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

+ TAKEDA GMBH

0.08MG/INH

N021658 002 Jan 10, 2008

Jan CRLD

CILASTATIN SODIUM; IMIPENEM

POWDER; INTRAMUSCULAR

PRIMAXIN

@ MERCK

EQ 500MG BASE/VIAL; 500MG/VIAL

N050630 001 Dec 14, 1990

May DISC

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

>D>	@	MUTUAL PHARM	50MG	A077208	002	Mar 29, 2006	Jun CAHN
>D>	@		100MG	A077208	001	Mar 29, 2006	Jun CAHN
>A>	@	SUN PHARM INDS	50MG	A077208	002	Mar 29, 2006	Jun CAHN
>A>	@		100MG	A077208	001	Mar 29, 2006	Jun CAHN
>D> AB		TEVA	50MG	A077027	001	Nov 24, 2004	Jun CRLD
>A> AB	+		50MG	A077027	001	Nov 24, 2004	Jun CRLD
>D> AB			100MG	A077027	002	Nov 24, 2004	Jun CRLD
>A> AB	+		100MG	A077027	002	Nov 24, 2004	Jun CRLD
>D>		PLETAL					
>D> AB	+	OTSUKA	50MG	N020863	001	Jan 15, 1999	Jun DISC
>A>	@		50MG	N020863	001	Jan 15, 1999	Jun DISC
>D> AB	+		100MG	N020863	002	Jan 15, 1999	Jun DISC
>A>	@		100MG	N020863	002	Jan 15, 1999	Jun DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@	IDT AUSTRALIA LTD	EQ 100MG BASE
@		EQ 250MG BASE
@		EQ 500MG BASE
@		EQ 750MG BASE

A075939	001	Mar 03, 2005	May CAHN
A075939	002	Jun 09, 2004	May CAHN
A075939	003	Jun 09, 2004	May CAHN
A075939	004	Jun 09, 2004	May CAHN

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS; OTIC

OTOVEL

+ LABORATORIOS SALVAT EQ 0.3% BASE; 0.025%

N208251	001	Apr 29, 2016	Apr NEWA
---------	-----	--------------	----------

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

@	ACTAVIS LABS FL INC	212.6MG; EQ 287.5MG BASE
@		425.2MG; EQ 574.9MG BASE

A077417	001	Nov 30, 2010	Jan DISC
A077809	001	Nov 30, 2010	Jan DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@	SUN PHARM INDS	EQ 10MG BASE
@		EQ 20MG BASE
@		EQ 40MG BASE

A077052	001	Jul 03, 2006	Mar CAHN
A077052	002	Jul 03, 2006	Mar CAHN
A077052	003	Jul 03, 2006	Mar CAHN

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

AB	ALLIED PHARMA INC	500MG
	@ IDT AUSTRALIA LTD	500MG

A203243	001	Feb 29, 2016	Feb NEWA
A065250	001	Aug 25, 2005	May CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	MYLAN PHARMS INC	EQ 75MG BASE/5ML
----	------------------	------------------

A203063	001	May 25, 2016	May NEWA
---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDESSE

>D>	+	ELAN PHARMA INTL LTD	EQ 2% BASE
>A>	+	PERRIGO PHARMA INTL	EQ 2% BASE

N050793	001	Nov 30, 2004	Jun CAHN
N050793	001	Nov 30, 2004	Jun CAHN

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP	EUROHLTH INTL SARL	EQ 150MG BASE/ML
----	--------------------	------------------

A065206	001	Sep 24, 2004	Apr CAHN
---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX	+	AQUA PHARMS LLC	1.2%; 0.025%
----	---	-----------------	--------------

N050803	001	Jul 16, 2010	Jan CAHN
---------	-----	--------------	----------

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB	+	FOUGERA PHARMS	0.05%	A074407	001	Feb 23, 1996	Mar CRLD
		TEMOVATE					
	@	FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Mar DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

AB	+	MALLINCKRODT LLC	25MG	N019906	001	Dec 29, 1989	Jan CRLD
AB			50MG	N019906	002	Dec 29, 1989	Jan CRLD

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 0.1MG

A070887 001 Aug 31, 1988 Feb CAHN

@ 0.2MG

A070886 001 Aug 31, 1988 Feb CAHN

@ 0.3MG

A071294 001 Aug 31, 1988 Feb CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

>D>	AB	ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013	Jun DISC
>A>		@	EQ 75MG BASE	A090307	001	May 28, 2013	Jun DISC
	AB	SUN PHARM INDS	EQ 75MG BASE	A078133	001	Jun 10, 2013	Mar CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC 3.75MG

A072219 001 Aug 26, 1988 Apr CAHN

@ 7.5MG

A072220 001 Aug 26, 1988 Feb CAHN

@ 15MG

A072112 001 Aug 26, 1988 Feb CAHN

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC 3.75MG

A072512 001 May 11, 1990 Mar CAHN

@ 7.5MG

A072513 001 May 11, 1990 Mar CAHN

@ 15MG

A072514 001 May 11, 1990 Feb CAHN

TRANXENE

>D>	AB	RECORDATI RARE	3.75MG	N017105	006		Jun DISC
>A>		@	3.75MG	N017105	006		Jun DISC

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA		NOSTRUM LABS INC	10MG/5ML; 6.25MG/5ML	A090180	001	Mar 17, 2010	Feb CAHN
----	--	------------------	----------------------	---------	-----	--------------	----------

COLCHICINE

CAPSULE; ORAL

MITIGARE

+	HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	Mar CRLD
---	-------------------	-------	---------	-----	--------------	----------

COLCHICINE; PROBENECID

TABLET; ORAL

PROBENECID AND COLCHICINE

AB		INGENUS PHARMS NJ	0.5MG; 500MG	A040618	001	May 13, 2008	Jan CAHN
----	--	-------------------	--------------	---------	-----	--------------	----------

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+	ENDO PHARMS INC	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML	N050356	001		Feb CAHN
---	-----------------	--	---------	-----	--	----------

CORTICOTROPIN

INJECTABLE; INJECTION

PURIFIED CORTROPHIN GEL

@ ANI PHARMS 40 UNITS/ML

N008975 001 Feb CAHN

@ 80 UNITS/ML

N008975 002 Feb CAHN

CORTICOTROPIN-ZINC HYDROXIDEINJECTABLE; INJECTION
CORTROPHIN-ZINC

@ ANI PHARMS 40 UNITS/ML

N009854 001

Feb CAHN

CROFELEMERTABLET, DELAYED RELEASE; ORAL
FULYZAQ

>A> + NAPO PHARMS INC 125MG

N202292 001 Dec 31, 2012 Jun CAHN

>D> + SALIX PHARMS 125MG

N202292 001 Dec 31, 2012 Jun CAHN

CYANOCOBALAMININJECTABLE; INJECTION
CYANOCOBALAMIN

AP SOMERSET THERAPS LLC 1MG/ML

A206503 001 Dec 11, 2015 Mar CAHN

SPRAY, METERED; NASAL
NASCOBAL

+ ENDO PHARMS INC 0.5MG/SPRAY

N021642 001 Jan 31, 2005 Feb CAHN

CYCLOPHOSPHAMIDEINJECTABLE; INJECTION
CYTOXAN (LYOPHILIZED)

@ BAXTER HLTHCARE 500MG/VIAL

N012142 003

Mar DISC

@ 1GM/VIAL

N012142 004 Aug 30, 1982 Mar DISC

@ 2GM/VIAL

N012142 005 Aug 30, 1982 Mar DISC

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA INGENUS PHARMS NJ 4MG

A205087 001 Sep 23, 2015 Jan CAHN

CYTARABINEINJECTABLE; INJECTION
CYTARABINE

AP MYLAN PHARMS INC 20MG/ML

A200915 001 Dec 13, 2011 Mar CAHN

AP 20MG/ML

A200916 001 Dec 13, 2011 Mar CAHN

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL

DAKLINZA

BRISTOL-MYERS SQUIBB EQ 90MG BASE

N206843 003 Apr 13, 2016 Apr NEWA

DACTINOMYCININJECTABLE; INJECTION
DACTINOMYCIN

@ EUROHLTH INTL SARL 0.5MG/VIAL

A090304 001 Mar 16, 2010 Feb DISC

DALBAVANCIN HYDROCHLORIDEPOWDER; IV (INFUSION)
DALVANCE

+ DURATA THERAPS INTL EQ 500MG BASE/VIAL

N021883 001 May 23, 2014 Jan CDFR

DANTROLENE SODIUMFOR SUSPENSION; INTRAVENOUS
RYANODEX

>D> EAGLE PHARMS 250MG/VIAL

N205579 001 Jul 22, 2014 Jun CRLD

>A> + 250MG/VIAL

N205579 001 Jul 22, 2014 Jun CRLD

INJECTABLE; INJECTION
DANTROLENE SODIUM

AP MYLAN INSTITUTIONAL 20MG/VIAL

A205239 001 Feb 18, 2016 Feb NEWA

DAPSONEGEL; TOPICAL
ACZONE

+ ALLERGAN INC 7.5%

N207154 001 Feb 24, 2016 Feb NEWA

TABLET; ORAL

DAPSONE

AB ALVOGEN 25MG

A205429 001 Jan 07, 2016 Mar CAHN

AB 100MG

A205429 002 Jan 07, 2016 Mar CAHN

AB NORTH CREEK PHARMS 25MG

A204074 001 May 10, 2016 Apr NEWA

TABLET; ORAL

DAPSONE

AB		100MG	A204074	002	May 10, 2016	Apr NEWA
AB	NOSTRUM LABS INC	25MG	A203887	001	May 06, 2016	Apr NEWA
AB		100MG	A203887	002	May 06, 2016	Apr NEWA

DAPTOMYCIN

POWDER; INTRAVENOUS

CUBICIN

AP	+ CUBIST	500MG/VIAL	N021572	002	Sep 12, 2003	Jan CDFR
DAPTOMYCIN						
>A> AP	CRANE PHARMS LLC	500MG/VIAL	A206005	001	Jun 15, 2016	Jun NEWA
AP	HOSPIRA INC	500MG/VIAL	A202857	001	Sep 12, 2014	Jan CDFR
AP	TEVA PARENTERAL	500MG/VIAL	A091039	001	Mar 25, 2016	Mar NEWA
POWDER; IV (INFUSION)						
CUBICIN						
	@ CUBIST	250MG/VIAL	N021572	001	Sep 12, 2003	Jan CDFR

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

ENABLEX

AB	APIL	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Jan CAHN
AB	+	EQ 15MG BASE	N021513	002	Dec 22, 2004	Jan CAHN

DASATINIB

TABLET; ORAL

DASATINIB

AB	APOTEX INC	20MG	A202103	001	Jun 10, 2016	May NEWA
AB		50MG	A202103	002	Jun 10, 2016	May NEWA
AB		70MG	A202103	003	Jun 10, 2016	May NEWA
AB		100MG	A202103	004	Jun 10, 2016	May NEWA
SPRYCEL						
AB	BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006	May CFTG
AB		50MG	N021986	002	Jun 28, 2006	May CFTG
AB		70MG	N021986	003	Jun 28, 2006	May CFTG
AB	+	100MG	N021986	004	May 30, 2008	May CFTG

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

DAUNOXOME

@ GALEN (UK)

EQ 2MG BASE/ML

N050704	002	Apr 08, 1996	May DISC
---------	-----	--------------	----------

DEFERASIROX

TABLET, FOR SUSPENSION; ORAL

DEFERASIROX

AB	ACTAVIS ELIZABETH	125MG	A203560	001	Jan 26, 2016	Jan NEWA
AB		250MG	A203560	002	Jan 26, 2016	Jan NEWA
AB		500MG	A203560	003	Jan 26, 2016	Jan NEWA
EXJADE						
AB	NOVARTIS	125MG	N021882	001	Nov 02, 2005	Jan CFTG
AB		250MG	N021882	002	Nov 02, 2005	Jan CFTG
AB	+	500MG	N021882	003	Nov 02, 2005	Jan CFTG

DEFIBROTIDE SODIUM

SOLUTION; IV (INFUSION)

DEFITELIO

+ GENTIUM SPA 200MG/2.5ML (80MG/ML)

N208114	001	Mar 30, 2016	Mar NEWA
---------	-----	--------------	----------

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DEMECLOCYCLINE HYDROCHLORIDE

@ IMPAX LABS

150MG

A065094	001	Mar 22, 2004	Mar DISC
---------	-----	--------------	----------

@

300MG

A065094	002	Mar 22, 2004	Mar DISC
---------	-----	--------------	----------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	10MG	A208105	001	Mar 17, 2016	Mar NEWA
AB		25MG	A208105	002	Mar 17, 2016	Mar NEWA
AB		50MG	A208105	003	Mar 17, 2016	Mar NEWA
AB		75MG	A208105	004	Mar 17, 2016	Mar NEWA
AB		100MG	A208105	005	Mar 17, 2016	Mar NEWA

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

AB		150MG	A208105	006	Mar 17, 2016	Mar NEWA
>A>	AB	HERITAGE PHARMS INC 10MG	A207433	001	May 05, 2016	Jun CAHN
>A>	AB	25MG	A207433	002	May 05, 2016	Jun CAHN
>A>	AB	50MG	A207433	003	May 05, 2016	Jun CAHN
>A>	AB	75MG	A207433	004	May 05, 2016	Jun CAHN
>A>	AB	100MG	A207433	005	May 05, 2016	Jun CAHN
>A>	AB	150MG	A207433	006	May 05, 2016	Jun CAHN
>D>	AB	INDICUS PHARMA 10MG	A207433	001	May 05, 2016	Jun CAHN
	AB	10MG	A207433	001	May 05, 2016	Apr NEWA
>D>	AB	25MG	A207433	002	May 05, 2016	Jun CAHN
	AB	25MG	A207433	002	May 05, 2016	Apr NEWA
>D>	AB	50MG	A207433	003	May 05, 2016	Jun CAHN
	AB	50MG	A207433	003	May 05, 2016	Apr NEWA
>D>	AB	75MG	A207433	004	May 05, 2016	Jun CAHN
	AB	75MG	A207433	004	May 05, 2016	Apr NEWA
>D>	AB	100MG	A207433	005	May 05, 2016	Jun CAHN
	AB	100MG	A207433	005	May 05, 2016	Apr NEWA
>D>	AB	150MG	A207433	006	May 05, 2016	Jun CAHN
	AB	150MG	A207433	006	May 05, 2016	Apr NEWA
		NORPRAMIN				
AB		US PHARM HOLDINGS 10MG	N014399	007	Feb 11, 1982	Jan CAHN
AB		25MG	N014399	001		Jan CAHN
AB		50MG	N014399	003		Jan CAHN
AB		75MG	N014399	004		Jan CAHN
AB	+	100MG	N014399	005		Jan CAHN
AB		150MG	N014399	006		Jan CAHN

DESLORATADINE

SOLUTION;ORAL

DESLORATADINE

AA		TARO 0.5MG/ML	A202936	001	May 26, 2016	May NEWA
----	--	---------------	---------	-----	--------------	----------

DESMOPRESSIN ACETATE

TABLET;ORAL

DESMOPRESSIN ACETATE

>D>		FERRING 0.1MG	N021795	001	May 08, 2008	Jun DISC
>A>	@	0.1MG	N021795	001	May 08, 2008	Jun DISC
>D>	+	0.2MG	N021795	002	May 08, 2008	Jun DISC
>A>	@	0.2MG	N021795	002	May 08, 2008	Jun DISC

DESONIDE

CREAM;TOPICAL

DESONIDE

AB		G AND W LABS INC 0.05%	A074027	001	Sep 28, 1992	Jan CAHN
----	--	------------------------	---------	-----	--------------	----------

DESOXIMETASONE

OINTMENT;TOPICAL

DESOXIMETASONE

AB		NOVEL LABS INC 0.25%	A206792	001	May 10, 2016	Apr NEWA
AB		PERRIGO ISRAEL 0.25%	A077770	001	Apr 20, 2015	May CAHN
AB		TELIGENT PHARMA INC 0.25%	A208101	001	Feb 25, 2016	Feb NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

AB		ROXANE EQ 50MG BASE	A204082	001	Feb 16, 2016	Feb NEWA
AB		EQ 100MG BASE	A204083	001	Feb 16, 2016	Feb NEWA

DEXAMETHASONE

TABLET;ORAL

DEXAMETHASONE

@	IDT AUSTRALIA LTD	0.75MG	A080399	001		May CAHN
@	SUN PHARM INDS	0.25MG	A084013	001		Mar CAHN
@		0.25MG	A084764	001		Mar CAHN
@		0.5MG	A084084	001		Mar CAHN
@		0.5MG	A084766	001		Mar CAHN
@		0.75MG	A084081	001		Mar CAHN
@		0.75MG	A084765	001		Mar CAHN
@		1.5MG	A084086	001		Mar CAHN
@		1.5MG	A084763	001		Mar CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP	+	FRESENIUS KABI USA	EQ 10MG PHOSPHATE/ML	A040491	001	Apr 11, 2003	Mar CTNA
----	---	--------------------	----------------------	---------	-----	--------------	----------

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
DEXILANT SOLUTAB

	+	TAKEDA PHARMS USA	30MG	N208056	001	Jan 26, 2016	Jan NEWA
--	---	-------------------	------	---------	-----	--------------	----------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204023	001	Feb 09, 2016	Jan NEWA
AP		AUROBINDO PHARMA LTD	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A205867	001	Mar 17, 2016	Mar NEWA
AP		SANDOZ INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A091465	001	Jun 14, 2016	May NEWA
		PRECEDEX					
	+	HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Feb CRLD

DESMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL
DESMETHYLPHENIDATE HYDROCHLORIDE

AB		SUN PHARM INDS	2.5MG	A201231	001	Sep 24, 2015	Feb CAHN
AB			5MG	A201231	002	Sep 24, 2015	Feb CAHN
AB			10MG	A201231	003	Sep 24, 2015	Feb CAHN

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION
TOTECT

	+	CLINIGEN HLTHCARE	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Mar CAHN
--	---	-------------------	--------------------	---------	-----	--------------	----------

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL
DEXTROAMPHETAMINE SULFATE

AB		MYLAN PHARMS INC	5MG	A206735	001	Jan 27, 2016	Jan NEWA
AB			10MG	A206735	002	Jan 27, 2016	Jan NEWA
AB			15MG	A206735	003	Jan 27, 2016	Jan NEWA

TABLET;ORAL

DEXTROAMPHETAMINE SULFATE

AA		NESHER PHARMS	5MG	A206588	001	Mar 28, 2016	Mar NEWA
AA			10MG	A206588	002	Mar 28, 2016	Mar NEWA
AA		NOVEL LABS INC	5MG	A204330	001	Mar 16, 2016	Feb NEWA
AA			10MG	A204330	002	Mar 16, 2016	Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@ ANI PHARMS	15MG/5ML;6.25MG/5ML	N011265	002	Apr 02, 1984	Feb CMS1
--------------	---------------------	---------	-----	--------------	----------

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE	5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML	N017484	001		Feb CMS1
-----------------	--	---------	-----	--	----------

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	5GM/100ML;205MG/100ML;100MG/100ML;120MG/100ML;220MG/100ML	N018840	001	Jun 29, 1983	Feb CMS1
-------------------	---	---------	-----	--------------	----------

DIAZEPAM

INJECTABLE;INJECTION

DIAZEPAM

@ EUROHLTH INTL SARL	5MG/ML	A070313	001	Dec 16, 1985	Jan CAHN
----------------------	--------	---------	-----	--------------	----------

		SOLUTION;ORAL							
>A>		DIAZEPAM							
>A>	AA	LANNETT HOLDINGS INC	5MG/5ML	A206477	001	Jun 24, 2016	Jun	NEWA	
>D>	+	ROXANE	5MG/5ML	A070928	001	Apr 03, 1987	Jun	CFTG	
>A>	AA	+	5MG/5ML	A070928	001	Apr 03, 1987	Jun	CFTG	
		TABLET;ORAL							
		DIAZEPAM							
		DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985	Jan	NEWA	
			5MG	A070228	003	Sep 26, 1985	Jan	NEWA	
<u>DICLOFENAC POTASSIUM</u>									
		CAPSULE;ORAL							
		DICLOFENAC POTASSIUM							
AB		BIONPHARMA INC	25MG	A204648	001	Feb 23, 2016	Feb	NEWA	
		ZIPSOR							
AB	+	DEPOMED INC	25MG	N022202	001	Jun 16, 2009	Feb	CFTG	
		FOR SOLUTION;ORAL							
		CAMBIA							
AB	+	DEPOMED INC	50MG	N022165	001	Jun 17, 2009	Apr	CFTG	
		DICLOFENAC POTASSIUM							
AB		PAR FORM	50MG	A202964	001	May 02, 2016	Apr	NEWA	
		TABLET;ORAL							
		CATAFLAM							
		@ NOVARTIS	50MG	N020142	002	Nov 24, 1993	Mar	DISC	
		DICLOFENAC POTASSIUM							
>D>		@ MUTUAL PHARM	50MG	A075470	001	Feb 21, 2002	Jun	CAHN	
AB	+	MYLAN	50MG	A075463	001	Jul 26, 1999	Mar	CRLD	
>A>		@ SUN PHARM INDS	50MG	A075470	001	Feb 21, 2002	Jun	CAHN	
<u>DICLOFENAC SODIUM</u>									
		GEL;TOPICAL							
		DICLOFENAC SODIUM							
AB		AMNEAL PHARMS	1%	A208077	001	Mar 18, 2016	Mar	NEWA	
AB		TARO	3%	A206298	001	Apr 28, 2016	Apr	NEWA	
		VOLTAREN							
AB	+	GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Mar	CFTG	
		SOLUTION;TOPICAL							
		DICLOFENAC SODIUM							
AT		TELIGENT PHARMA INC	1.5%	A202769	001	Jul 08, 2015	May	CAHN	
		SOLUTION/DROPS;OPHTHALMIC							
		DICLOFENAC SODIUM							
AT		RIISING PHARMS INC	0.1%	A078553	001	Dec 28, 2007	Jan	CAHN	
		TABLET, EXTENDED RELEASE;ORAL							
		DICLOFENAC SODIUM							
AB	+	ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Feb	CRLD	
		VOLTAREN-XR							
		@ NOVARTIS	100MG	N020254	001	Mar 08, 1996	Feb	DISC	
<u>DICLOFENAC SODIUM; MISOPROSTOL</u>									
		TABLET, DELAYED RELEASE;ORAL							
		DICLOFENAC SODIUM AND MISOPROSTOL							
AB		EXELA PHARMA SCS LLC	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar	CAHN	
AB			75MG;0.2MG	A200540	002	Mar 14, 2014	Mar	CAHN	
<u>DICYCLOMINE HYDROCHLORIDE</u>									
		CAPSULE;ORAL							
		DICYCLOMINE HYDROCHLORIDE							
		@ SUN PHARM INDS	10MG	A084505	001	Oct 21, 1986	Mar	CAHN	
		INJECTABLE;INJECTION							
		DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)							
AP		EUROHLTH INTL SARL	10MG/ML	A040465	001	Jun 30, 2003	Mar	CMS1	
		SYRUP;ORAL							
		BENTYL							
		@ APTALIS PHARMA US	10MG/5ML	N007961	002	Oct 15, 1984	Jan	DISC	
		DICYCLOMINE HYDROCHLORIDE							
		+ MIKART	10MG/5ML	A040169	001	Mar 24, 2005	Jan	CRLD	
		TABLET;ORAL							
		DICYCLOMINE HYDROCHLORIDE							
		@ SUN PHARM INDS	20MG	A084600	001	Jul 29, 1985	Mar	CAHN	

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL

ESTRADIOL VALERATE AND DIENOGEST

AB		WATSON LABS INC	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M G, N/A	A202349	001	May 06, 2016	Apr	NEWA
AB	+	NATAZIA BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M G, N/A	N022252	001	May 06, 2010	Apr	CFTG

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

		@ COREPHARMA	25MG	A040828	001	Nov 05, 2008	Mar	DISC
		TENUATE						
AA	+	ACTAVIS LABS UT INC	25MG	N011722	002		Apr	CAHN
AA	+	ALLERGAN SALES LLC	25MG	N011722	002		Mar	CAHN
		TABLET, EXTENDED RELEASE; ORAL						
		TENUATE DOSPAN						
AB	+	ACTAVIS LABS UT INC	75MG	N012546	001		Apr	CAHN
AB	+	ALLERGAN SALES LLC	75MG	N012546	001		Mar	CAHN

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

		@ IDT AUSTRALIA LTD	500MG	A074604	001	Jun 10, 1996	May	CAHN
--	--	---------------------	-------	---------	-----	--------------	-----	------

DIGOXIN

INJECTABLE; INJECTION

LANOXIN

>D>	AP	+	COVIS INJECTABLES	0.25MG/ML	N009330	002		Jun	CAHN
>A>	AP	+	COVIS PHARMA SARL	0.25MG/ML	N009330	002		Jun	CAHN
			LANOXIN PEDIATRIC						
>D>		+	COVIS INJECTABLES	0.1MG/ML	N009330	004		Jun	CAHN
>A>		+	COVIS PHARMA SARL	0.1MG/ML	N009330	004		Jun	CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

DIHYDROERGOTAMINE MESYLATE

AP		EUROHLTH INTL SARL	1MG/ML	A040453	001	Jun 09, 2003	Apr	CAHN
----	--	--------------------	--------	---------	-----	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

		@ ACTAVIS LABS FL INC	120MG	A074852	001	Oct 10, 1997	Jan	DISC
		@	180MG	A074852	002	Oct 10, 1997	Jan	DISC
		@	240MG	A074852	003	Oct 10, 1997	Jan	DISC
AB3		VALEANT PHARMS NORTH	120MG	A075116	001	Dec 23, 1999	Jan	CAHN
AB3			180MG	A075116	002	Dec 23, 1999	Jan	CAHN
AB3			240MG	A075116	003	Dec 23, 1999	Jan	CAHN
AB3			300MG	A075116	004	Dec 23, 1999	Jan	CAHN

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

>A>	AP	+	AMPHASTAR PHARMS INC	5MG/ML	A074617	001	Feb 28, 1996	Jun	CAHN
>D>	AP	+	EUROHLTH INTL SARL	5MG/ML	A074617	001	Feb 28, 1996	Jun	CAHN
	AP	+		5MG/ML	A074617	001	Feb 28, 1996	Apr	CAHN

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

		+	FERRING PHARMS INC	10MG	N020411	001	Mar 30, 1995	Jan	CAHN
--	--	---	--------------------	------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

>A>		@	HIKMA INTL PHARMS	50MG	A083567	001		Jun	CAHN
>D>		@	HIKMA PHARMS	50MG	A083567	001		Jun	CAHN
		@		50MG	A083567	001		Feb	CAHN
>D>		@	MUTUAL PHARM	50MG	A089489	001	Jan 02, 1987	Jun	CAHN
		@	SUN PHARM INDS	25MG	A089488	001	Jan 02, 1987	Mar	CAHN
>A>		@		50MG	A089489	001	Jan 02, 1987	Jun	CAHN

DIPYRIDAMOLEINJECTABLE;INJECTION
DIPYRIDAMOLE

>A>	AP	+	AMPHASTAR PHARMS INC	5MG/ML	A 074939	001	Apr 13, 1998	Jun	CAHN
>D>	AP	+	EUROHLTH INTL SARL	5MG/ML	A 074939	001	Apr 13, 1998	Jun	CAHN
	AP	+		5MG/ML	A 074939	001	Apr 13, 1998	Apr	CAHN

TABLET;ORAL

DIPYRIDAMOLE

	@	IDT AUSTRALIA LTD	25MG	A 086944	002	Apr 16, 1991	May	CAHN
	@		50MG	A 087562	001	Feb 25, 1992	May	CAHN
	@		75MG	A 087561	001	Feb 25, 1992	May	CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

	@	AUROLIFE PHARMA LLC	EQ 100MG BASE	A 070470	001	Dec 10, 1985	Feb	CAHN
	@		EQ 150MG BASE	A 070471	001	Dec 10, 1985	Feb	CAHN
	@	SUN PHARM INDS	EQ 100MG BASE	A 070351	001	Dec 17, 1985	Mar	CAHN
	@		EQ 150MG BASE	A 070352	001	Dec 17, 1985	Mar	CAHN

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB		ALVOGEN MALTA	250MG	A 091681	001	Aug 08, 2013	Jan	CAHN
----	--	---------------	-------	----------	-----	--------------	-----	------

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

	@	IMPAX LABS	EQ 250MG VALPROIC ACID	A 078791	001	May 06, 2009	Feb	DISC
	@		EQ 500MG VALPROIC ACID	A 078791	002	Aug 04, 2009	Feb	DISC

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

	@	TELIGENT PHARMA INC	EQ 12.5MG BASE/ML	A 074098	001	Feb 21, 1995	Jan	CAHN
--	---	---------------------	-------------------	----------	-----	--------------	-----	------

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

>A>		HOSPIRA INC	20MG/ML (20MG/ML)	N 022234	004	Jun 23, 2016	Jun	NEWA
>A>			80MG/4ML (20MG/ML)	N 022234	005	Jun 23, 2016	Jun	NEWA
>A>			120MG/6ML (20MG/ML)	N 022234	006	Jun 23, 2016	Jun	NEWA

SOLUTION;IV (INFUSION)

DOCETAXEL

		EAGLE PHARMS	20MG/ML (20MG/ML)	N 205934	001	Dec 22, 2015	Jan	CAHN
			80MG/4ML (20MG/ML)	N 205934	002	Dec 22, 2015	Jan	CAHN
			160MG/8ML (20MG/ML)	N 205934	003	Dec 22, 2015	Jan	CAHN

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

AB		TIGER PHARMS LLC	0.125MG	A 207058	001	Jun 06, 2016	May	NEWA
AB			0.25MG	A 207058	002	Jun 06, 2016	May	NEWA
AB			0.5MG	A 207058	003	Jun 06, 2016	May	NEWA

TIKOSYN

AB		PFIZER	0.125MG	N 020931	001	Oct 01, 1999	May	CFTG
AB			0.25MG	N 020931	002	Oct 01, 1999	May	CFTG
AB	+		0.5MG	N 020931	003	Oct 01, 1999	May	CFTG

DOLASETRON MESYLATE

INJECTABLE;INJECTION

ANZEMET

	+	US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N 020624	002	Sep 11, 1997	Jan	CAHN
	+		12.5MG/0.625ML (20MG/ML)	N 020624	002	Sep 11, 1997	Jan	CAHN
	+		100MG/5ML (20MG/ML)	N 020624	001	Sep 11, 1997	Jan	CAHN
>D>	+		500MG/25ML (20MG/ML)	N 020624	003	Dec 11, 2001	Jun	DISC
>A>	@		500MG/25ML (20MG/ML)	N 020624	003	Dec 11, 2001	Jun	DISC
	+		500MG/25ML (20MG/ML)	N 020624	003	Dec 11, 2001	Jan	CAHN

TABLET;ORAL

ANZEMET

US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997	Jan CAHN
+	100MG	N020623	002	Sep 11, 1997	Jan CAHN

DOLUTEGRAVIR SODIUM

TABLET;ORAL

TIVICAY

>A>	VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016	Jun NEWA
>A>		EQ 25MG BASE	N204790	003	Jun 09, 2016	Jun NEWA

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB	DEXCEL PHARMA	23MG	A203713	001	Feb 19, 2016	Feb NEWA
AB	INDICUS PHARMA	23MG	A203419	001	Apr 12, 2016	Mar NEWA
>D> AB	OSMOTICA PHARM CORP	23MG	A203114	001	Jan 26, 2016	Jun CAHN
AB		23MG	A203114	001	Jan 26, 2016	Jan NEWA
>A> AB	OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016	Jun CAHN
>A> AB	UNICHEM LABS LTD	5MG	A203656	001	Jun 23, 2016	Jun NEWA
>A> AB		10MG	A203656	002	Jun 23, 2016	Jun NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

DONEPEZIL HYDROCHLORIDE

@ SUN PHARM INDS	5MG	A077975	002	Dec 11, 2009	Mar CAHN
@	10MG	A077975	001	Dec 11, 2009	Mar CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOXAPRAM HYDROCHLORIDE

>A> AP	AMPHASTAR PHARMS INC	20MG/ML	A076266	001	Jan 10, 2003	Jun CAHN
>D> AP	EUROHLTH INTL SARL	20MG/ML	A076266	001	Jan 10, 2003	Jun CAHN
AP		20MG/ML	A076266	001	Jan 10, 2003	Apr CAHN

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

@ IDT AUSTRALIA LTD	EQ 1MG BASE	A075432	001	Oct 18, 2000	Mar CAHN
@	EQ 2MG BASE	A075432	002	Oct 18, 2000	Mar CAHN
@	EQ 4MG BASE	A075432	003	Oct 18, 2000	Mar CAHN
@	EQ 8MG BASE	A075432	004	Oct 18, 2000	Mar CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

@ SUN PHARM INDS	EQ 25MG BASE	A071502	001	Feb 18, 1988	Mar CAHN
@	EQ 50MG BASE	A071653	001	Feb 18, 1988	Mar CAHN
@	EQ 75MG BASE	A071654	001	Feb 18, 1988	Mar CAHN
@	EQ 100MG BASE	A071521	001	Feb 18, 1988	Mar CAHN

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan NEWA
AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan NEWA

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP	AKORN INC	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016	Mar NEWA
AP	HECTOROL					
AP	GENZYME CORP	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000	Mar CFTG

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ACTAVIS INC	2MG/ML	A203622	001	Jun 27, 2014	May CRLD	
AP		200MG/100ML	A203622	002	Jun 27, 2014	May CRLD	
AP	+	PHARMACIA AND UPJOHN	2MG/ML	N050629	001	Dec 23, 1987	May CRLD
AP	+		200MG/100ML	N050629	002	May 03, 1988	May CRLD

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB	G AND W LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	Mar CAHN
AB		EQ 75MG BASE	A204446	002	May 28, 2015	Mar CAHN
AB		EQ 100MG BASE	A204446	003	May 28, 2015	Mar CAHN
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A205115	001	Feb 18, 2016	Feb NEWA
AB		EQ 75MG BASE	A205115	002	Feb 18, 2016	Feb NEWA
AB		EQ 100MG BASE	A205115	003	Feb 18, 2016	Feb NEWA

TABLET;ORAL

DOXYCYCLINE

>D>	@ MUTUAL PHARM	EQ 50MG BASE	A065471	001	Apr 17, 2009	Jun CAHN
>D>	@	EQ 75MG BASE	A065471	002	Apr 17, 2009	Jun CAHN
>D>	@	EQ 100MG BASE	A065471	003	Apr 17, 2009	Jun CAHN
>A>	@ SUN PHARM INDS	EQ 50MG BASE	A065471	001	Apr 17, 2009	Jun CAHN
>A>	@	EQ 75MG BASE	A065471	002	Apr 17, 2009	Jun CAHN
>A>	@	EQ 100MG BASE	A065471	003	Apr 17, 2009	Jun CAHN

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

ACTICLATE CAP

	+ AQUA PHARMS	EQ 75MG BASE	N208253	001	Apr 26, 2016	Apr NEWA
--	---------------	--------------	---------	-----	--------------	----------

DOXYCYCLINE HYCLATE

>A>	AB	AMNEAL PHARMS	EQ 100MG BASE	A207289	001	Jun 27, 2016	Jun NEWA
	AB	SUN PHARM INDS	EQ 100MG BASE	A062676	001	Jul 10, 1986	Mar CAHN

TABLET;ORAL

DOXYCYCLINE HYCLATE

	@ COREPHARMA	EQ 20MG BASE	A065182	001	May 13, 2005	Mar DISC
AB	SUN PHARM INDS	EQ 20MG BASE	A065134	001	May 13, 2005	Mar CAHN
AB		EQ 100MG BASE	A062677	001	Jul 10, 1986	Mar CAHN
	@ VINTAGE PHARMS	EQ 100MG BASE	A062538	001	Apr 07, 1986	Mar DISC

TABLET, DELAYED RELEASE;ORAL

DORYX

AB	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr CFTG
AB	+ DOXYCYCLINE HYCLATE	EQ 200MG BASE	N050795	005	Apr 11, 2013	May CFTG
	@ IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010	Mar DISC
	@	EQ 100MG BASE	A090505	002	Dec 28, 2010	Mar DISC
AB	MYLAN	EQ 50MG BASE	A090431	003	May 23, 2016	May NEWA
AB		EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr NEWA
AB		EQ 200MG BASE	A090431	005	May 19, 2016	May NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

MELAMISA

AB	NOVAST LABS LTD	3MG;0.02MG	A202016	001	Jan 26, 2016	Jan NEWA
----	-----------------	------------	---------	-----	--------------	----------

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	GLENMARK PHARMS LTD	3MG;0.03MG	A204848	001	Mar 25, 2016	Mar NEWA
----	---------------------	------------	---------	-----	--------------	----------

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

AB	AUROLIFE PHARMA LLC	0.5MG	A202660	001	Nov 20, 2015	Apr CAHN
AB	BIONPHARMA INC	0.5MG	A200899	001	Nov 20, 2015	Jan CAHN
AB	INTERGEL PHARMS INC	0.5MG	A206373	001	Mar 17, 2016	Feb NEWA
AB	MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016	May NEWA
AB	STRIDES PHARMA	0.5MG	A204262	001	Nov 20, 2015	Mar CAHN

DYPHYLLINE

TABLET;ORAL

LUFYLLIN

>D>	MEDA PHARMS	200MG	A084566	001		Jun DISC
>A>	@	200MG	A084566	001		Jun DISC
>D>	+	400MG	A084566	002		Jun DISC
>A>	@	400MG	A084566	002		Jun DISC

ECONAZOLE NITRATECREAM; TOPICAL
ECONAZOLE NITRATE

AB		TELIGENT PHARMA INC	1%	A076574	001	Dec 17, 2004	May CAHN
----	--	---------------------	----	---------	-----	--------------	----------

EDROPHONIUM CHLORIDEINJECTABLE; INJECTION
TENSILON

	@	TELIGENT PHARMA INC	10MG/ML	N007959	001		Jan CAHN
--	---	---------------------	---------	---------	-----	--	----------

TENSILON PRESERVATIVE FREE

	@	TELIGENT PHARMA INC	10MG/ML	N007959	002		Jan CAHN
--	---	---------------------	---------	---------	-----	--	----------

EFAVIRENZTABLET; ORAL
EFAVIRENZ

>D>	AB	MYLAN LABS LTD	600MG	A091471	001	Feb 17, 2016	Jun CAHN
-----	----	----------------	-------	---------	-----	--------------	----------

AB			600MG	A091471	001	Feb 17, 2016	Feb NEWA
----	--	--	-------	---------	-----	--------------	----------

>A>	AB	MYLAN PHARMS INC	600MG	A091471	001	Feb 17, 2016	Jun CAHN
-----	----	------------------	-------	---------	-----	--------------	----------

SUSTIVA

AB	+	BRISTOL MYERS SQUIBB	600MG	N021360	002	Feb 01, 2002	Feb CFTG
----	---	----------------------	-------	---------	-----	--------------	----------

ELBASVIR; GRAZOPREVRTABLET; ORAL
ZEPATIER

+	MERCK SHARP DOHME	50MG;100MG	N208261	001	Jan 28, 2016	Jan NEWA
---	-------------------	------------	---------	-----	--------------	----------

ELUXADOLINETABLET; ORAL
VIBERZI

	ALLERGAN HOLDINGS	75MG	N206940	001	May 27, 2015	May CAHN
--	-------------------	------	---------	-----	--------------	----------

+		100MG	N206940	002	May 27, 2015	May CAHN
---	--	-------	---------	-----	--------------	----------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATETABLET; ORAL
ODEFSEY

+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Apr CAIN
---	---------------------	---------------------------------	---------	-----	--------------	----------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
ODEFSEY

+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;EQ 25MG BASE	N208351	001	Mar 01, 2016	Mar NEWA
---	---------------------	---------------------------------	---------	-----	--------------	----------

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATETABLET; ORAL
DESCOVY

+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE	N208215	001	Apr 04, 2016	Apr NEWA
---	---------------------	--------------------	---------	-----	--------------	----------

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
TRUVADA

	GILEAD	100MG;150MG	N021752	002	Mar 10, 2016	Mar NEWA
--	--------	-------------	---------	-----	--------------	----------

		133MG;200MG	N021752	003	Mar 10, 2016	Mar NEWA
--	--	-------------	---------	-----	--------------	----------

		167MG;250MG	N021752	004	Mar 10, 2016	Mar NEWA
--	--	-------------	---------	-----	--------------	----------

ENALAPRILATINJECTABLE; INJECTION
ENALAPRILAT

>A>	AP	+	AMPHASTAR PHARMS INC	1.25MG/ML	A075634	001	Aug 22, 2000	Jun CAHN
-----	----	---	----------------------	-----------	---------	-----	--------------	----------

>D>	AP	+	EUROHLTH INTL SARL	1.25MG/ML	A075634	001	Aug 22, 2000	Jun CAHN
-----	----	---	--------------------	-----------	---------	-----	--------------	----------

AP	+		1.25MG/ML	A075634	001	Aug 22, 2000	Apr CAHN
----	---	--	-----------	---------	-----	--------------	----------

EPHEDRINE SULFATESOLUTION; INTRAVENOUS
AKOVAZ

+	FLAMEL IRELAND LTD	50MG/ML	N208289	001	Apr 29, 2016	Apr NEWA
---	--------------------	---------	---------	-----	--------------	----------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC						
EPINASTINE HYDROCHLORIDE						
AT	SOMERSET THERAPS LLC	0.05%	A090951	001	Oct 31, 2011	Mar CAHN

EPINEPHRINE

INJECTABLE;INJECTION						
SUS-PHRINE SULFITE FREE						
	@ FOREST LABS	1.5MG/AMP	N007942	003	Feb 05, 1999	Mar CMS1
	@	5MG/ML	N007942	001		Mar CMS1
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS						
AUVI-Q						
BX	+ KALEO INC	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012	Mar CAHN
BX		EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012	Mar CAHN
	TWINJECT 0.15					
	@ AMEDRA PHARMS	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	May DISC
	TWINJECT 0.3					
	@ AMEDRA PHARMS	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	May DISC

EPINEPHRINE HYDROCHLORIDE

SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS						
EPINEPHRINE						
	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Feb CDFR

ERGOCALCIFEROL

CAPSULE;ORAL						
DRISDOL						
AA	+ US PHARM HOLDINGS	50,000 IU	N003444	001		Jan CAHN
	VITAMIN D					
AA	BIONPHARMA INC	50,000 IU	A080704	001		Jan CAHN

ERGOLOID MESYLATES

TABLET;ORAL						
ERGOLOID MESYLATES						
AB	SUN PHARM INDS	1MG	A081113	001	Oct 31, 1991	Mar CAHN
TABLET;SUBLINGUAL						
ERGOLOID MESYLATES						
>D>	@ MUTUAL PHARM	0.5MG	A087407	001		Jun CAHN
>D>	@	1MG	A087552	001		Jun CAHN
>A>	@ SUN PHARM INDS	0.5MG	A087407	001		Jun CAHN
>A>	@	1MG	A087552	001		Jun CAHN

ERYTHROMYCIN

SOLUTION;TOPICAL						
C-SOLVE-2						
	@ FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Feb DISC
ERYTHRO-STATIN						
	@ HI TECH PHARMA	2%	A064101	001	Oct 22, 1996	Feb DISC
ERYTHROMYCIN						
AT	+ FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997	Jan CRLD
AT	PERRIGO NEW YORK	2%	A063038	001	Jan 11, 1991	Jan CRLD

ESCITALOPRAM OXALATE

SOLUTION;ORAL						
ESCITALOPRAM OXALATE						
AA	MACLEODS PHARMS LTD	EQ 5MG BASE/5ML	A202754	001	Mar 31, 2016	Mar NEWA

ESMOLOL HYDROCHLORIDE

SOLUTION;INTRAVENOUS						
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER						
	+ HQ SPCLT PHARMA	2GM/100ML (20MG/ML)	N205703	002	Apr 07, 2016	Apr NEWA
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER						
>D>	HQ SPCLT PHARMA	2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Jun CRLD
>A>	+	2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Jun CRLD
		2.5GM/250ML (10MG/ML)	N205703	001	Apr 07, 2016	Apr NEWA

ESOMEPRAZOLE MAGNESIUMCAPSULE, DELAYED REL PELLETS;ORAL
ESOMEPRAZOLE MAGNESIUM

AB	AUROBINDO PHARMA LTD	EQ 20MG BASE	A205606	001	Apr 21, 2016	Apr NEWA
AB		EQ 40MG BASE	A205606	002	Apr 21, 2016	Apr NEWA
BX	HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Apr CTEC
BX		EQ 40MG BASE	A202784	002	Sep 21, 2015	Apr CTEC

ESTRADIOLCREAM;VAGINAL
ESTRACE

+ ALLERGAN SALES LLC 0.01%

A086069 001 Jan 31, 1984 Apr CAHN

FILM, EXTENDED RELEASE;TRANSDERMAL
ALORA

BX	ALLERGAN SALES LLC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar CAHN
BX		0.05MG/24HR	N020655	001	Dec 20, 1996	Mar CAHN
BX		0.075MG/24HR	N020655	002	Dec 20, 1996	Mar CAHN
BX		0.1MG/24HR	N020655	003	Dec 20, 1996	Mar CAHN

ESTRADIOL ACETATEINSERT, EXTENDED RELEASE;VAGINAL
FEMRING+ APIL EQ 0.05MG BASE/24HR
EQ 0.1MG BASE/24HR

N021367	001	Mar 20, 2003	Jan CAHN
N021367	002	Mar 20, 2003	Jan CAHN

TABLET;ORAL
FEMTRACE+ APIL 0.45MG
0.9MG
1.8MG

N021633	001	Aug 20, 2004	Jan CAHN
N021633	002	Aug 20, 2004	Jan CAHN
N021633	003	Aug 20, 2004	Jan CAHN

ESTRADIOL HEMIHYDRATEEMULSION;TOPICAL
ESTRASORB

>A>	+	EXELTIS USA INC	0.25%	N021371	001	Oct 09, 2003	Jun CAHN
>D>	+	MEDICIS	0.25%	N021371	001	Oct 09, 2003	Jun CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

>A>	AMABELZ						
>A>	AB	LUPIN LTD	0.5MG;0.1MG	A203339	001	Jun 20, 2016	Jun NEWA
>A>	AB		1MG;0.5MG	A203339	002	Jun 20, 2016	Jun NEWA

>D> ESTROGENS, CONJUGATED SYNTHETIC A

TABLET;ORAL

>D>	CENESTIN						
>D>	TEVA BRANDED PHARM	0.3MG		N020992	001	Jun 21, 2002	Jun DISC
>A>	@	0.3MG		N020992	001	Jun 21, 2002	Jun DISC
>D>		0.45MG		N020992	005	Feb 05, 2004	Jun DISC
>A>	@	0.45MG		N020992	005	Feb 05, 2004	Jun DISC
>D>		0.625MG		N020992	002	Mar 24, 1999	Jun DISC
>A>	@	0.625MG		N020992	002	Mar 24, 1999	Jun DISC
>D>		0.9MG		N020992	003	Mar 24, 1999	Jun DISC
>A>	@	0.9MG		N020992	003	Mar 24, 1999	Jun DISC
>D>	+	1.25MG		N020992	004	Mar 13, 2000	Jun DISC
>A>	@	1.25MG		N020992	004	Mar 13, 2000	Jun DISC

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL

>D>	ENJUVIA						
>D>	TEVA WOMENS	0.625MG		N021443	003	May 10, 2004	Jun DISC
>A>	@	0.625MG		N021443	003	May 10, 2004	Jun DISC

ETHACRYNIC ACIDTABLET;ORAL
EDECRIN

>D>	+	ATON	25MG	N016092	001		Jun CFTG
>A>	AB	+	25MG	N016092	001		Jun CFTG
>A>		ETHACRYNIC ACID					
>A>	AB	EDENBRIDGE PHARMS	25MG	A205609	001	Jun 30, 2016	Jun NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB	JAI PHARMA LTD	0.05MG;1MG	A204704	001	Feb 09, 2016	Jan NEWA
	ZOVIA 1/50E-28					
AB	+ WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991	Jan CTEC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

FAYOSIM

AB	LUPIN LTD	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	A205943	001	Mar 29, 2016	Mar NEWA
	QUARTETTE					
AB	+ TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar CFTG

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1	AMNEAL PHARMS	0.02MG;0.1MG	A201108	001	Feb 05, 2014	May CAHN
-----	---------------	--------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BREVICON 21-DAY

@ ALLERGAN SALES LLC

0.035MG;0.5MG

N017566 001

Apr CAHN

NORINYL 1+35 21-DAY

AB	ALLERGAN SALES LLC	0.035MG;1MG	N017565	001		Mar CAHN
----	--------------------	-------------	---------	-----	--	----------

TABLET; ORAL-28

BREVICON 28-DAY

AB	ALLERGAN SALES LLC	0.035MG;0.5MG	N017743	001		Mar CAHN
----	--------------------	---------------	---------	-----	--	----------

NORINYL 1+35 28-DAY

AB	ALLERGAN SALES LLC	0.035MG;1MG	N017565	002		Mar CAHN
----	--------------------	-------------	---------	-----	--	----------

TABLET, CHEWABLE; ORAL

FEMCON FE

AB	+ APIL	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Jan CAHN
----	--------	---------------	---------	-----	--------------	----------

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	+ APIL	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jan CAHN
----	--------	---------------	---------	-----	--------------	----------

AB	LUPIN LTD	0.035MG;0.4MG	A091332	001	Mar 23, 2016	Mar NEWA
----	-----------	---------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

@ APIL

0.02MG;1MG

N204426 001 Apr 19, 2013 Apr CAHN

TABLET; ORAL

FEMHRT

AB	APIL	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Jan CAHN
----	------	----------------	---------	-----	--------------	----------

@

0.005MG;1MG

N021065 002 Oct 15, 1999 Jan CAHN

LERIBANE

AB	NOVAST LABS LTD	0.0025MG;0.5MG	A203435	002	Jun 03, 2016	May NEWA
----	-----------------	----------------	---------	-----	--------------	----------

AB		0.005MG;1MG	A203435	001	Jun 03, 2016	May NEWA
----	--	-------------	---------	-----	--------------	----------

LO LOESTRIN FE

AB	+ APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	May CFTG
----	--------	-----------------------	---------	-----	--------------	----------

+ 0.01MG,0.01MG;1MG,N/A

N022501 001 Oct 21, 2010 Jan CAHN

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	JAI PHARMA LTD	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016	May NEWA
----	----------------	-----------------------	---------	-----	--------------	----------

TABLET; ORAL-21

ESTROSTEP 21

@ APIL

0.02MG,0.03MG,0.035MG;1MG,1MG,1MG

N020130 001 Oct 09, 1996 Jan CAHN

LOESTRIN 21 1.5/30

AB	APIL	0.03MG;1.5MG	N017875	001		Apr CAHN
----	------	--------------	---------	-----	--	----------

LOESTRIN 21 1/20

AB	APIL	0.02MG;1MG	N017876	001		Apr CAHN
----	------	------------	---------	-----	--	----------

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	GLENMARK PHARMS LTD	0.02MG;1MG	A206969	001	Jan 20, 2016	Jan NEWA
----	---------------------	------------	---------	-----	--------------	----------

TABLET; ORAL-28

ESTROSTEP FE

AB	+ APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996	Jan CAHN
----	--------	-----------------------------------	---------	-----	--------------	----------

LOESTRIN FE 1.5/30

AB	+ APIL	0.03MG;1.5MG	N017355	001		Apr CAHN
----	--------	--------------	---------	-----	--	----------

LOESTRIN FE 1/20

AB	APIL	0.02MG;1MG	N017354	001		Apr CAHN
----	------	------------	---------	-----	--	----------

TABLET, CHEWABLE;ORAL
MIBELAS 24 FE

AB	LUPIN ATLANTIS	0.02MG;1MG	A206287	001	May 24, 2016	May NEWA
----	----------------	------------	---------	-----	--------------	----------

MINASTRIN 24 FE

AB	+ APIL	0.02MG;1MG	N203667	001	May 08, 2013	May CFTG
	+	0.02MG;1MG	N203667	001	May 08, 2013	Jan CAHN

TABLET, CHEWABLE, TABLET;ORAL
LO MINASTRIN FE

+	APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jan CAHN
---	------	-------------------------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

>A>	MILI					
>A>	AB AUROBINDO PHARMA LTD	0.035MG;0.25MG	A205449	001	Jul 07, 2016	Jun NEWA
	NORGESTIMATE AND ETHINYL ESTRADIOL					
	AB AMNEAL PHARMS	0.035MG;0.25MG	A203865	001	Oct 27, 2015	May CAHN
>A>	AB GLENMARK PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A204057	001	Feb 23, 2016	Jun CAHN
		15MG,0.25MG				
>D>	AB GLENMARK PHARMS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A204057	001	Feb 23, 2016	Jun CAHN
		15MG,0.25MG				
	AB	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A204057	001	Feb 23, 2016	Feb NEWA
		15MG,0.25MG				
	AB HAUPT PHARMA	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A203873	001	May 12, 2016	May NEWA
		15MG,0.25MG				
	AB JAI PHARMA LTD	0.035MG, 0.035MG, 0.035MG;0.18MG,	A201897	001	Jan 27, 2016	Jan NEWA
		0.215MG, 0.25MG				
	AB	0.035MG;0.25MG	A201896	001	Jan 27, 2016	Jan NEWA
	AB LUPIN LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A205588	001	Apr 26, 2016	Apr NEWA
		15MG,0.25MG				
>A>	TRI-MILI					
>A>	AB AUROBINDO PHARMA LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A205441	001	Jul 06, 2016	Jun NEWA
		15MG,0.25MG				

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21

LO/OVRAL

>A>	@ PELAGIUS	0.03MG;0.3MG	N017612	001		Jun CAHN
>D>	@ WYETH PHARMS INC	0.03MG;0.3MG	N017612	001		Jun CAHN

TABLET;ORAL-28

LO/OVRAL-28

>D>	AB WYETH PHARMS	0.03MG;0.3MG	N017802	001		Jun DISC
>A>	@	0.03MG;0.3MG	N017802	001		Jun DISC
>A>	NORGESTREL AND ETHINYL ESTRADIOL					
>A>	AB JAI PHARMA LTD	0.03MG;0.3MG	A201828	001	Jun 21, 2016	Jun NEWA

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB	BIONPHARMA INC	250MG	A040430	001	Oct 28, 2002	Jan CAHN
----	----------------	-------	---------	-----	--------------	----------

ETIDRONATE DISODIUM

TABLET;ORAL

DIDRONEL

AB	APIL	200MG	N017831	001		Apr CAHN
AB	+	400MG	N017831	002		Apr CAHN

ETODOLAC

CAPSULE;ORAL

ETODOLAC

@	IDT AUSTRALIA LTD	200MG	A074840	001	Aug 29, 1997	May CAHN
@		300MG	A074840	002	Aug 29, 1997	May CAHN
@	LEHIGH VALLEY	300MG	A074929	001	Jan 30, 1998	Feb CAHN

ETOMIDATE

INJECTABLE;INJECTION

ETOMIDATE

AP	EUROHLTH INTL SARL	2MG/ML	A074593	001	Nov 04, 1996	Apr CAHN
AP	HIKMA FARMACEUTICA	2MG/ML	A202354	001	Feb 25, 2016	Feb NEWA

EXEMESTANETABLET; ORAL
EXEMESTANE

AB	ALVOGEN MALTA	25MG	A200898	001	Jul 28, 2014	Jan CAHN
----	---------------	------	---------	-----	--------------	----------

EXENATIDE SYNTHETICFOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS
BYDUREON PEN

+	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014	Feb NEWA
---	----------------	-----	---------	-----	--------------	----------

FAMOTIDINEINJECTABLE; INJECTION
FAMOTIDINE

>A>	AP	AMPHASTAR PHARMS INC	10MG/ML	A075651	001	Apr 16, 2001	Jun CAHN
>A>	AP		10MG/ML	A075684	001	Apr 16, 2001	Jun CAHN
>D>	AP	EUROHLTH INTL SARL	10MG/ML	A075651	001	Apr 16, 2001	Jun CAHN
	AP		10MG/ML	A075651	001	Apr 16, 2001	Apr CAHN
>D>	AP		10MG/ML	A075684	001	Apr 16, 2001	Jun CAHN
	AP		10MG/ML	A075684	001	Apr 16, 2001	Apr CAHN

FAMOTIDINE PRESERVATIVE FREE

>A>	AP	AMPHASTAR PHARMS INC	10MG/ML	A075622	001	Apr 16, 2001	Jun CAHN
>A>	AP		10MG/ML	A075825	001	Apr 17, 2001	Jun CAHN
>D>	AP	EUROHLTH INTL SARL	10MG/ML	A075622	001	Apr 16, 2001	Jun CAHN
	AP		10MG/ML	A075622	001	Apr 16, 2001	Apr CAHN
>D>	AP		10MG/ML	A075825	001	Apr 17, 2001	Jun CAHN
	AP		10MG/ML	A075825	001	Apr 17, 2001	Apr CAHN

TABLET; ORAL

FAMOTIDINE

@ SUN PHARM INDS

@

20MG

40MG

A075639 002 Dec 12, 2001 Mar CAHN

A075639 001 Dec 12, 2001 Mar CAHN

FELODIPINETABLET, EXTENDED RELEASE; ORAL
FELODIPINE

AB	SUN PHARM INDS	2.5MG	A075896	001	Nov 02, 2004	Mar CAHN
AB		5MG	A075896	002	Nov 02, 2004	Mar CAHN
AB		10MG	A075896	003	Nov 02, 2004	Mar CAHN

FENOFIBRATE

TABLET; ORAL

FENOFIBRATE

AB	AUROBINDO PHARMA LTD	48MG	A205118	001	May 05, 2016	Apr NEWA	
AB		145MG	A205118	002	May 05, 2016	Apr NEWA	
>A>	AB	HETERO LABS LTD III	48MG	A204598	001	Jul 12, 2016	Jun NEWA
>A>	AB		145MG	A204598	002	Jul 12, 2016	Jun NEWA
>A>	AB	MYLAN	40MG	A204475	001	Jun 23, 2016	Jun NEWA
>A>	AB		120MG	A204475	002	Jun 23, 2016	Jun NEWA

FENOGLIDE

>D>		SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Jun CFTG
>A>	AB		40MG	N022118	001	Aug 10, 2007	Jun CFTG
>D>	+		120MG	N022118	002	Aug 10, 2007	Jun CFTG
>A>	AB	+	120MG	N022118	002	Aug 10, 2007	Jun CFTG

FENOFIBRIC ACID

TABLET; ORAL

FIBRICOR

>D>		ARALENZ PHARMS	35MG	N022418	001	Aug 14, 2009	Jun CAHN
			35MG	N022418	001	Aug 14, 2009	Apr CAHN
>D>	+		105MG	N022418	002	Aug 14, 2009	Jun CAHN
	+		105MG	N022418	002	Aug 14, 2009	Apr CAHN
>A>		ARALEZ PHARMS INC	35MG	N022418	001	Aug 14, 2009	Jun CAHN
>A>	+		105MG	N022418	002	Aug 14, 2009	Jun CAHN

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

@ AUROLIFE PHARMA LLC

@

EQ 200MG BASE

EQ 300MG BASE

A072394 001 Oct 17, 1988 Mar CAHN

A072395 001 Oct 17, 1988 Feb CAHN

TABLET; ORAL

FENOPROFEN CALCIUM

@ AUROLIFE PHARMA LLC

EQ 600MG BASE

A072396 001 Oct 17, 1988 Feb CAHN

TABLET;ORAL

FENOPROFEN CALCIUM

@ SUN PHARM INDS	EQ 600MG BASE	A072902	001	Dec 21, 1990	Mar CAHN
------------------	---------------	---------	-----	--------------	----------

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-12

AB	AVEVA	12.5MCG/HR	A077449	005	Sep 11, 2015	Jan NEWA
----	-------	------------	---------	-----	--------------	----------

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION;INTRAVENOUS

TRIFERIC

+	ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016	Apr NEWA
---	----------------------	-------------------	---------	-----	--------------	----------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

@ ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	Jan DISC
------------------	-----	---------	-----	--------------	----------

@	8MG	A204827	002	Dec 10, 2015	Jan DISC
---	-----	---------	-----	--------------	----------

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ BARR	60MG;120MG	A076236	001	Apr 14, 2005	Mar DISC
--------	------------	---------	-----	--------------	----------

@ IMPAX PHARMS	60MG;120MG	A076298	001	Nov 12, 2010	Mar DISC
----------------	------------	---------	-----	--------------	----------

FLAVOXATE HYDROCHLORIDE

TABLET;ORAL

FLAVOXATE HYDROCHLORIDE

@ IMPAX PHARMS	100MG	A076234	001	Aug 28, 2003	Mar DISC
----------------	-------	---------	-----	--------------	----------

FLECAINIDE ACETATE

TABLET;ORAL

FLECAINIDE ACETATE

@ IDT AUSTRALIA LTD	50MG	A076030	001	Oct 28, 2002	May CAHN
---------------------	------	---------	-----	--------------	----------

@	100MG	A076030	002	Oct 28, 2002	May CAHN
---	-------	---------	-----	--------------	----------

@	150MG	A076030	003	Oct 28, 2002	May CAHN
---	-------	---------	-----	--------------	----------

FLUCICLOVINE F-18

SOLUTION;INTRAVENOUS

AXUMIN

+	BLUE EARTH	9-221mCi/ML	N208054	001	May 27, 2016	May NEWA
---	------------	-------------	---------	-----	--------------	----------

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

@ SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Feb DISC
----------------------	----------	---------	-----	--------------	----------

@	200MG/5ML	A076332	002	Jul 29, 2004	Feb DISC
---	-----------	---------	-----	--------------	----------

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

EUROHLTH INTL SARL	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Apr CAHN
--------------------	---------------------	---------	-----	--------------	----------

AP		200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Apr CAHN
----	--	----------------------	---------	-----	--------------	----------

AP		400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Apr CAHN
----	--	----------------------	---------	-----	--------------	----------

@ TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	Jan DISC
-------------------	----------------------	---------	-----	--------------	----------

@	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	Jan DISC
---	----------------------	---------	-----	--------------	----------

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar CMS1
----	--------------------	----------------------	---------	-----	--------------	----------

AP		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar CMS1
----	--	----------------------	---------	-----	--------------	----------

>D> AP	BEDFORD LABS	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jun CAHN
--------	--------------	----------------------	---------	-----	--------------	----------

>D> AP		400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jun CAHN
--------	--	----------------------	---------	-----	--------------	----------

>A> AP	EUROHLTH INTL SARL	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jun CAHN
--------	--------------------	----------------------	---------	-----	--------------	----------

>A> AP		400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jun CAHN
--------	--	----------------------	---------	-----	--------------	----------

TABLET;ORAL

FLUCONAZOLE

@ IDT AUSTRALIA LTD	50MG	A076086	001	Jul 29, 2004	May CAHN
---------------------	------	---------	-----	--------------	----------

@	100MG	A076086	002	Jul 29, 2004	May CAHN
---	-------	---------	-----	--------------	----------

@	150MG	A076086	003	Jul 29, 2004	May CAHN
---	-------	---------	-----	--------------	----------

@	200MG	A076086	004	Jul 29, 2004	May CAHN
---	-------	---------	-----	--------------	----------

FLUDEOXYGLUCOSE F-18INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP	KREITCHMAN PET CTR	10-100mCi/ML	A203942	001	Apr 11, 2016	Mar NEWA
AP	+ QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Mar CTEC
AP	ZEVACOR PHARMA INC	20-300mCi/ML	A203591	001	Aug 31, 2015	Feb CAHN

FLUMAZENILINJECTABLE; INJECTION
FLUMAZENIL

AP	EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Apr CAHN
AP		1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Apr CAHN

FLUOCINOLONE ACETONIDEOIL; TOPICAL
FLUOCINOLONE ACETONIDE

AT	LYNE	0.01%	A090982	001	Apr 25, 2016	Apr NEWA
AT		0.01%	A203377	001	Apr 25, 2016	Apr NEWA
AT	TARO	0.01%	A202368	001	May 19, 2016	May NEWA
AT		0.01%	A209336	001	May 19, 2016	May NEWA

OIL/DROPS; OTIC
FLUOCINOLONE ACETONIDE

AT	LYNE	0.01%	A203378	001	Apr 25, 2016	Apr NEWA
----	------	-------	---------	-----	--------------	----------

FLUOROURACILINJECTABLE; INJECTION
FLUOROURACIL

AP	SAGENT PHARMS	2.5GM/50ML (50MG/ML)	A203609	001	Feb 17, 2016	Feb NEWA
AP		5GM/100ML (50MG/ML)	A203609	002	Feb 17, 2016	Feb NEWA
	@ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan CAHN

FLUOXETINE HYDROCHLORIDECAPSULE; ORAL
FLUOXETINE

@	SUN PHARM INDS	EQ 10MG BASE	A075787	001	Jan 29, 2002	Mar CAHN
@		EQ 20MG BASE	A075787	002	Jan 29, 2002	Mar CAHN

TABLET; ORAL
FLUOXETINE HYDROCHLORIDE

+	EDGEMONT PHARMS LLC	EQ 60MG BASE	N202133	001	Oct 06, 2011	Mar CRLD
	SARAFEM					
AB1	APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Jan CAHN
AB1		EQ 15MG BASE	N021860	002	May 19, 2006	Jan CAHN
AB1	+	EQ 20MG BASE	N021860	003	May 19, 2006	Jan CAHN

FLURANDRENOLIDECREAM; TOPICAL
CORDRAN SP

AT	+ AQUA PHARMS	0.05%	N012806	002		Mar CFTG
----	---------------	-------	---------	-----	--	----------

FLURANDRENOLIDE

AT	TELIGENT PHARMA INC	0.05%	A205342	001	Apr 13, 2016	Mar NEWA
----	---------------------	-------	---------	-----	--------------	----------

TAPE; TOPICAL
CORDRAN

+	ALLERGAN SALES LLC	0.004MG/SQ CM	N016455	001		Apr CAHN
---	--------------------	---------------	---------	-----	--	----------

FLURANDRENOLIDE; NEOMYCIN SULFATECREAM; TOPICAL
CORDRAN N

@	LILLY	0.05%; EQ 3.5MG BASE/GM	N050346	001		Mar CMS1
---	-------	-------------------------	---------	-----	--	----------

OINTMENT; TOPICAL
CORDRAN N

@	LILLY	0.05%; EQ 3.5MG BASE/GM	N050345	001		Mar CMS1
---	-------	-------------------------	---------	-----	--	----------

FLURAZEPAM HYDROCHLORIDECAPSULE; ORAL
FLURAZEPAM HYDROCHLORIDE

@	AUROLIFE PHARMA LLC	15MG	A071716	001	Jul 31, 1991	Feb CAHN
@		30MG	A071717	001	Jul 31, 1991	Feb CAHN
@	HIKMA INTL PHARMS	15MG	A071107	001	Dec 08, 1986	May CAHN
@	SUN PHARM INDS	15MG	A070454	001	Aug 04, 1986	Mar CAHN
@		30MG	A070455	001	Aug 04, 1986	Mar CAHN

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

@ AUROLIFE PHARMA LLC

50MG

A074448 001 Jul 28, 1995 Feb CAHN

@

100MG

A074448 002 Jul 28, 1995 Feb CAHN

FLUTICASONE FUROATE

POWDER; INHALATION

ARNUITY ELLIPTA

+ GLAXOSMITHKLINE

0.1MG/INH

N205625 001 Aug 20, 2014 Mar CRLD

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREQ ELLIPTA

+ GLAXO GRP LTD

0.2MG/INH; EQ 0.025MG BASE/INH

N204275 002 Apr 30, 2015 Mar CRLD

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

FLONASE

>D>

>D> AB

+ GLAXOSMITHKLINE

0.05MG/SPRAY

N020121 001 Oct 19, 1994 Jun DISC

>A>

@

0.05MG/SPRAY

N020121 001 Oct 19, 1994 Jun DISC

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE; ORAL

FLUVASTATIN SODIUM

AB MYLAN PHARMS INC

EQ 80MG BASE

A202458 001 Sep 11, 2015 May CPOT

AB TEVA PHARMS USA

EQ 80MG BASE

A079011 001 Jan 27, 2016 May CPOT

AB

80MG

A079011 001 Jan 27, 2016 Jan NEWA

LESCOL XL

AB + NOVARTIS

EQ 80MG BASE

N021192 001 Oct 06, 2000 May CPOT

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@ NOSTRUM LABS INC

25MG

A075900 001 Feb 23, 2006 Feb CAHN

@

50MG

A075900 002 Feb 23, 2006 Feb CAHN

@

100MG

A075900 003 Feb 23, 2006 Feb CAHN

@ SUN PHARM INDS

25MG

A076125 001 Apr 29, 2002 Mar CAHN

@

50MG

A076125 002 Apr 29, 2002 Mar CAHN

@

100MG

A076125 003 Apr 29, 2002 Mar CAHN

FOLIC ACID

INJECTABLE; INJECTION

FOLVITE

@ WYETH PHARMS INC

5MG/ML

N005897 008 May CAHN

TABLET; ORAL

FOLIC ACID

@ SUN PHARM INDS

1MG

A040582 001 Jul 18, 2005 Mar CAHN

FOLVITE

@ WYETH PHARMS INC

1MG

N005897 004 May CAHN

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

>D> + ORGANON USA INC

75 IU/0.5ML

N021273 001 Aug 26, 2005 Jun DISC

>A>

@

75 IU/0.5ML

N021273 001 Aug 26, 2005 Jun DISC

>D>

+

150 IU/0.5ML

N021273 002 Aug 26, 2005 Jun DISC

>A>

@

150 IU/0.5ML

N021273 002 Aug 26, 2005 Jun DISC

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BEVESPI AEROSPHERE

+ PEARL THERAPS INC

0.0048MG/INH; 0.0090MG/INH

N208294 001 Apr 25, 2016 Apr NEWA

FOSAMPRENAVIR CALCIUM

TABLET; ORAL

FOSAMPRENAVIR CALCIUM

AB MYLAN PHARMS INC

EQ 700MG BASE

A204060 001 Apr 15, 2016 Apr NEWA

LEXIVA

AB + VIIV HLTHCARE

EQ 700MG BASE

N021548 001 Oct 20, 2003 Apr CFTG

FOSAPREPITANT DIMEGLUMINEPOWDER; INTRAVENOUS
EMEND

AP	+	MERCK AND CO INC	EQ 150MG BASE/VIAL	N022023	002	Nov 12, 2010	May CFTG
AP		FOSAPREPITANT DIMEGLUMINE					
AP		FRESENIUS KABI USA	EQ 150MG BASE/VIAL	A206197	001	Jun 09, 2016	May NEWA

FOSINOPRIL SODIUMTABLET; ORAL
FOSINOPRIL SODIUM

@	ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004	Jan DISC
@		20MG	A076620	002	Oct 15, 2004	Jan DISC
@		40MG	A076620	003	Oct 15, 2004	Jan DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDETABLET; ORAL
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@	ACTAVIS LABS FL INC	10MG; 12.5MG	A076608	001	Dec 03, 2004	Jan DISC
@		20MG; 12.5MG	A076608	002	Dec 03, 2004	Jan DISC
@	SUN PHARM INDS LTD	10MG; 12.5MG	A076739	001	Dec 17, 2004	Feb DISC
@		20MG; 12.5MG	A076739	002	Dec 17, 2004	Feb DISC

FOSPHENYTOIN SODIUMINJECTABLE; INJECTION
FOSPHENYTOIN SODIUM

>D>	AP	BEDFORD	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jun CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jun CAHN

FROVATRIPTAN SUCCINATETABLET; ORAL
FROVATRIPTAN SUCCINATE

AB		GLENMARK PHARMS LTD	EQ 2.5MG BASE	A204730	001	Mar 11, 2016	Feb NEWA
----	--	---------------------	---------------	---------	-----	--------------	----------

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDE

AP		CLARIS	10MG/ML	A202747	001	Jan 27, 2014	May CAHN
	@	EUROHLTH INTL SARL	10MG/ML	A071439	001	Sep 14, 1990	Jan CAHN
	@	LUITPOLD	10MG/ML	N018579	001	Nov 30, 1983	Feb DISC

TABLET; ORAL

FUROSEMIDE

	@	SUN PHARM INDS	20MG	A070043	001	Sep 26, 1985	Mar CAHN
	@		80MG	A070100	001	Jan 26, 1988	Mar CAHN
		LASIX					
AB		US PHARM HOLDINGS	20MG	N016273	002		Jan CAHN
AB			40MG	N016273	001		Jan CAHN
AB	+		80MG	N016273	003		Jan CAHN

GABAPENTINCAPSULE; ORAL
GABAPENTIN

AB		SCIEGEN PHARMS INC	100MG	A204989	001	Feb 18, 2016	Feb NEWA
AB			300MG	A204989	002	Feb 18, 2016	Feb NEWA
AB			400MG	A204989	003	Feb 18, 2016	Feb NEWA
	@	SUN PHARM INDS	100MG	A076537	001	Jun 30, 2005	Mar CAHN
	@		300MG	A076537	002	Jun 30, 2005	Mar CAHN
	@		400MG	A076537	003	Jun 30, 2005	Mar CAHN

SOLUTION; ORAL
GABAPENTIN

AA		TRIS PHARMA INC	250MG/5ML	A091286	001	Mar 14, 2016	Feb NEWA
		TABLET; ORAL					
		GABAPENTIN					
AB		SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan NEWA
AB			800MG	A205101	002	Feb 04, 2016	Jan NEWA

GALANTAMINE HYDROBROMIDECAPSULE, EXTENDED RELEASE;ORAL
GALANTAMINE HYDROBROMIDE

@ IMPAX LABS	EQ 8MG BASE	A078484	001	May 27, 2009	Feb DISC
@	EQ 16MG BASE	A078484	002	May 27, 2009	Feb DISC
@	EQ 24MG BASE	A078484	003	May 27, 2009	Feb DISC

SOLUTION;ORAL

GALANTAMINE HYDROBROMIDE

+ ROXANE	4MG/ML	A078185	001	Jan 30, 2009	May CRLD
RAZADYNE					
@ JANSSEN PHARMS	4MG/ML	N021224	001	Jun 22, 2001	May DISC

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

>A> AT	ALCON RES LTD	0.5%	A204227	001	Jul 11, 2016	Jun NEWA
--------	---------------	------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP	ACTAVIS INC	200MG/5.26ML (38MG/ML)	A204549	001	Apr 11, 2016	Mar NEWA
AP		1GM/26.3ML (38MG/ML)	A204549	002	Apr 11, 2016	Mar NEWA
AP		2GM/52.6ML (38MG/ML)	A204549	003	Apr 11, 2016	Mar NEWA
AP	+ HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Mar CFTG
AP	+	1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Mar CFTG
AP	+	2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Mar CFTG

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

>A> AB	CADILA PHARMS LTD	600MG	A203266	001	Jun 17, 2016	Jun NEWA
--------	-------------------	-------	---------	-----	--------------	----------

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

@ ACTAVIS LABS FL INC	1MG	A076995	001	Apr 27, 2010	Jan DISC
@	2MG	A076995	002	Apr 27, 2010	Jan DISC
@	4MG	A076995	003	Apr 27, 2010	Jan DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

+ TEVA PHARMS USA	1MG;4MG	A078709	001	Apr 01, 2016	Mar NEWA
	2MG;4MG	A078709	002	Apr 01, 2016	Mar NEWA
	2MG;8MG	A078709	004	Apr 01, 2016	Mar NEWA
	4MG;4MG	A078709	003	Apr 01, 2016	Mar NEWA
	4MG;8MG	A078709	005	Apr 01, 2016	Mar NEWA

GLYBURIDE

TABLET;ORAL

GLYBURIDE

AB1	PHARMADAX INC	1.25MG	A203581	001	Apr 14, 2016	Apr NEWA
AB1		2.5MG	A203581	002	Apr 14, 2016	Apr NEWA
AB1		5MG	A203581	003	Apr 14, 2016	Apr NEWA
AB1	ZYDUS PHARMS USA INC	1.25mg	A206749	001	May 10, 2016	Apr NEWA
AB1		2.5mg	A206749	002	May 10, 2016	Apr NEWA
AB1		5MG	A206749	003	May 10, 2016	Apr NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

@ COREPHARMA	1.25MG;250MG	A076731	001	Nov 19, 2004	Jan DISC	
@	2.5MG;500MG	A076731	002	Nov 19, 2004	Jan DISC	
@	5MG;500MG	A076731	003	Nov 19, 2004	Jan DISC	
AB	ZYDUS PHARMS USA INC	1.25MG;250MG	A206748	001	Feb 29, 2016	Feb NEWA
AB		2.5MG;500MG	A206748	002	Feb 29, 2016	Feb NEWA
AB		5MG;500MG	A206748	003	Feb 29, 2016	Feb NEWA

GLYCOPYRROLATEINJECTABLE; INJECTION
GLYCOPYRROLATE

AP	+	HIKMA FARMACEUTICA	0.2MG/ML	A090963	001	Sep 21, 2011	Feb CRLD
		ROBINUL					
	@	EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Feb DISC

TABLET; ORAL

GLYCOPYRROLATE

	@	HIKMA INTL PHARMS	1MG	A040836	001	Mar 05, 2009	May CAHN
	@		2MG	A040836	002	Mar 05, 2009	May CAHN
>A>	AA	NATCO PHARMA LTD	1MG	A091413	001	Jun 20, 2016	Jun NEWA
>A>	AA		2MG	A091413	002	Jun 20, 2016	Jun NEWA
	AA	RISING PHARMS INC	1MG	A040821	001	Dec 29, 2008	Jan CAHN
	AA		2MG	A040821	002	Dec 29, 2008	Jan CAHN
		ROBINUL					
AA	+	CASPER PHARMA LLC	1MG	N012827	001		Jan CAHN
		ROBINUL FORTE					
AA	+	CASPER PHARMA LLC	2MG	N012827	002		Jan CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>A>	AP	AUROBINDO PHARMA LTD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016	Jun NEWA
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204238	002	Jul 06, 2016	Jun NEWA
>D>	AP	BEDFORD LABS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jun CAHN
>D>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jun CAHN
>D>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jun CAHN
	AP	BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
	@	CLARIS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	May CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jun CAHN
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jun CAHN
>A>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jun CAHN
	AP	HIKMA FARMACEUTICA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078629	001	Dec 23, 2009	Jan CMS1
	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078629	002	Dec 23, 2009	Jan CMS1
		GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP		BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN
		TABLET; ORAL					
		GRANISETRON HYDROCHLORIDE					
	@	COREPHARMA	EQ 1MG BASE	A078260	001	Dec 31, 2007	Mar DISC

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYCOFENIX

+	MISSION PHARMACAL CO	200MG/5ML; 2.5MG/5ML; 30MG/5ML	N022279	001	May 14, 2015	Apr CAHN
---	----------------------	--------------------------------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

@	IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015	Mar DISC
@		EQ 2MG BASE	A202238	002	Oct 20, 2015	Mar DISC
@		EQ 3MG BASE	A202238	003	Oct 20, 2015	Mar DISC
@		EQ 4MG BASE	A202238	004	Oct 20, 2015	Mar DISC

HALOBETASOL PROPIONATE

LOTION; TOPICAL

ULTRAVATE

>D>	+	FERNDALE LABS INC	0.05%	N208183	001	Nov 06, 2015	Jun CAHN
>A>	+	SUN PHARM INDS	0.05%	N208183	001	Nov 06, 2015	Jun CAHN

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

	@	CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Jan CAHN
>D>	@	MUTUAL PHARM	0.5MG	A071156	001	Jan 02, 1987	Jun CAHN
>D>	@		1MG	A071157	001	Jan 02, 1987	Jun CAHN
>A>	@	SUN PHARM INDS	0.5MG	A071156	001	Jan 02, 1987	Jun CAHN
>A>	@		1MG	A071157	001	Jan 02, 1987	Jun CAHN

TABLET;ORAL
HALOPERIDOL

@	2MG	A071172	001	Jan 02, 1987	Mar CAHN
@	5MG	A071212	001	Jan 07, 1988	Mar CAHN
@	10MG	A071173	001	Jan 07, 1988	Mar CAHN
@	20MG	A071177	001	Jan 07, 1988	Mar CAHN
@ VINTAGE	0.5MG	A071235	002	Nov 03, 1986	Jan CMS1
@	1MG	A071235	003	Nov 03, 1986	Jan CMS1
@	5MG	A071235	004	Nov 03, 1986	Jan CMS1
@	10MG	A071235	005	Jul 20, 1987	Jan CMS1

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM

AP	FRESENIUS KABI USA	5,000 UNITS/ML	A206552	001	Jun 10, 2016	May NEWA
----	--------------------	----------------	---------	-----	--------------	----------

HEXACHLOROPHENE

EMULSION;TOPICAL
PHISOHEX

@ SANOFI AVENTIS US	3%	N006882	001		May DISC
---------------------	----	---------	-----	--	----------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET;ORAL
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE
@ ACTAVIS ELIZABETH 1.5MG;5MG

A040295	001	Dec 01, 2000	Jan CMS1
---------	-----	--------------	----------

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
HYDRALAZINE HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016	Apr NEWA
----	---------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

@ ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr DISC
@	25MG	A091679	002	Mar 04, 2013	Apr DISC
@	50MG	A091679	003	Mar 04, 2013	Apr DISC
@	100MG	A091679	004	Mar 04, 2013	Apr DISC
>D> @ MUTUAL PHARM	100MG	A088729	001	Apr 11, 1985	Jun CAHN
@ SUN PHARM INDS	10MG	A089359	001	Jul 25, 1986	Mar CAHN
>A> @	100MG	A088729	001	Apr 11, 1985	Jun CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
HYDRALAZINE AND HYDROCHLOROTHIAZIDE
@ WATSON LABS 25MG;15MG

A085827	001		Feb CMS1
---------	-----	--	----------

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL
RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE
@ SUN PHARM INDS 25MG;15MG;0.1MG

A088570	001	Apr 10, 1984	Mar CAHN
---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL
MICROZIDE

AB	+ ALLERGAN SALES LLC	12.5MG	N020504	001	Dec 27, 1996	Apr CAHN
----	----------------------	--------	---------	-----	--------------	----------

TABLET;ORAL

HYDROCHLOROTHIAZIDE

@ AUROLIFE PHARMA LLC	25MG	A083899	001		Feb CAHN
@	50MG	A085219	001		Feb CAHN
@ HIKMA INTL PHARMS	25MG	A084878	002	Jul 12, 2006	May CAHN
AB @	50MG	A084878	001		May CAHN
@ SUN PHARM INDS	25MG	A083972	001		Mar CAHN
@	50MG	A083972	002		Mar CAHN
@	100MG	A083972	003		Mar CAHN
ORETIC					
@ ABBVIE	50MG	N011971	002		Jan DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	25MG;300MG	A203630	003	Mar 31, 2016	Mar NEWA
AB	INTL SPECLT CHEMS	12.5MG;150MG	A203036	001	Jan 15, 2016	Jan NEWA
AB		12.5MG;300MG	A203036	002	Jan 15, 2016	Jan NEWA
AB		25MG;300MG	A203036	003	Jan 15, 2016	Mar CTEC
		25MG;300MG	A203036	003	Jan 15, 2016	Jan NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

ZESTORETIC

AB	ALVOGEN MALTA	12.5MG;10MG	N019888	003	Nov 18, 1993	Jan CAHN
AB	+	12.5MG;20MG	N019888	001	Sep 20, 1990	Jan CAHN
AB	+	25MG;20MG	N019888	002	Jul 20, 1989	Jan CAHN

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS	25MG;25MG	A089534	001	Jul 02, 1987	Mar CAHN
----	----------------	-----------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG;80MG	A206083	001	Feb 08, 2016	Jan NEWA
AB		12.5MG;160MG	A206083	002	Feb 08, 2016	Jan NEWA
AB		12.5MG;320MG	A206083	003	Feb 08, 2016	Jan NEWA
AB		25MG;160MG	A206083	004	Feb 08, 2016	Jan NEWA
AB		25MG;320MG	A206083	005	Feb 08, 2016	Jan NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

	@ ACTAVIS LABS FL INC	5MG;200MG	A077454	001	Jun 23, 2010	Jan DISC
AB	AUROLIFE PHARMA LLC	7.5MG;200MG	A204575	001	Jun 02, 2016	May NEWA

HYDROCORTISONE

TABLET; ORAL

HYDROCORTISONE

AB	PHARMACEUTICS INTL	5MG	A207029	001	Apr 26, 2016	Apr NEWA
AB		10MG	A207029	002	Apr 26, 2016	Apr NEWA
AB		20MG	A207029	003	Apr 26, 2016	Apr NEWA

HYDROCORTISONE VALERATE

CREAM; TOPICAL

WESTCORT

>D>	@ RANBAXY	0.2%	N017950	001		Jun CAHN
>A>	@ SUN PHARM INDS LTD	0.2%	N017950	001		Jun CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

PEDIOTIC

	@ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062822	001	Sep 29, 1987	Jan DISC
--	------------------	-------------------------------------	---------	-----	--------------	----------

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	2MG	A205814	001	May 13, 2016	May NEWA
AB		4MG	A205814	002	May 13, 2016	May NEWA
AB		8MG	A205814	003	May 13, 2016	May NEWA

TABLET, EXTENDED RELEASE; ORAL

EXALGO

>D>	+	MALLINCKRODT INC	32MG	N021217	004	Aug 24, 2012	Jun CFTG
>A>	AB	+	32MG	N021217	004	Aug 24, 2012	Jun CFTG

HYDROMORPHONE HYDROCHLORIDE

>A>	AB	ACTAVIS LABS FL INC	32MG	A202144	004	Jun 30, 2016	Jun NEWA
>A>	AB	OSMOTICA	8MG	A205629	001	Jul 07, 2016	Jun NEWA
>A>	AB		12MG	A205629	002	Jul 07, 2016	Jun NEWA
>A>	AB		16MG	A205629	003	Jul 07, 2016	Jun NEWA
>A>	AB		32MG	A205629	004	Jul 07, 2016	Jun NEWA

HYDROXOCOBALAMININJECTABLE; INJECTION
CYANOKIT@ SERB SA 2.5GM/VIAL (5GM/KIT)
+ 5GM/VIAL (5GM/KIT)N022041 002 Dec 15, 2006 Jan CAHN
N022041 001 Apr 08, 2011 Jan CAHNHYDROXYCHLOROQUINE SULFATETABLET; ORAL
HYDROXYCHLOROQUINE SULFATE

AB WATSON LABS 200MG

A040133 001 Nov 30, 1995 Feb CMFD

HYDROXYPROGESTERONE CAPROATEINJECTABLE; INJECTION
HYDROXYPROGESTERONE CAPROATE+ ASPEN GLOBAL INC 250MG/ML
SOLUTION; INTRAMUSCULAR
MAKENA

A200271 001 Aug 24, 2015 Jan CAHN

>A> + AMAG PHARMA USA 250MG/ML (250MG/ML)
>A> + 1250MG/5ML (250MG/ML)
>D> + LUMARA HEALTH INC 250MG/ML (250MG/ML)
+ 250MG/ML (250MG/ML)
>D> + 1250MG/5ML (250MG/ML)N021945 002 Feb 19, 2016 Jun CAHN
N021945 001 Feb 03, 2011 Jun CAHN
N021945 002 Feb 19, 2016 Jun CAHN
N021945 002 Feb 19, 2016 Feb NEWA
N021945 001 Feb 03, 2011 Jun CAHNHYDROXYZINE HYDROCHLORIDETABLET; ORAL
HYDROXYZINE HYDROCHLORIDE@ AUROLIFE PHARMA LLC 10MG
@ 25MG
@ 50MGA087869 001 Dec 20, 1982 Feb CAHN
A087870 001 Dec 20, 1982 Feb CAHN
A087871 001 Dec 20, 1982 Feb CAHN

AB ECI PHARMS LLC 10MG

A040804 001 Jun 30, 2008 May CAHN

AB 25MG

A040804 002 Jun 30, 2008 May CAHN

AB 50MG

A040804 003 Jun 30, 2008 May CAHN

>A> AB ELITE LABS INC 10MG

A040604 002 Dec 28, 2004 Jun NEWA

>A> AB 25MG

A040604 003 Dec 28, 2004 Jun NEWA

@ SUN PHARM INDS 10MG

A089381 001 May 19, 1986 Mar CAHN

@ 25MG

A089382 001 May 19, 1986 Mar CAHN

@ 50MG

A089383 001 May 19, 1986 Mar CAHN

@ 100MG

A087862 001 Apr 18, 1983 Mar CAHN

IBANDRONATE SODIUMINJECTABLE; INTRAVENOUS
IBANDRONATE SODIUM

AP ACCORD HLTHCARE EQ 3MG BASE/3ML

A206058 001 Feb 05, 2016 Jan NEWA

TABLET; ORAL

IBANDRONATE SODIUM

AB AUROBINDO PHARMA LTD EQ 150MG BASE

A204502 001 Mar 11, 2016 Feb NEWA

AB SUN PHARM INDS EQ 150MG BASE

A078996 001 Aug 15, 2012 Mar CAHN

IBUPROFENTABLET; ORAL
IBUPROFEN@ AUROLIFE PHARMA LLC 300MG
@ 400MG
@ 600MG
@ 800MGA070734 001 Jun 12, 1986 Feb CAHN
A070735 001 Jun 12, 1986 Feb CAHN
A070736 001 Jun 12, 1986 Feb CAHN
A071938 001 Jan 14, 1988 Mar CAHN

AB STRIDES PHARMA 400MG

A078329 001 Feb 05, 2009 May CAHN

AB 600MG

A078329 002 Feb 05, 2009 May CAHN

AB 800MG

A078329 003 Feb 05, 2009 May CAHN

@ SUN PHARM INDS 400MG

A070079 001 Jul 24, 1985 Mar CAHN

@ 600MG

A070080 001 Jul 24, 1985 Mar CAHN

@ 800MG

A071448 001 Feb 18, 1987 Mar CAHN

IBUPROFEN LYSINEINJECTABLE; INTRAVENOUS
IBUPROFEN LYSINE

AP EXELA PHARMA SCIENCE EQ 20MG BASE/2ML (EQ 10MG BASE/ML)

A202402 001 Mar 30, 2016 Mar NEWA

NEOPROFEN

AP + RECORDATI RARE EQ 20MG BASE/2ML (EQ 10MG BASE/ML)

N021903 001 Apr 13, 2006 Mar CFTG

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB	SUN PHARM INDS	10MG	A081048	001	Jun 05, 1990	Mar CAHN
AB		25MG	A081049	001	Jun 05, 1990	Mar CAHN
AB		50MG	A081050	001	Jun 05, 1990	Mar CAHN

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

AB	+ ROXANE	EQ 75MG HCL	A091099	001	Apr 16, 2010	Feb CRLD
	TOFRANIL-PM					
	@ MALLINCKRODT INC	EQ 75MG HCL	N017090	001		Feb DISC
	@	EQ 100MG HCL	N017090	004		Feb DISC
	@	EQ 125MG HCL	N017090	003		Feb DISC
	@	EQ 150MG HCL	N017090	002		Feb DISC

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDIUM IN 111 CHLORIDE

+	MALLINKRODT NUCLEAR	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan CAHN
---	---------------------	------------	---------	-----	--------------	----------

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN 111 OXYQUINOLINE

+	GE HEALTHCARE	1mCi/ML	N019044	001	Dec 24, 1985	Mar CMS1
---	---------------	---------	---------	-----	--------------	----------

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN

+	MALLINKRODT NUCLEAR	3mCi/ML	N020314	001	Jun 02, 1994	Jan CAHN
---	---------------------	---------	---------	-----	--------------	----------

INDOCYANINE GREEN

INJECTABLE; INJECTION

INDOCYANINE GREEN

AP	DIAGNOSTIC GREEN	25MG/VIAL	A040811	001	Nov 21, 2007	Jan CAHN
----	------------------	-----------	---------	-----	--------------	----------

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOMETHACIN SODIUM

AP	HOSPIRA INC	EQ 1MG BASE/VIAL	A204118	001	Apr 19, 2016	Apr NEWA
----	-------------	------------------	---------	-----	--------------	----------

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS

LEVEMIR FLEXPEN

@	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	002	Jun 16, 2005	Feb DISC
---	------------------	------------------------------	---------	-----	--------------	----------

INSULIN HUMAN

SOLUTION; SUBCUTANEOUS

HUMULIN R

+	LILLY	10000 UNITS/20ML (500 UNITS/ML)	N018780	004	Mar 31, 1994	Jan CAIN
---	-------	---------------------------------	---------	-----	--------------	----------

HUMULIN R KWIKPEN

+	LILLY	1500 UNITS/3ML (500 UNITS/ML)	N018780	002	Dec 29, 2015	Jan NEWA
---	-------	-------------------------------	---------	-----	--------------	----------

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION

AFREZZA

	MANNKIND	4 UNITS/INH	N022472	001	Jun 27, 2014	Mar CAHN
+		8 UNITS/INH	N022472	002	Jun 27, 2014	Mar CAHN
		12 UNITS/INH	N022472	003	Apr 17, 2015	Mar CAHN

>D> IOXILAN

>D> INJECTABLE; INJECTION

>D> OXILAN-300

>D>	GUERBET	62%	N020316	001	Dec 21, 1995	Jun DISC
-----	---------	-----	---------	-----	--------------	----------

>A>	@	62%	N020316	001	Dec 21, 1995	Jun DISC
-----	---	-----	---------	-----	--------------	----------

>D> OXILAN-350

>D>	GUERBET	73%	N020316	002	Dec 21, 1995	Jun DISC
-----	---------	-----	---------	-----	--------------	----------

>A>	@	73%	N020316	002	Dec 21, 1995	Jun DISC
-----	---	-----	---------	-----	--------------	----------

IRBESARTAN

TABLET; ORAL
IRBESARTAN

AB	HISUN PHARM HANGZHOU	75MG	A206194	001	Jun 14, 2016	May NEWA
AB		150MG	A206194	002	Jun 14, 2016	May NEWA
AB		300MG	A206194	003	Jun 14, 2016	May NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
CAMPTOSAR

AP	+	PFIZER INC	300MG/15ML (20MG/ML)	N020571	003	Aug 05, 2010	Apr CTEC
IRINOTECAN HYDROCHLORIDE							
>D>	AP	BEDFORD LABS	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Jun CAHN
>D>	AP		100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Jun CAHN
>A>	AP	EUROHLTH INTL SARL	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Jun CAHN
>A>	AP		100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Jun CAHN
	AP	QILU PHARM CO LTD	40MG/2ML (20MG/ML)	A203380	001	May 03, 2016	Apr NEWA
	AP		100MG/5ML (20MG/ML)	A203380	002	May 03, 2016	Apr NEWA
	AP		300MG/15ML (20MG/ML)	A203380	003	May 03, 2016	Apr NEWA
	AP	SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jan CAHN
	AP		100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jan CAHN

IRON DEXTRAN

INJECTABLE; INJECTION
INFED

BP	+	ALLERGAN SALES LLC	EQ 50MG IRON/ML	N017441	001		Apr CAHN
----	---	--------------------	-----------------	---------	-----	--	----------

ISONIAZID

TABLET; ORAL
ISONIAZID

>D>		@ MIKART	100MG	A040090	001	Jun 26, 1997	Jun CMFD
>A>	AA		100MG	A040090	001	Jun 26, 1997	Jun CMFD
>D>		@	300MG	A040090	002	Jun 26, 1997	Jun CMFD
>A>	AA		300MG	A040090	002	Jun 26, 1997	Jun CMFD
		@ SUN PHARM INDS	100MG	A080136	001		Mar CAHN
		@	300MG	A083633	001		Mar CAHN

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR

+ AUXILIUM PHARMS INC 40MG

N019790	001	Sep 02, 1988	Mar CAHN
---------	-----	--------------	----------

TABLET; ORAL

ISOSORBIDE DINITRATE

>D>		@ MUTUAL PHARM	10MG	A086169	001	Sep 19, 1986	Jun CAHN
>D>		@	20MG	A086167	001	Sep 19, 1986	Jun CAHN
>D>		@	30MG	A087564	001	Sep 18, 1986	Jun CAHN
		@ SUN PHARM INDS	5MG	A086166	002	Sep 19, 1986	Mar CAHN
>A>		@	10MG	A086169	001	Sep 19, 1986	Jun CAHN
>A>		@	20MG	A086167	001	Sep 19, 1986	Jun CAHN
>A>		@	30MG	A087564	001	Sep 18, 1986	Jun CAHN

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

>D>		@ MUTUAL PHARM	2.5MG	A084204	001	Sep 18, 1986	Jun CAHN
>D>		@	5MG	A086168	001	Sep 18, 1986	Jun CAHN
>D>		@	10MG	A087545	001	Sep 18, 1986	Jun CAHN
>A>		@ SUN PHARM INDS	2.5MG	A084204	001	Sep 18, 1986	Jun CAHN
>A>		@	5MG	A086168	001	Sep 18, 1986	Jun CAHN
>A>		@	10MG	A087545	001	Sep 18, 1986	Jun CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

@ COREPHARMA 40MG
+ SUN PHARM INDS INC 40MG

A040723	001	Mar 17, 2008	Mar DISC
A040009	001	Dec 30, 1998	Mar CTEC

ISOSULFAN BLUE

INJECTABLE; INJECTION
ISOSULFAN BLUE

AP	AUROBINDO PHARMA LTD	1%	A206831	001	Feb 02, 2016	Jan NEWA	
AP	+	MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	Jan CTEC

ITRACONAZOLE

CAPSULE;ORAL							
ITRACONAZOLE							
AB	ACCORD HLTHCARE	100MG	A205991	001	May 26, 2016	May	NEWA
SOLUTION;ORAL							
ITRACONAZOLE							
	@ AMNEAL PHARMS	10MG/ML	A205573	001	Oct 30, 2015	Apr	DISC
SPORANOX							
+	JANSSEN PHARMS	10MG/ML	N020657	001	Feb 21, 1997	Apr	CTEC

IVERMECTIN

LOTION;TOPICAL							
SKLICE							
+	ARBOR PHARMS LLC	0.5%	N202736	001	Feb 07, 2012	May	CAHN

KETOCONAZOLE

TABLET;ORAL							
KETOCONAZOLE							
	@ SUN PHARM INDS	200MG	A075314	001	Jun 15, 1999	Jan	CAHN

KETOPROFEN

CAPSULE;ORAL							
KETOPROFEN							
	@ AUROLIFE PHARMA LLC	50MG	A074024	001	Dec 29, 1995	Feb	CAHN
	@	75MG	A074024	002	Dec 29, 1995	Feb	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION							
KETOROLAC TROMETHAMINE							
	@ EUROHLTH INTL SARL	15MG/ML	A075222	001	Apr 26, 1999	Apr	CAHN
	@	30MG/ML	A075222	002	Apr 26, 1999	Apr	CAHN
	@	30MG/ML	A075228	001	Apr 26, 1999	May	CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION							
LABETALOL HYDROCHLORIDE							
AP	SAGENT STRIDES	5MG/ML	A079134	001	Feb 03, 2010	Jan	CTNA
TRANDATE							
	@ SEBELA IRELAND LTD	5MG/ML	N019425	001	Dec 31, 1985	Jan	CAHN
TABLET;ORAL							
LABETALOL HYDROCHLORIDE							
AB	NOSTRUM LABS INC	100MG	A075215	001	Jul 29, 1999	Jan	CAHN
AB		200MG	A075215	002	Jul 29, 1999	Jan	CAHN
AB		300MG	A075215	003	Jul 29, 1999	Jan	CAHN

LACOSAMIDE

SOLUTION;ORAL							
LACOSAMIDE							
AA	AMNEAL PHARMS	10MG/ML	A204839	001	Apr 28, 2016	Apr	NEWA
VIMPAT							
AA	+ UCB INC	10MG/ML	N022255	001	Apr 20, 2010	Apr	CFTG
TABLET;ORAL							
LACOSAMIDE							
AB	ACTAVIS LABS FL INC	50MG	A204855	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A204855	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A204855	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A204855	004	Apr 28, 2016	Apr	NEWA
AB	ALEMBIC PHARMS LTD	50MG	A204974	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A204974	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A204974	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A204974	004	Apr 28, 2016	Apr	NEWA
AB	AUROBINDO PHARMA LTD	50MG	A204994	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A204994	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A204994	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A204994	004	Apr 28, 2016	Apr	NEWA
AB	MSN LABS PVT LTD	50MG	A204921	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A204921	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A204921	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A204921	004	Apr 28, 2016	Apr	NEWA
AB	MYLAN PHARMS INC	50MG	A205026	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A205026	002	Apr 28, 2016	Apr	NEWA

TABLET;ORAL
LACOSAMIDE

AB		150MG	A205026	003	Apr 28, 2016	Apr NEWA
AB		200MG	A205026	004	Apr 28, 2016	Apr NEWA
AB	SUN PHARMA GLOBAL	50MG	A205031	001	Apr 28, 2016	Apr NEWA
AB		100MG	A205031	002	Apr 28, 2016	Apr NEWA
AB		150MG	A205031	003	Apr 28, 2016	Apr NEWA
AB		200MG	A205031	004	Apr 28, 2016	Apr NEWA

VIMPAT

AB	UCB INC	50MG	N022253	001	Oct 28, 2008	Apr CFTG
AB		100MG	N022253	002	Oct 28, 2008	Apr CFTG
AB		150MG	N022253	003	Oct 28, 2008	Apr CFTG
AB	+	200MG	N022253	004	Oct 28, 2008	Apr CFTG

LAMIVUDINE

TABLET;ORAL
LAMIVUDINE

AB	MYLAN PHARMS INC	150MG	A204528	001	Mar 04, 2016	Feb NEWA
AB		300MG	A204528	002	Mar 04, 2016	Feb NEWA

LAMOTRIGINE

TABLET;ORAL
LAMOTRIGINE

>D>	AB	CADISTA PHARMS	25MG	A079132	001	Jan 27, 2009	Jun CAHN
>D>	AB		100MG	A079132	002	Jan 27, 2009	Jun CAHN
>D>	AB		150MG	A079132	003	Jan 27, 2009	Jun CAHN
>D>	AB		200MG	A079132	004	Jan 27, 2009	Jun CAHN
>A>	AB	JUBILANT CADISTA	25MG	A079132	001	Jan 27, 2009	Jun CAHN
>A>	AB		100MG	A079132	002	Jan 27, 2009	Jun CAHN
>A>	AB		150MG	A079132	003	Jan 27, 2009	Jun CAHN
>A>	AB		200MG	A079132	004	Jan 27, 2009	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR

AB	+	GLAXOSMITHKLINE LLC	200MG	N022115	004	May 29, 2009	Jan CRLD
----	---	---------------------	-------	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL

LAMOTRIGINE

>A>	AB	SCIEGEN PHARMS INC	25MG	A206382	001	Jun 17, 2016	Jun NEWA
>A>	AB		50MG	A206382	002	Jun 17, 2016	Jun NEWA
>A>	AB		100MG	A206382	003	Jun 17, 2016	Jun NEWA
>A>	AB		200MG	A206382	004	Jun 17, 2016	Jun NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

AT	FDC LTD	0.005%	A202442	001	Apr 22, 2016	Apr NEWA
----	---------	--------	---------	-----	--------------	----------

LETROZOLE

TABLET;ORAL

LETROZOLE

AB	HIKMA PHARMS	2.5MG	A203796	001	Jun 03, 2016	May NEWA
AB	KREMERS URBAN PHARMS	2.5MG	A091098	001	Jun 03, 2011	Jan CAHN

LEUCOVORIN CALCIUM

TABLET;ORAL

LEUCOVORIN CALCIUM

>D>	AB	@ IDT AUSTRALIA LTD	EQ 15MG BASE	A075327	001	Mar 24, 1999	May CAHN
>A>	AB	ROXANE	EQ 15MG BASE	A072735	001	Feb 22, 1993	Jun CTEC
>A>			EQ 15MG BASE	A072735	001	Feb 22, 1993	Jun CTEC

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN	RTEDOSE CORP	EQ 0.0103% BASE	A203653	001	Mar 22, 2016	Mar NEWA
AN		EQ 0.021% BASE	A203653	002	Mar 22, 2016	Mar NEWA
AN		EQ 0.042% BASE	A203653	003	Mar 22, 2016	Mar NEWA

LEVETIRACETAM

INJECTABLE;IV (INFUSION)

LEVETIRACETAM

AP	AUROBINDO PHARMA LTD	500MG/5ML (100MG/ML)	A204312	001	Feb 01, 2016	Jan NEWA
AP	JUBILANT LIFE	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	May NEWA

TABLET, EXTENDED RELEASE;ORAL
LEVETIRACETAM

AB	INTELLIPHARMACEUTICS	500MG	A204511	001	Feb 23, 2016	Feb NEWA
AB		750MG	A204511	002	Feb 23, 2016	Feb NEWA
AB	LOTUS PHARM CO LTD	500MG	A202095	002	Jun 06, 2016	May NEWA
AB		750MG	A202095	001	Jun 06, 2016	May NEWA
AB	SUN PHARM INDS	500MG	A091285	001	Sep 12, 2011	Mar CAHN
AB		750MG	A091285	002	Sep 12, 2011	Mar CAHN

TABLET, FOR SUSPENSION;ORAL
SPRITAM

	APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Feb CDFR
		500MG	N207958	002	Jul 31, 2015	Feb CDFR
		750MG	N207958	003	Jul 31, 2015	Feb CDFR
+		1GM	N207958	004	Jul 31, 2015	Mar CRLD
		1GM	N207958	004	Jul 31, 2015	Feb CDFR

LEVOFLOXACIN

INJECTABLE;INJECTION

>D>	LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
>D> AP	+ JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jun DISC
>A>	@	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jun DISC
>D> AP	+	EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jun DISC
>A>	@	EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jun DISC
>D> AP	+	EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jun DISC
>A>	@	EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jun DISC
	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	AUROBINDO PHARMA LTD	EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016	Jan NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016	Jan NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016	Jan NEWA

SOLUTION/DROPS;OPHTHALMIC
LEVOFLOXACIN

AT	+ RISING PHARMS INC	0.5%	A077700	001	Dec 20, 2010	Jan CAHN
----	---------------------	------	---------	-----	--------------	----------

LEVOLEUCOVORIN CALCIUM

POWDER;IV (INFUSION)
FUSILEV

>D>	+ SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Jun CFTG
>A> AP	+	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Jun CFTG
>A>	LEVOLEUCOVORIN CALCIUM					
>A> AP	EUROHLTH INTL SARL	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	Jun NEWA

LEVONORGESTREL

TABLET;ORAL
LEVONORGESTREL

+	PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010	Apr CRLD
@	WATSON LABS	0.75MG	A078665	001	Aug 28, 2009	Apr DISC
	PLAN B					
@	TEVA BRANDED PHARM	0.75MG	N021045	002	Aug 24, 2006	Apr DISC

LEVOTHYROXINE SODIUM

POWDER;INTRAVENOUS
LEVOTHYROXINE SODIUM

>A> AP	FERA PHARMS LLC	100MCG/VIAL	A206163	001	Jun 29, 2016	Jun NEWA
>A> AP		500MCG/VIAL	A206163	002	Jun 29, 2016	Jun NEWA
>D>	+ FRESENIUS KABI USA	100MCG/VIAL	N202231	001	Jun 24, 2011	Jun CFTG
>A> AP	+	100MCG/VIAL	N202231	001	Jun 24, 2011	Jun CFTG
>D>	+	500MCG/VIAL	N202231	003	Jun 24, 2011	Jun CFTG
>A> AP	+	500MCG/VIAL	N202231	003	Jun 24, 2011	Jun CFTG

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL
LEVOTHROID

@	LLOYD	0.025MG	N021116	001	Oct 24, 2002	May DISC
@		0.05MG	N021116	002	Oct 24, 2002	May DISC
@		0.075MG	N021116	003	Oct 24, 2002	May DISC
@		0.088MG	N021116	010	Oct 24, 2002	May DISC
@		0.1MG	N021116	004	Oct 24, 2002	May DISC
@		0.112MG	N021116	011	Oct 24, 2002	May DISC
@		0.125MG	N021116	005	Oct 24, 2002	May DISC
@		0.137MG	N021116	012	Dec 07, 2004	May DISC
@		0.15MG	N021116	006	Oct 24, 2002	May DISC

TABLET;ORAL
LEVOTHROID

@	0.175MG	N021116	007	Oct 24, 2002	May DISC
@	0.2MG	N021116	008	Oct 24, 2002	May DISC
@	0.3MG	N021116	009	Oct 24, 2002	May DISC
LEVOTHYROXINE SODIUM					
AB1, MYLAN	0.3MG	A076187	011	Jun 05, 2002	May CRLD
AB2,					
AB3,					
AB4, +					

LIDOCAINE

OINTMENT;TOPICAL
LIDOCAINE

>D> AT	NOVOCOL INC	5%	A040911	001	May 23, 2011	Jun CAHN
>A> AT	SEPTODONT INC	5%	A040911	001	May 23, 2011	Jun CAHN
AT	TELIGENT PHARMA INC	5%	A205318	001	Feb 01, 2016	Jan NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA 400MG/100ML

N018388 002

Feb DISC

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA 800MG/100ML

N018388 003

Nov 05, 1982

Feb DISC

JELLY;TOPICAL

ANESTACON

@ BIONPHARMA INC 2%

A080429 001

Jan CAHN

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE

AT TELIGENT PHARMA INC 4%

A204494 001

Mar 12, 2014

May CAHN

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

JENTADUETO XR

BOEHRINGER INGELHEIM 2.5MG;1GM

N208026 001

May 27, 2016

May NEWA

+ 5MG;1GM

N208026 002

May 27, 2016

May NEWA

LINEZOLID

SOLUTION;IV (INFUSION)

LINEZOLID

AP FRESENIUS KABI USA 600MG/300ML (2MG/ML)

A204764 001

Mar 15, 2016

Feb NEWA

TABLET;ORAL

LINEZOLID

AB GATE PHARMS 600MG

A091210 001

Feb 05, 2016

Jan NEWA

AB GLENMARK PHARMS 600MG

A078987 001

Dec 21, 2015

Mar CAHN

LIOTHYRONINE SODIUM

TABLET;ORAL

LIOTHYRONINE SODIUM

AB MAYNE PHARMA INC EQ 0.005MG BASE

A090097 001

Mar 20, 2009

Mar CAHN

AB EQ 0.025MG BASE

A090097 002

Mar 20, 2009

Mar CAHN

AB EQ 0.05MG BASE

A090097 003

Mar 20, 2009

Mar CAHN

AB SUN PHARM INDS LTD EQ 0.005MG BASE

A091382 001

Apr 20, 2016

Apr NEWA

AB EQ 0.025MG BASE

A091382 002

Apr 20, 2016

Apr NEWA

AB EQ 0.05MG BASE

A091382 003

Apr 20, 2016

Apr NEWA

LISINOPRIL

TABLET;ORAL

ZESTRIL

AB ALVOGEN MALTA 2.5MG

N019777 005

Apr 29, 1993

Jan CAHN

AB 5MG

N019777 001

May 19, 1988

Jan CAHN

AB 10MG

N019777 002

May 19, 1988

Jan CAHN

AB 20MG

N019777 003

May 19, 1988

Jan CAHN

AB 30MG

N019777 006

Jan 20, 1999

Jan CAHN

AB + 40MG

N019777 004

May 19, 1988

Jan CAHN

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

AB DELCOR ASSET CORP 150MG

A076243 002

Feb 24, 2003

Feb CAHN

AB 300MG

A076243 001

Jun 27, 2002

Feb CAHN

AB 600MG

A078763 001

Apr 15, 2008

Feb CAHN

CAPSULE;ORAL							
LITHIUM CARBONATE							
AB	HIKMA PHARMS	600MG	A078763	001	Apr 15, 2008	Jan	CMFD
<u>LOMITAPIDE MESYLATE</u>							
CAPSULE;ORAL							
JUXTAPID							
	AEGERION	EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan	CRLD
+		EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan	CRLD
<u>LOPERAMIDE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
IMODIUM							
	@ J AND J CONSUMER INC	2MG	N017694	001		Feb	DISC
LOPERAMIDE HYDROCHLORIDE							
AB	+ MYLAN	2MG	A072741	001	Sep 18, 1991	Feb	CRLD
<u>LOSARTAN POTASSIUM</u>							
TABLET;ORAL							
LOSARTAN POTASSIUM							
BX	HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Apr	CTEC
BX		50MG	A203835	002	Aug 12, 2015	Apr	CTEC
BX		100MG	A203835	003	Aug 12, 2015	Apr	CTEC
BX	LUPIN LTD	25MG	A078232	001	Oct 06, 2010	Apr	CTEC
BX		50MG	A078232	002	Oct 06, 2010	Apr	CTEC
BX		100MG	A078232	003	Oct 06, 2010	Apr	CTEC
<u>LOVASTATIN</u>							
TABLET;ORAL							
LOVASTATIN							
AB	SUN PHARM INDS	10MG	A077520	001	Apr 14, 2006	Mar	CAHN
AB		20MG	A077520	002	Apr 14, 2006	Mar	CAHN
AB		40MG	A077520	003	Apr 14, 2006	Mar	CAHN
<u>LOXAPINE</u>							
POWDER;INHALATION							
ADASUVE							
+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012	Feb	CAHN
<u>MAGNESIUM SULFATE</u>							
INJECTABLE;INJECTION							
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	FRESENIUS KABI USA	1GM/100ML	A206486	001	Mar 07, 2016	Feb	NEWA
AP	+ HOSPIRA	1GM/100ML	N020488	001	Jul 11, 1995	Feb	CFTG
AP	HQ SPCLT PHARMA	1GM/100ML	A207349	001	Mar 02, 2016	Feb	NEWA
MAGNESIUM SULFATE IN PLASTIC CONTAINER							
AP	FRESENIUS KABI USA	4GM/100ML (40MG/ML)	A206485	001	Mar 15, 2016	Feb	NEWA
AP		4GM/50ML (80MG/ML)	A206485	002	Mar 15, 2016	Feb	NEWA
AP		2GM/50ML (40MG/ML)	A206485	003	Mar 15, 2016	Mar	NEWA
AP		20GM/500ML (40MG/ML)	A206485	004	Mar 15, 2016	Mar	NEWA
AP		40GM/1000ML (40MG/ML)	A206485	005	Mar 15, 2016	Mar	NEWA
AP	HOSPIRA	2GM/50ML (40MG/ML)	N020309	003	Jan 26, 2007	Mar	CFTG
AP	+	4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994	Feb	CFTG
AP	+	4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994	Feb	CFTG
AP		20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995	Mar	CFTG
AP		40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995	Mar	CFTG
SOLUTION;INTRAMUSCULAR, INTRAVENOUS							
MAGNESIUM SULFATE							
+	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan	NEWA
+		25GM/50ML (500MG/ML)	N019316	004	Jan 29, 2016	Jan	NEWA
<u>MECLIZINE HYDROCHLORIDE</u>							
TABLET;ORAL							
MECLIZINE HYDROCHLORIDE							
	@ RISING PHARMS INC	12.5MG	A040179	001	Jan 30, 1997	Jan	CAHN
	@	25MG	A040179	002	Jan 30, 1997	Jan	CAHN
>D>	TABLET, CHEWABLE;ORAL						
>D>	ANTIVERT						
>D>	+	CASPER PHARMA LLC	25MG	N010721	005	Jun	DISC
>A>	@	25MG	N010721	005		Jun	DISC

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

@ HIKMA INTL PHARMS

250MG

A077699 001 Apr 21, 2010 May CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE ES

AB + ENDO PHARMS INC

125MG/ML

N021778 001 Jul 05, 2005 Feb CAHN

MELOXICAM

TABLET; ORAL

MELOXICAM

@ SUN PHARM INDS

7.5MG

A077935 001 Jul 19, 2006 Jan CAHN

@

15MG

A077935 002 Jul 19, 2006 Jan CAHN

MELPHALAN

TABLET; ORAL

ALKERAN

+ APOTEX INC

2MG

N014691 002 Jan CAHN

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

AP + APOTEX INC

EQ 50MG BASE/VIAL

N020207 001 Nov 18, 1992 Jan CAHN

POWDER; IV (INFUSION)

EVOMELA

SPECTRUM PHARMS

EQ 50MG BASE/VIAL

N207155 001 Mar 10, 2016 Mar NEWA

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

@ US PHARM HOLDINGS

25MG/ML

N005010 007 Jan CAHN

@

50MG/ML

N005010 002 Jan CAHN

@

75MG/ML

N005010 009 Jan CAHN

@

100MG/ML

N005010 003 Jan CAHN

SYRUP; ORAL

DEMEROL

@ US PHARM HOLDINGS

50MG/5ML

N005010 005 Jan CAHN

TABLET; ORAL

DEMEROL

AA + US PHARM HOLDINGS

50MG

N005010 001 Jan CAHN

AA +

100MG

N005010 004 Jan CAHN

MEPERIDINE HYDROCHLORIDE

@ SUN PHARM INDS

50MG

A080448 001 Mar CAHN

@

100MG

A080448 002 Mar CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

@ AUROLIFE PHARMA LLC

400MG

A080655 001 Feb CAHN

@ SUN PHARM INDS

200MG

A080699 001 Mar CAHN

@

400MG

A080699 002 Mar CAHN

MERCAPTOPURINE

TABLET; ORAL

MERCAPTOPURINE

AB DR REDDYS LABS INTL

50MG

A040461 001 Feb 11, 2004 Apr CAHN

PURINETHOL

@ STASON PHARMS

50MG

N009053 002 Jan CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP AMNEAL PHARMS

500MG/VIAL

A205883 001 Apr 12, 2016 Mar NEWA

AP

1GM/VIAL

A205883 002 Apr 12, 2016 Mar NEWA

AP GLAND PHARMA LTD

500MG/VIAL

A206141 001 Jun 08, 2016 May NEWA

AP

1GM/VIAL

A206141 002 Jun 08, 2016 May NEWA

AP PAR STERILE PRODUCTS

500MG/VIAL

A204139 001 Jun 09, 2016 May NEWA

AP

1GM/VIAL

A204139 002 Jun 09, 2016 May NEWA

INJECTABLE; INJECTION

MEROPENEM

AP	SAVIOR LIFETEC CORP	500MG/VIAL	A206086	001	Apr 19, 2016	Apr NEWA
AP		1GM/VIAL	A206086	002	Apr 19, 2016	Apr NEWA

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

+	APIL	400MG	N204412	001	Feb 01, 2013	Jan CAHN
---	------	-------	---------	-----	--------------	----------

TABLET, DELAYED RELEASE; ORAL

ASACOL

@	APIL	400MG	N019651	001	Jan 31, 1992	Jan CAHN
---	------	-------	---------	-----	--------------	----------

ASACOL HD

+	APIL	800MG	N021830	001	May 29, 2008	Jan CAHN
---	------	-------	---------	-----	--------------	----------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

>A>	AB	CSPC OUYI PHARM CO	500MG	A205096	001	Jul 11, 2016	Jun NEWA
>A>	AB		850MG	A205096	002	Jul 11, 2016	Jun NEWA
>A>	AB		1GM	A205096	003	Jul 11, 2016	Jun NEWA
	AB	SUN PHARM INDS	500MG	A076038	001	Feb 21, 2002	Mar CAHN
	AB		850MG	A076038	002	Feb 21, 2002	Mar CAHN
	AB		1GM	A076038	003	Feb 21, 2002	Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

GLUMETZA

AB3		SANTARUS INC	500MG	N021748	001	Jun 03, 2005	Jan CTEC
AB3	+		1GM	N021748	002	Jun 03, 2005	Jan CTEC
		METFORMIN HYDROCHLORIDE					
	@	IMPAX LABS	500MG	A076249	001	Jul 30, 2004	Mar DISC
	@		750MG	A076985	001	Sep 13, 2005	Mar DISC
AB1		MARKSANS PHARMA	500MG	A090295	001	Apr 29, 2016	Apr NEWA
AB			750MG	A090295	002	Apr 29, 2016	Apr NEWA
	@	SUN PHARM INDS	500MG	A077124	001	Dec 21, 2005	Mar CAHN

METHENAMINE HIPPURATE

TABLET; ORAL

HIPREX

AB	+	US PHARM HOLDINGS	1GM	N017681	001		Jan CAHN
		METHENAMINE HIPPURATE					
>A>	AB	AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016	Jun NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB		RISEING PHARMS INC	5MG	A202068	001	Mar 07, 2012	Jan CAHN
AB			10MG	A202068	002	Mar 07, 2012	Jan CAHN

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

AP		AUROBINDO PHARMA LTD	1GM/10ML (100MG/ML)	A206128	001	May 27, 2016	May NEWA
----	--	----------------------	---------------------	---------	-----	--------------	----------

TABLET; ORAL

METHOCARBAMOL

@	SANDOZ	500MG	A084616	001		Feb DISC
---	--------	-------	---------	-----	--	----------

@		750MG	A084615	001		Feb DISC
---	--	-------	---------	-----	--	----------

@	SUN PHARM INDS	500MG	A084488	001		Mar CAHN
---	----------------	-------	---------	-----	--	----------

@		750MG	A084486	001		Mar CAHN
---	--	-------	---------	-----	--	----------

ROBAXIN

AA	+	AUXILIUM PHARMS INC	500MG	N011011	004		Mar CAHN
----	---	---------------------	-------	---------	-----	--	----------

ROBAXIN-750

AA	+	AUXILIUM PHARMS INC	750MG	N011011	006		Mar CAHN
----	---	---------------------	-------	---------	-----	--	----------

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

>D>	+	PAR STERILE PRODUCTS	200MG/VIAL	N011559	004	Dec 21, 2012	Jun DISC
>A>	@		200MG/VIAL	N011559	004	Dec 21, 2012	Jun DISC

METHOTREXATESOLUTION;SUBCUTANEOUS
OTREXUP

ANTARES PHARMA INC	12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	May NEWA
	17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	May NEWA
	22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	May NEWA

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	SANDOZ INC	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Jan CAHN
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Jan CAHN
AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Jan CAHN

METHOXSALENINJECTABLE;INJECTION
UVADEX

+	MALLINCKRODT HOSP	0.02MG/ML	N020969	001	Feb 25, 1999	Apr CAHN
---	-------------------	-----------	---------	-----	--------------	----------

METHYLDOPA

TABLET;ORAL

METHYLDOPA

@	SUN PHARM INDS	125MG	A070073	001	Oct 09, 1986	Mar CAHN
@		250MG	A070060	001	Oct 09, 1986	Mar CAHN
@		500MG	A070074	001	Oct 09, 1986	Mar CAHN

METHYLENE BLUESOLUTION;INTRAVENOUS
PROVAYBLUE

+	PROVEPHARM SAS	50MG/10ML (5MG/ML)	N204630	001	Apr 08, 2016	Apr NEWA
---	----------------	--------------------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHERGINE

@	EDISON THERAPS LLC	0.2MG	N006035	003		Jan DISC
---	--------------------	-------	---------	-----	--	----------

METHYLERGONOVINE MALEATE

+	NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Jan CRLD
---	----------------	-------	---------	-----	--------------	----------

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

>A>	AB1	WATSON LABS INC	60MG	A078458	004	Jun 23, 2016	Jun NEWA
		RITALIN LA					
>D>	+	NOVARTIS	60MG	N021284	005	Oct 27, 2014	Jun CFTG
>A>	AB1	+	60MG	N021284	005	Oct 27, 2014	Jun CFTG

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	NOSTRUM LABS INC	5MG/5ML	A201466	001	Nov 12, 2013	Feb CAHN
AA		10MG/5ML	A201466	002	Nov 12, 2013	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	TEDOR PHARMA INC	10MG	A204772	001	Feb 29, 2016	Feb NEWA
AB		20MG	A204772	002	Feb 29, 2016	Feb NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A202691	001	Feb 16, 2016	Feb NEWA
AP		EQ 1GM BASE/VIAL	A202691	002	Feb 16, 2016	Feb NEWA
AP	SAGENT PHARMS	EQ 40MG BASE/VIAL	A040888	001	Jul 18, 2011	Jan CAHN
AP		EQ 125MG BASE/VIAL	A040888	002	Jul 18, 2011	Jan CAHN
AP		EQ 500MG BASE/VIAL	A040888	003	Jul 18, 2011	Jan CAHN
AP		EQ 1GM BASE/VIAL	A040888	004	Jul 18, 2011	Jan CAHN
AP		EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jan CAHN

METHYLTESTOSTERONE

TABLET; ORAL

ANDROID 10

@ VALEANT PHARM INTL

10MG

A086450 001

Apr DISC

METHYLTESTOSTERONE

@ IMPAX LABS

25MG

A084310 001

Mar DISC

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB SUN PHARM INDS

EQ 5MG BASE

A071536 002

Jan 16, 1997

Mar CAHN

@

EQ 10MG BASE

A071536 001

Apr 28, 1993

Mar CAHN

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

AP EUROHLTH INTL SARL

1MG/ML

A076495 001

Jul 07, 2003

Apr CAHN

TABLET; ORAL

METOPROLOL TARTRATE

@ SANDOZ

50MG

A073288 001

Mar 25, 1994

May DISC

@

100MG

A073289 001

Mar 25, 1994

May DISC

AB SUN PHARM INDS

25MG

A073654 002

Jul 15, 2009

Mar CAHN

AB

100MG

A073654 001

Dec 21, 1993

Mar CAHN

METRONIDAZOLE

GEL; VAGINAL

NUVESSA

+ ALLERGAN SALES LLC

1.3%

N205223 001

Mar 24, 2014

Apr CAHN

TABLET; ORAL

METRONIDAZOLE

AB FLAMINGO PHARMS

250MG

A207309 001

May 16, 2016

May NEWA

AB

500MG

A207309 002

May 16, 2016

May NEWA

AB NOSTRUM LABS INC

250MG

A070772 001

Jul 16, 1986

Jan CAHN

AB

500MG

A070773 001

Jul 16, 1986

Jan CAHN

AB STRIDES PHARMA

250MG

A208162 001

May 25, 2016

May NEWA

AB

500MG

A208162 002

May 25, 2016

May NEWA

AB VIVIMED LABS

250MG

A070040 001

Jan 29, 1985

May CMFD

AB

500MG

A070039 001

Jan 29, 1985

May CMFD

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+ MIDATECH PHARMA US

50MG

N022404 001

Apr 16, 2010

Jan CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP EUROHLTH INTL SARL

EQ 1MG BASE/ML

A075247 002

Jun 23, 2000

May CAHN

AP

EQ 1MG BASE/ML

A075421 002

Jun 20, 2000

Apr CAHN

AP

EQ 5MG BASE/ML

A075247 001

Jun 23, 2000

May CAHN

AP

EQ 5MG BASE/ML

A075421 001

Jun 20, 2000

Apr CAHN

MIGLITOL

TABLET; ORAL

GLYSET

AB + PHARMACIA AND UPJOHN

25MG

N020682 001

Dec 18, 1996

Feb CRLD

AB

100MG

N020682 003

Dec 18, 1996

Feb CRLD

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

AB AMNEAL PHARMS

12.5MG

A205081 001

Apr 22, 2016

Apr NEWA

AB

25MG

A205081 002

Apr 22, 2016

Apr NEWA

AB

50MG

A205081 003

Apr 22, 2016

Apr NEWA

AB

100MG

A205081 004

Apr 22, 2016

Apr NEWA

@ LIBERTY PHARMA INC

12.5MG

A205071 001

Jan 27, 2016

Jan DISC

@

12.5MG

A205071 001

Jan 27, 2016

Jan NEWA

@

25MG

A205071 002

Jan 27, 2016

Jan DISC

@

25MG

A205071 002

Jan 27, 2016

Jan NEWA

@

50MG

A205071 003

Jan 27, 2016

Jan DISC

@

50MG

A205071 003

Jan 27, 2016

Jan NEWA

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

	@	100MG	A205071	004	Jan 27, 2016	Jan DISC
		100MG	A205071	004	Jan 27, 2016	Jan NEWA
	SAVELLA					
AB	CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009	Apr CFTG
AB		25MG	N022256	002	Jan 14, 2009	Apr CFTG
AB	+	50MG	N022256	003	Jan 14, 2009	Apr CFTG
AB		100MG	N022256	004	Jan 14, 2009	Apr CFTG

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE

AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Apr CAHN
	MILRINONE LACTATE IN DEXTROSE 5%					
AP	CLARIS	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Mar CAHN
	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
>D> AP	BEDFORD LABS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jun CAHN
>D> AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jun CAHN
	@ CLARIS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Mar CAHN
>A> AP	EUROHLTH INTL SARL	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jun CAHN
>A> AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jun CAHN

MINOCYCLINE HYDROCHLORIDE

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jan NEWA
AB		EQ 75MG BASE	A090217	002	Jan 29, 2016	Jan NEWA
AB		EQ 100MG BASE	A090217	003	Jan 29, 2016	Jan NEWA

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 80MG BASE	A202261	006	Jun 13, 2016	May NEWA
AB		EQ 105MG BASE	A202261	007	Jun 13, 2016	May NEWA
	@ IMPAX LABS INC	EQ 45MG BASE	A090024	001	Feb 03, 2009	Mar DISC
	@	EQ 90MG BASE	A090024	002	Feb 03, 2009	Mar DISC
	@	EQ 135MG BASE	A090024	003	Feb 03, 2009	Mar DISC

MINOXIDIL

TABLET;ORAL

MINOXIDIL

AB	SUN PHARM INDS	10MG	A072709	001	Dec 14, 1995	Mar CAHN
----	----------------	------	---------	-----	--------------	----------

MIPOMERSEN SODIUM

SOLUTION;SUBCUTANEOUS

KYNAMRO

>D>	+	GENZYME CORP	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jun CAHN
>A>	+	KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jun CAHN

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

@	ACTAVIS LABS FL INC	15MG
@		30MG
@		45MG

A076336	001	Jun 20, 2003	Jan DISC
A076336	002	Jun 20, 2003	Jan DISC
A076336	003	Jun 20, 2003	Jan DISC

MITOMYCIN

INJECTABLE;INJECTION

MITOMYCIN

AP	EUROHLTH INTL SARL	5MG/VIAL	A064117	001	Apr 19, 1995	Apr CAHN
AP		5MG/VIAL	A064180	001	Dec 23, 1999	Jan CAHN
AP		20MG/VIAL	A064117	002	Apr 19, 1995	Apr CAHN
AP		20MG/VIAL	A064180	002	Dec 23, 1999	Jan CAHN

MODAFINILTABLET;ORAL
MODAFINIL

AB	WATSON LABS INC	100MG	A076715	001	Nov 01, 2012	Jan CAHN
AB		200MG	A076715	002	Nov 01, 2012	Jan CAHN

MOMETASONE FUROATESPRAY, METERED;NASAL
MOMETASONE FUROATE

AB	APOTEX INC	EQ 0.05MG BASE/SPRAY	A091161	001	Mar 22, 2016	Mar NEWA
	NASONEX					
AB	+ MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997	Mar CFTG

MORPHINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
KADIAN

AB	+ ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Feb CTEC
AB		20MG	N020616	001	Jul 03, 1996	Feb CTEC
AB		30MG	N020616	004	Mar 09, 2001	Feb CTEC
AB		40MG	N020616	009	Jul 09, 2012	Feb CTEC
AB		50MG	N020616	002	Jul 03, 1996	Feb CTEC
AB		60MG	N020616	005	Mar 09, 2001	Feb CTEC
AB		70MG	N020616	010	Jul 09, 2012	Feb CTEC
AB		80MG	N020616	006	Oct 27, 2006	Feb CTEC
AB	+	100MG	N020616	003	Jul 03, 1996	Feb CTEC
	+	200MG	N020616	007	Feb 27, 2007	Feb CTEC
AB	+ ALLERGAN SALES LLC	10MG	N020616	008	Apr 20, 2007	Apr CAHN
AB		20MG	N020616	001	Jul 03, 1996	Apr CAHN
AB		30MG	N020616	004	Mar 09, 2001	Apr CAHN
AB		40MG	N020616	009	Jul 09, 2012	Apr CAHN
AB		50MG	N020616	002	Jul 03, 1996	Apr CAHN
AB		60MG	N020616	005	Mar 09, 2001	Apr CAHN
AB		70MG	N020616	010	Jul 09, 2012	Apr CAHN
AB		80MG	N020616	006	Oct 27, 2006	Apr CAHN
AB	+	100MG	N020616	003	Jul 03, 1996	Apr CAHN
		130MG	N020616	011	Jul 09, 2012	Apr CAHN
		150MG	N020616	012	Jul 09, 2012	Apr CAHN
	+	200MG	N020616	007	Feb 27, 2007	Apr CAHN

MORPHINE SULFATE

AB	IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016	Mar NEWA
AB		30MG	A200411	002	Apr 12, 2016	Mar NEWA
AB		50MG	A200411	003	Apr 12, 2016	Mar NEWA
AB		60MG	A200411	004	Apr 12, 2016	Mar NEWA
AB		80MG	A200411	005	Apr 12, 2016	Mar NEWA
AB		100MG	A200411	006	Apr 12, 2016	Mar NEWA
AB	PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Feb CTEC
AB		30MG	A200812	002	Nov 10, 2011	Feb CTEC
AB		50MG	A200812	003	Nov 10, 2011	Feb CTEC
AB		60MG	A200812	004	Nov 10, 2011	Feb CTEC
AB		80MG	A200812	005	Nov 10, 2011	Feb CTEC
AB		100MG	A200812	006	Nov 10, 2011	Feb CTEC
AB	TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Feb CTEC
AB		30MG	A202718	002	Dec 29, 2014	Feb CTEC
AB		40MG	A202718	007	Jun 03, 2015	Feb CTEC
AB		50MG	A202718	003	Dec 29, 2014	Feb CTEC
AB		60MG	A202718	004	Dec 29, 2014	Feb CTEC
AB		70MG	A202718	008	Jun 03, 2015	Feb CTEC
AB		80MG	A202718	005	Dec 29, 2014	Feb CTEC
AB		100MG	A202718	006	Dec 29, 2014	Feb CTEC
AB	UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	Feb CTEC
AB		20MG	A202104	002	Jun 03, 2013	Feb CTEC
AB		30MG	A202104	003	Jun 03, 2013	Feb CTEC
AB		50MG	A202104	004	Jun 03, 2013	Feb CTEC
AB		60MG	A202104	005	Jun 03, 2013	Feb CTEC
AB		80MG	A202104	006	Jun 03, 2013	Feb CTEC
AB		100MG	A202104	007	Jun 03, 2013	Feb CTEC

SOLUTION;ORAL

MORPHINE SULFATE

AA	NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014	Mar CAHN
AA		20MG/5ML	A201011	002	Feb 05, 2014	Mar CAHN
>A>	RHODES PHARMS	20MG/5ML	A206420	001	Jul 12, 2016	Jun NEWA
AA	TRIS PHARMA INC	20MG/5ML	A203519	001	May 18, 2016	May NEWA

TABLET, EXTENDED RELEASE;ORAL
MORPHINE SULFATE

>A>	AB	COREPHARMA	15MG	A091357	001	Jun 23, 2016	Jun NEWA
>A>	AB		30MG	A091357	002	Jun 23, 2016	Jun NEWA
>A>	AB		60MG	A091357	003	Jun 23, 2016	Jun NEWA
>A>	AB		100MG	A091357	004	Jun 23, 2016	Jun NEWA
>A>	AB		200MG	A091357	005	Jun 23, 2016	Jun NEWA

MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL

AB		CROSSMEDIKA SA	EQ 400MG BASE	A205348	001	Jan 14, 2016	Jan NEWA
----	--	----------------	---------------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

>D>	AB	CADISTA PHARMS	250MG	A090762	001	Dec 15, 2014	Jun CAHN
>A>	AB	JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014	Jun CAHN

TABLET;ORAL

MYCOPHENOLATE MOFETIL

>D>	AB	CADISTA PHARMS	500MG	A090661	001	Dec 15, 2014	Jun CAHN
>A>	AB	JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014	Jun CAHN

NALIDIXIC ACID

TABLET;ORAL

NALIDIXIC ACID

>D>		@ MUTUAL PHARM	500MG	A070271	001	Jun 29, 1988	Jun CAHN
		@ SUN PHARM INDS	250MG	A070270	001	Jun 29, 1988	Mar CAHN
>A>		@	500MG	A070271	001	Jun 29, 1988	Jun CAHN
		@	1GM	A070272	001	Jun 29, 1988	Mar CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

>A>	AP	MYLAN INSTITUTIONAL	0.4MG/ML	A205014	001	Jun 29, 2016	Jun NEWA
-----	----	---------------------	----------	---------	-----	--------------	----------

NAPROXEN

SUSPENSION;ORAL

NAPROSYN

>A>	AB	+ ATNAHS PHARMA US	25MG/ML	N018965	001	Mar 23, 1987	Jun CAHN
>D>	AB	+ PEDIAPHARM INC	25MG/ML	N018965	001	Mar 23, 1987	Jun CAHN

TABLET;ORAL

NAPROSYN

AB		ATNAHS PHARMA US	250MG	N017581	002		Feb CAHN
AB			375MG	N017581	003		Feb CAHN
AB	+		500MG	N017581	004	Apr 15, 1982	Feb CAHN
		NAPROXEN					
		@ SANDOZ	250MG	A074140	001	Dec 21, 1993	Feb DISC
		@	375MG	A074140	002	Dec 21, 1993	Feb DISC
		@	500MG	A074140	003	Dec 21, 1993	Feb DISC

TABLET, DELAYED RELEASE;ORAL

EC-NAPROSYN

AB	+	ATNAHS PHARMA US	375MG	N020067	002	Oct 14, 1994	Feb CAHN
AB	+		500MG	N020067	003	Oct 14, 1994	Feb CAHN
		NAPROXEN					
		@ SANDOZ	375MG	A075061	001	Feb 18, 1998	Feb DISC
		@	500MG	A075061	002	Feb 18, 1998	Feb DISC

NAPROXEN SODIUM

TABLET;ORAL

ANAPROX

AB		ATNAHS PHARMA US	EQ 250MG BASE	N018164	001		Feb CAHN
		ANAPROX DS					
AB	+	ATNAHS PHARMA US	EQ 500MG BASE	N018164	003	Sep 30, 1987	Feb CAHN

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

>A>	AB	ZYDUS PHARMS USA INC	60MG	A205248	001	Jul 06, 2016	Jun NEWA
>A>	AB		120MG	A205248	002	Jul 06, 2016	Jun NEWA

>A>	<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN</u>				
>A>	TABLET;ORAL				
>A>	BYVALSON				
>A>	FOREST LABS LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016 Jun NEWA
<u>NEFAZODONE HYDROCHLORIDE</u>					
TABLET;ORAL					
NEFAZODONE HYDROCHLORIDE					
	@ SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003 Feb DISC
	@	100MG	A076409	002	Sep 16, 2003 Feb DISC
	@	150MG	A076409	003	Sep 16, 2003 Feb DISC
	@	200MG	A076409	004	Sep 16, 2003 Feb DISC
	@	250MG	A076409	005	Sep 16, 2003 Feb DISC
<u>NEOMYCIN SULFATE</u>					
TABLET;ORAL					
NEOMYCIN SULFATE					
AA	LANNETT HOLDINGS INC	500MG	A204435	001	Jun 10, 2016 May NEWA
<u>NICARDIPINE HYDROCHLORIDE</u>					
CAPSULE;ORAL					
CARDENE					
	@ CHIESI USA INC	20MG	N019488	001	Dec 21, 1988 May DISC
	@	30MG	N019488	002	Dec 21, 1988 May DISC
NICARDIPINE HYDROCHLORIDE					
AB	+ MYLAN	30MG	A074642	002	Jul 18, 1996 May CRLD
INJECTABLE;INJECTION					
NICARDIPINE HYDROCHLORIDE					
>D> AP	BEDFORD	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009 Jun CAHN
>A> AP	EUROHLTH INTL SARL	25MG/10ML (2.5MG/ML)	A078714	001	Dec 28, 2009 Jun CAHN
<u>NIFEDIPINE</u>					
CAPSULE;ORAL					
NIFEDIPINE					
	@ VALIDUS PHARMS	10MG	A073250	001	Oct 08, 1991 Mar CAHN
	@	20MG	A074045	001	Apr 30, 1992 Mar CAHN
TABLET, EXTENDED RELEASE;ORAL					
ADALAT CC					
AB1	ALVOGEN	30MG	N020198	001	Apr 21, 1993 Feb CAHN
AB1	+	60MG	N020198	002	Apr 21, 1993 Feb CAHN
AB1	+	90MG	N020198	003	Apr 21, 1993 Feb CAHN
NIFEDIPINE					
>D> AB2	OSMOTICA PHARM	30MG	A077127	001	Nov 21, 2005 Jun CAHN
>D> AB2		60MG	A077127	002	Nov 21, 2005 Jun CAHN
>A> AB2	OSMOTICA PHARM US	30MG	A077127	001	Nov 21, 2005 Jun CAHN
>A> AB2		60MG	A077127	002	Nov 21, 2005 Jun CAHN
AB1	VALEANT PHARMS NORTH	30MG	A075269	001	Dec 04, 2000 Jan CAHN
AB1		60MG	A075269	002	Dec 04, 2000 Jan CAHN
AB1		90MG	A076070	001	Aug 16, 2002 Jan CAHN
<u>NIMODIPINE</u>					
CAPSULE;ORAL					
NIMODIPINE					
AB	+ BIONPHARMA INC	30MG	A076740	001	Jan 17, 2008 Jan CAHN
<u>NITISINONE</u>					
CAPSULE;ORAL					
ORFADIN					
>A>	+ SWEDISH ORPHAN	20MG	N021232	004	Jun 13, 2016 Jun NEWA
SUSPENSION;ORAL					
ORFADIN					
	+ SWEDISH ORPHAN	4MG/ML	N206356	001	Apr 22, 2016 Apr NEWA
<u>NITRIC OXIDE</u>					
GAS;INHALATION					
INOMAX					
	+ MALLINCKRODT HOSP	800PPM	N020845	003	Dec 23, 1999 Jan CAHN

NITROFURANTOINSUSPENSION;ORAL
FURADANTIN

>A>	AB	+	CASPER PHARMA LLC	25MG/5ML	N009175	001		Jun	CAHN
>D>	AB	+	SHIONOGI INC	25MG/5ML	N009175	001		Jun	CAHN
<u>NITROFURANTOIN</u>									
	AB		ACTAVIS MID ATLANTIC	25MG/5ML	A205180	001	May 03, 2016	Apr	NEWA
	AB		NOSTRUM LABS INC	25MG/5ML	A201355	001	Aug 14, 2013	Feb	CAHN

NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL
NITROFURANTOIN

	AB		SUN PHARM INDS	25MG	A201722	001	Feb 16, 2016	Feb	NEWA
	AB			50MG	A201722	002	Feb 16, 2016	Feb	NEWA
	AB			100MG	A201722	003	Feb 16, 2016	Feb	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL
MACROBID

	AB	+	ALVOGEN MALTA	75MG;25MG	N020064	001	Dec 24, 1991	Jan	CAHN
--	----	---	---------------	-----------	---------	-----	--------------	-----	------

NITROGLYCERINFILM, EXTENDED RELEASE;TRANSDERMAL
MINITRAN

	AB1		VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996	May	CAHN
>A>			POWDER;SUBLINGUAL						
>A>			GONITRO						
>A>		+	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016	Jun	NEWA

NIZATIDINESOLUTION;ORAL
AXID@ BRAINTREE
NIZATIDINE

+ AMNEAL PHARMS

N021494	001	May 25, 2004	Feb	DISC
A090576	001	Nov 18, 2009	Feb	CRLD

NOREPINEPHRINE BITARTRATEINJECTABLE;INJECTION
NOREPINEPHRINE BITARTRATE

AP		CLARIS	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Jan	CAHN
AP		EUROHLTH INTL SARL	EQ 1MG BASE/ML	A040462	001	Oct 31, 2003	Apr	CAHN

NORETHINDRONETABLET;ORAL-28
NOR-QD

AB1	+	APIL	0.35MG	N017060	001		Jan	CAHN
-----	---	------	--------	---------	-----	--	-----	------

NORTRIPTYLINE HYDROCHLORIDECAPSULE;ORAL
NORTRIPTYLINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC	EQ 10MG BASE
@	EQ 25MG BASE
@	EQ 50MG BASE
@	EQ 75MG BASE
@ IDT AUSTRALIA LTD	EQ 10MG BASE
@	EQ 25MG BASE
@	EQ 50MG BASE
@	EQ 75MG BASE

A074835	001	Jun 30, 1997	Feb	CAHN
A074835	002	Jun 30, 1997	Feb	CAHN
A074835	003	Jun 30, 1997	Feb	CAHN
A074835	004	Jun 30, 1997	Feb	CAHN
A074054	001	Dec 31, 1992	May	CAHN
A074054	002	Dec 31, 1992	May	CAHN
A074054	003	Dec 31, 1992	May	CAHN
A074054	004	Dec 31, 1992	May	CAHN

NYSTATINTABLET;ORAL
NYSTATIN

AA		SUN PHARM INDS	500,000 UNITS	A062838	001	Dec 22, 1988	Mar	CAHN
----	--	----------------	---------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDECREAM;TOPICAL
NYSTATIN TRIAMCINOLONE ACETONIDE

@ PHARMADERM

A062596	001	Oct 08, 1985	Mar	CMS1
---------	-----	--------------	-----	------

OINTMENT;TOPICAL
MYKACET

AT	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733	001	Mar 06, 1987	May CMS1
	NYSTATIN AND TRIAMCINOLONE ACETONIDE					
>A> AT	GLENMARK PHARMS LTD	100,000 UNITS/GM;0.1%	A208300	001	Jun 23, 2016	Jun NEWA

OBETICHOLIC ACID

TABLET;ORAL
OCALIVA

	INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016	May NEWA
+		10MG	N207999	002	May 27, 2016	May NEWA

OCTREOTIDE ACETATE

INJECTABLE;INJECTION
OCTREOTIDE ACETATE

@	WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011	Jan DISC
@		EQ 1MG BASE/ML	A090986	002	May 11, 2011	Jan DISC
	OCTREOTIDE ACETATE (PRESERVATIVE FREE)					
@	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Jan DISC
@		EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Jan DISC
@		EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Jan DISC
	OCTREOTIDE ACETATE PRESERVATIVE FREE					
@	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Feb CMS1
@		EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Feb CMS1
@		EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Feb CMS1

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC
OFLOXACIN

AT	ALVOGEN	0.3%	A076830	001	Aug 31, 2004	Mar CAHN
	SOLUTION/DROPS;OTIC					
	FLOXIN OTIC					
	@ DAIICHI	0.3%	N020799	001	Dec 16, 1997	Feb DISC
	OFLOXACIN					
AT	ALVOGEN	0.3%	A090395	001	Aug 11, 2009	Mar CAHN
AT	+ BAUSCH AND LOMB	0.3%	A076128	001	Mar 17, 2008	Feb CRLD

OLANZAPINE

TABLET;ORAL
OLANZAPINE

AB	INVAGEN PHARMS	2.5MG	A203333	001	Mar 15, 2016	Feb NEWA
AB		5MG	A203333	002	Mar 15, 2016	Feb NEWA
AB		7.5MG	A203333	003	Mar 15, 2016	Feb NEWA
AB		10MG	A203333	004	Mar 15, 2016	Feb NEWA
AB		15MG	A203333	005	Mar 15, 2016	Feb NEWA
AB		20MG	A203333	006	Mar 15, 2016	Feb NEWA
AB	QILU PHARM CO LTD	2.5MG	A204319	001	Jan 27, 2016	Jan NEWA
AB		5MG	A204319	002	Jan 27, 2016	Jan NEWA
AB		7.5MG	A204319	003	Jan 27, 2016	Jan NEWA
AB		10MG	A204319	004	Jan 27, 2016	Jan NEWA
AB		15MG	A204319	005	Jan 27, 2016	Jan NEWA
AB		20MG	A204319	006	Jan 27, 2016	Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

AB	INVAGEN PHARMS	5MG	A203456	001	Mar 16, 2016	Feb NEWA
AB		10MG	A203456	002	Mar 16, 2016	Feb NEWA
AB		15MG	A203456	003	Mar 16, 2016	Feb NEWA
AB		20MG	A203456	004	Mar 16, 2016	Feb NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT	SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Mar CAHN
----	----------------------	--------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

AB	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Jan CMS1
----	---------------	--	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS TYPE A

CAPSULE;ORAL

OMTRYG

+	TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Mar CAIN
---	-------	--	---------	-----	--------------	----------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

AB	+	SANDOZ	20MG	A075757	002	Jan 28, 2003	Mar CRLD
AB	+		40MG	A076515	001	Jan 21, 2009	Mar CRLD
>D>		PRILOSEC					
>D>	AB	ASTRAZENECA PHARMS	10MG	N019810	003	Oct 05, 1995	Jun DISC
>A>		@	10MG	N019810	003	Oct 05, 1995	Jun DISC
>D>	AB	+	20MG	N019810	001	Sep 14, 1989	Jun DISC
>A>		@	20MG	N019810	001	Sep 14, 1989	Jun DISC
>D>	AB	+	40MG	N019810	002	Jan 15, 1998	Jun DISC
>A>		@	40MG	N019810	002	Jan 15, 1998	Jun DISC

ONDANSETRON

FILM;ORAL

ZUPLENZ

>D>		GALENA BIOPHARMA INC	4MG	N022524	001	Jul 02, 2010	Jun CAHN
>D>	+		8MG	N022524	002	Jul 02, 2010	Jun CAHN
>A>		MIDATECH PHARMA US	4MG	N022524	001	Jul 02, 2010	Jun CAHN
>A>	+		8MG	N022524	002	Jul 02, 2010	Jun CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP		EUROHLTH INTL SARL	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Apr CAHN
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP		ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	Feb NEWA
AP		EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Apr CAHN

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

@	HIKMA INTL PHARMS	EQ 4MG BASE	A077545	001	Sep 06, 2007	May CAHN
@		EQ 8MG BASE	A077545	002	Sep 06, 2007	May CAHN
@		EQ 24MG BASE	A077545	003	Sep 06, 2007	May CAHN

OXALIPLATIN

INJECTABLE;IV (INFUSION)

ELOXATIN

>D>	AP	+	SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jun DISC
>A>		@		200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jun DISC
	AP	+		200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	May CFTG
			OXALIPLATIN					
	AP		QILU PHARM CO LTD	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	May NEWA
	AP			50MG/VIAL	A204616	001	May 11, 2016	Apr NEWA
	AP			100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	May NEWA
	AP			100MG/VIAL	A204616	002	May 11, 2016	Apr NEWA
>D>	AP			200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jun CRLD
>A>		+		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jun CRLD
	AP			200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	May NEWA
	AP		SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Jan CAHN
	AP			100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Jan CAHN

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

@	SUN PHARM INDS	10MG	A071026	002	Aug 10, 1987	Mar CAHN
@		15MG	A071026	003	Aug 10, 1987	Mar CAHN
@		30MG	A071026	001	Aug 10, 1987	Mar CAHN

TABLET;ORAL

OXAZEPAM

>D>		@	MUTUAL PHARM	15MG	A070683	001	Jan 16, 1987	Jun CAHN
>A>		@	SUN PHARM INDS	15MG	A070683	001	Jan 16, 1987	Jun CAHN

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

>D>	@ ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007	Jun CMFD
>A>	AB	150MG	A078005	001	Dec 11, 2007	Jun CMFD
>D>	@	300MG	A078005	002	Dec 11, 2007	Jun CMFD
>A>	AB	300MG	A078005	002	Dec 11, 2007	Jun CMFD
>D>	@	600MG	A078005	003	Dec 11, 2007	Jun CMFD
>A>	AB	600MG	A078005	003	Dec 11, 2007	Jun CMFD

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXICONAZOLE NITRATE

AB	TARO	EQ 1% BASE	A205076	001	Mar 07, 2016	Feb NEWA
AB	OXISTAT					
AB	+ FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988	Feb CFTG

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYTROL

AB	+ ALLERGAN SALES LLC	3.9MG/24HR	N021351	002	Feb 26, 2003	Apr CAHN
	GEL, METERED; TRANSDERMAL					
	GELNIQUE 3%					
	+ ALLERGAN SALES LLC	3%	N202513	001	Dec 07, 2011	Apr CAHN

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

	+ ALLERGAN SALES LLC	10% (100MG/PACKET)	N022204	001	Jan 27, 2009	Apr CAHN
--	----------------------	--------------------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

AB	ACCORD HLTHCARE	5MG	A207138	001	Feb 29, 2016	Feb NEWA
AB		10MG	A207138	002	Feb 29, 2016	Feb NEWA
AB		15MG	A207138	003	Feb 29, 2016	Feb NEWA
>D>	AB	OSMOTICA PHARM	A078503	001	Feb 04, 2009	Jun CAHN
>D>	AB		A078503	002	Feb 04, 2009	Jun CAHN
>D>	AB		A078503	003	Feb 04, 2009	Jun CAHN
>A>	AB	OSMOTICA PHARM US	A078503	001	Feb 04, 2009	Jun CAHN
>A>	AB		A078503	002	Feb 04, 2009	Jun CAHN
>A>	AB		A078503	003	Feb 04, 2009	Jun CAHN
AB	UNIQUE PHARM LABS	5MG	A206121	001	May 27, 2016	May NEWA
AB		10MG	A206121	002	May 27, 2016	May NEWA
AB		15MG	A206121	003	May 27, 2016	May NEWA

OXYCODONE

CAPSULE, EXTENDED RELEASE; ORAL

XTAMPZA ER

	COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016	May CAIN
		13.5MG	N208090	002	Apr 26, 2016	May CAIN
		18MG	N208090	003	Apr 26, 2016	May CAIN
		27MG	N208090	004	Apr 26, 2016	May CAIN
	+	36MG	N208090	005	Apr 26, 2016	May CAIN

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

AB	ANI PHARMS INC	5MG	A205177	001	Mar 31, 2016	Mar NEWA
----	----------------	-----	---------	-----	--------------	----------

CAPSULE, EXTENDED RELEASE; ORAL

XTAMPZA ER

	COLLEGIUM PHARM INC	EQ 9MG BASE	N208090	001	Apr 26, 2016	Apr NEWA
		EQ 13.5MG BASE	N208090	002	Apr 26, 2016	Apr NEWA
		EQ 18MG BASE	N208090	003	Apr 26, 2016	Apr NEWA
		EQ 27MG BASE	N208090	004	Apr 26, 2016	Apr NEWA
	+	EQ 36MG BASE	N208090	005	Apr 26, 2016	May CRLD
		EQ 36MG BASE	N208090	005	Apr 26, 2016	Apr NEWA

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB	ALVOGEN MALTA	5MG	A202116	001	Dec 30, 2011	Jan CAHN
AB		15MG	A202116	002	Dec 30, 2011	Jan CAHN
AB		30MG	A202116	003	Dec 30, 2011	Jan CAHN
AB	COASTAL PHARMS	10MG	A091313	004	Apr 29, 2016	Apr NEWA

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB		20MG	A091313	005	Apr 29, 2016	Apr	NEWA
AB	KEN LIFESCIENCE	5MG	A207119	001	Apr 12, 2016	Mar	NEWA
AB		10MG	A207119	002	Apr 12, 2016	Mar	NEWA
AB		15MG	A207119	003	Apr 12, 2016	Mar	NEWA
AB		20MG	A207119	004	Apr 12, 2016	Mar	NEWA
AB		30MG	A207119	005	Apr 12, 2016	Mar	NEWA

>A> OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

>A> SPRAY, METERED; NASAL

>A> KOVANAZE

>A>	+	ST RENATUS	0.1MG/SPRAY; 6MG/SPRAY	N208032	001	Jun 29, 2016	Jun	NEWA
-----	---	------------	------------------------	---------	-----	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	5MG	A204459	001	Apr 26, 2016	Apr	NEWA
AB		10MG	A204459	002	Apr 26, 2016	Apr	NEWA

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

AP	SANDOZ INC	6MG/ML	A078167	001	Dec 26, 2007	Jan	CAHN
----	------------	--------	---------	-----	--------------	-----	------

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

	JANSSEN PHARMS	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Mar	CRLD
+		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Mar	CRLD

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Apr	NEWA
AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr	NEWA

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Mar	NEWA
		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Mar	NEWA

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP	SAGENT PHARMS	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	Jan	CAHN
AP		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	Jan	CAHN

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

PANTOPRAZOLE SODIUM

AP	AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	A205675	001	Mar 30, 2016	Mar	NEWA
----	----------------------	-------------------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	AMNEAL PHARMS	EQ 20MG BASE	A205119	001	Jan 26, 2016	Jan	NEWA
AB		EQ 40MG BASE	A205119	002	Jan 26, 2016	Jan	NEWA

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

AB	BIONPHARMA INC	1MCG	A202539	001	Mar 27, 2014	Jan	CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan	CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan	CAHN
AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Feb	NEWA
AB		2MCG	A206710	002	Feb 24, 2016	Feb	NEWA
AB		4MCG	A206710	003	Feb 24, 2016	Feb	NEWA

SOLUTION; INTRAVENOUS

PARICALCITOL

AP	ACCORD HLTHCARE	0.002MG/ML (0.002MG/ML)	N207174	001	Feb 04, 2016	Feb	NEWA
----	-----------------	-------------------------	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS									
PARICALCITOL									
AP		0.005MG/ML (0.005MG/ML)		N207174	002	Feb 04, 2016	Feb	NEWA	
AP		0.01MG/2ML (0.005MG/ML)		N207174	003	Feb 04, 2016	Feb	NEWA	
<u>PAROXETINE HYDROCHLORIDE</u>									
TABLET, EXTENDED RELEASE; ORAL									
PAROXETINE HYDROCHLORIDE									
AB	KREMERS URBAN PHARMS	EQ 12.5MG BASE		A204744	001	Jun 10, 2016	May	NEWA	
AB		EQ 25MG BASE		A204744	002	Jun 10, 2016	May	NEWA	
AB		EQ 37.5MG BASE		A204744	003	Jun 10, 2016	May	NEWA	
<u>PENBUTOLOL SULFATE</u>									
TABLET; ORAL									
LEVATOL									
	@ AUXILIUM PHARMS INC	10MG		N018976	001	Dec 30, 1987	Mar	CAHN	
	@	20MG		N018976	004	Jan 05, 1989	Mar	CAHN	
<u>PENCICLOVIR</u>									
CREAM; TOPICAL									
DENA VIR									
+	DENCO ASSET	1%		N020629	001	Sep 24, 1996	Apr	CAIN	
<u>PENTETATE CALCIUM TRISODIUM</u>									
SOLUTION; INHALATION, INTRAVENOUS									
PENTETATE CALCIUM TRISODIUM									
+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)		N021749	001	Aug 11, 2004	Apr	CMFD	
	@	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)		N021749	001	Aug 11, 2004	Feb	CAHN	
<u>PENTETATE ZINC TRISODIUM</u>									
SOLUTION; INHALATION, INTRAVENOUS									
PENTETATE ZINC TRISODIUM									
+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)		N021751	001	Aug 11, 2004	Apr	CMFD	
	@	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)		N021751	001	Aug 11, 2004	Feb	CAHN	
<u>PENTOBARBITAL SODIUM</u>									
INJECTABLE; INJECTION									
NEMBUTAL SODIUM									
AP	+	OAK PHARMS	50MG/ML	A083246	001		May	CTEC	
PENTOBARBITAL SODIUM									
AP		MYLAN INSTITUTIONAL	50MG/ML	A206404	001	May 23, 2016	May	NEWA	
<u>PENTOXIFYLLINE</u>									
TABLET, EXTENDED RELEASE; ORAL									
PENTOXIFYLLINE									
AB	+	APOTEX	400MG	A075191	001	Jun 09, 1999	Mar	CRLD	
	@	IMPAX LABS	400MG	A075093	001	Aug 10, 1999	Mar	DISC	
	@	PLIVA	400MG	A074874	001	May 25, 1999	Mar	DISC	
TRENTAL									
	@	US PHARM HOLDINGS	400MG	N018631	001	Aug 30, 1984	Jan	CAHN	
<u>PERAMPANEL</u>									
SUSPENSION; ORAL									
FYCOMPA									
+	EISAI INC	0.5MG/ML		N208277	001	Apr 29, 2016	Apr	NEWA	
<u>PERPHENAZINE</u>									
TABLET; ORAL									
PERPHENAZINE									
AB		WILSHIRE PHARMS INC	2MG	A205973	001	Dec 17, 2015	Jan	CAHN	
AB			4MG	A205973	002	Dec 17, 2015	Jan	CAHN	
AB			8MG	A205973	003	Dec 17, 2015	Jan	CAHN	
AB			16MG	A205973	004	Dec 17, 2015	Jan	CAHN	
<u>PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM</u>									
TABLET; ORAL									
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE									
	@ ABLE	200MG, N/A, N/A; N/A, 800MG, 160MG		N021105	001	Jun 26, 2001	Jan	CMS1	

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

AA	SUN PHARM INDS	30MG	A040525	001	Oct 23, 2003	Mar CAHN
	@	37.5MG	A040527	001	Oct 23, 2003	Mar CAHN

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

AA	INGENUS PHARMS NJ	37.5MG	A091451	001	Sep 21, 2012	Jan CAHN
AA	SUN PHARM INDS	37.5MG	A040526	001	Oct 23, 2003	Mar CAHN

>D> TABLET, ORALLY DISINTEGRATING;ORAL

>D> SUPRENZA

>D>	CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011	Jun DISC
>A>	@	15MG	N202088	001	Jun 13, 2011	Jun DISC
>D>		30MG	N202088	002	Jun 13, 2011	Jun DISC
>A>	@	30MG	N202088	002	Jun 13, 2011	Jun DISC
>D>	+	37.5MG	N202088	003	Mar 27, 2012	Jun DISC
>A>	@	37.5MG	N202088	003	Mar 27, 2012	Jun DISC

PHENYLBUTAZONE

CAPSULE;ORAL

PHENYLBUTAZONE

@	SUN PHARM INDS	100MG	A088994	001	Dec 04, 1985	Mar CAHN
---	----------------	-------	---------	-----	--------------	----------

TABLET;ORAL

PHENYLBUTAZONE

@	SUN PHARM INDS	100MG	A088863	001	Dec 04, 1985	Mar CAHN
---	----------------	-------	---------	-----	--------------	----------

PHYTONADIONE

INJECTABLE;INJECTION

AQUAMEPHYTON

@	TELIGENT PHARMA INC	1MG/0.5ML	N012223	002		Jan CAHN
@		10MG/ML	N012223	001		Jan CAHN

PIMAVANSERIN TARTRATE

TABLET;ORAL

NUPLAZID

+	ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016	Apr NEWA
---	-------------------	--------------	---------	-----	--------------	----------

PINDOLOL

TABLET;ORAL

PINDOLOL

@	IDT AUSTRALIA LTD	5MG	A073608	001	Mar 29, 1993	May CAHN
@		10MG	A073609	001	Mar 29, 1993	May CAHN
AB	SUN PHARM INDS	5MG	A074063	001	Jan 27, 1994	Mar CAHN
AB		10MG	A074063	002	Jan 27, 1994	Mar CAHN

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB	MYLAN PHARMS INC	20MG	A074118	001	Jun 15, 1993	Jan CAHN
@	SUN PHARM INDS	20MG	A073536	001	Mar 12, 1993	Mar CAHN

PODOFILOX

GEL;TOPICAL

CONDYLOX

+	ALLERGAN SALES LLC	0.5%	N020529	001	Mar 13, 1997	Mar CAHN
---	--------------------	------	---------	-----	--------------	----------

SOLUTION;TOPICAL

CONDYLOX

AT	+	ALLERGAN SALES LLC	0.5%	N019795	001	Dec 13, 1990	Mar CAHN
----	---	--------------------	------	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

@	MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	May DISC
---	-------------	---	---------	-----	--------------	----------

POLYMYXIN B SULFATEINJECTABLE;INJECTION
POLYMYXIN B SULFATE

AP	AUROBINDO PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A206589	001	Apr 04, 2016	Mar NEWA
AP	GLAND PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	Apr NEWA

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB	GLENMARK PHARMS LTD	10MEQ	A202868	001	Jan 19, 2016	Jan NEWA
AB	KREMERS URBAN PHARMS	8MEQ	A204210	001	Mar 28, 2016	Mar NEWA
AB		10MEQ	A204210	002	Mar 28, 2016	Mar NEWA
AB	TRIS PHARMA INC	8MEQ	A201944	001	Mar 04, 2016	Feb NEWA
AB		10MEQ	A201944	002	Mar 04, 2016	Feb NEWA

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB1	NOVEL LABS INC	10MEQ	A206347	001	Jan 21, 2016	Jan NEWA
AB1		20MEQ	A206347	002	Jan 21, 2016	Jan NEWA

PRAMIPEXOLE DIHYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS ELIZABETH	0.375MG	A201963	001	Apr 21, 2016	Apr NEWA
AB		0.75MG	A201963	002	Apr 21, 2016	Apr NEWA
AB		1.5MG	A201963	003	Apr 21, 2016	Apr NEWA
AB		3MG	A201963	004	Apr 21, 2016	Apr NEWA
AB		4.5MG	A201963	005	Apr 21, 2016	Apr NEWA
>A> AB	MACLEODS PHARMS LTD	0.375MG	A206156	001	Jun 24, 2016	Jun NEWA
>A> AB		0.75MG	A206156	002	Jun 24, 2016	Jun NEWA
>A> AB		1.5MG	A206156	003	Jun 24, 2016	Jun NEWA
>A> AB		2.25MG	A206156	004	Jun 24, 2016	Jun NEWA
>A> AB		3MG	A206156	005	Jun 24, 2016	Jun NEWA
>A> AB		4.5MG	A206156	007	Jun 24, 2016	Jun NEWA

PRAVASTATIN SODIUMTABLET;ORAL
PRAVASTATIN SODIUM

AB	CIPLA LTD	80MG	A077904	004	Mar 22, 2016	Mar NEWA
	@ MYLAN	10MG	A077013	001	Oct 23, 2006	Mar DISC
	@	20MG	A077013	002	Oct 23, 2006	Mar DISC
	@	40MG	A077013	003	Oct 23, 2006	Mar DISC
	@	80MG	A077013	004	Dec 28, 2007	Mar DISC

PRAZOSIN HYDROCHLORIDECAPSULE;ORAL
PRAZOSIN HYDROCHLORIDE

@	IDT AUSTRALIA LTD	EQ 1MG BASE	A072576	001	May 16, 1989	May CAHN
@		EQ 2MG BASE	A072577	001	May 16, 1989	May CAHN
@		EQ 5MG BASE	A072578	001	May 16, 1989	May CAHN

PREDNISOLONETABLET;ORAL
PREDNISOLONE

@	AUROLIFE PHARMA LLC	5MG	A084773	001		Feb CAHN
---	---------------------	-----	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATESOLUTION;ORAL
ORAPRED

@	CONCORDIA PHARMS INC	EQ 15MG BASE/5ML	A075117	001	Dec 14, 2000	Mar DISC
AA	+ WOCKHARDT	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Mar CRLD

PREDNISONETABLET;ORAL
PREDNISONE

@	AUROLIFE PHARMA LLC	5MG	A084774	001		Mar CAHN
@		10MG	A089983	001	Jan 12, 1989	Mar CAHN
@		20MG	A085813	001		Mar CAHN
@		50MG	A089984	001	Jan 12, 1989	Mar CAHN
AB	DELCOR ASSET CORP	5MG	A080292	001		Mar CAHN
AB		10MG	A088832	001	Dec 04, 1985	Mar CAHN

TABLET;ORAL
PREDNISONE

AB		20MG	A083677	001		Mar CAHN
>D>	@ MUTUAL PHARM	50MG	A086596	001		Jun CAHN
AB	SUN PHARM INDS	20MG	A089247	001	Dec 04, 1985	Mar CAHN
>A>	@	50MG	A086596	001		Jun CAHN

PRIMAQUINE PHOSPHATE

TABLET;ORAL
PRIMAQUINE PHOSPHATE

>A>	AB	INGENUS PHARMS NJ	EQ 15MG BASE	A206043	001	Jun 23, 2016	Jun NEWA
-----	----	-------------------	--------------	---------	-----	--------------	----------

PRIMIDONE

TABLET;ORAL
PRIMIDONE

	@ IMPAX LABS	50MG	A040717	001	Feb 12, 2008	Mar DISC
	@	250MG	A040717	002	Feb 12, 2008	Mar DISC
AB	SUN PHARM INDS	50MG	A040626	001	Sep 29, 2005	Mar CAHN
AB		250MG	A040626	002	Sep 29, 2005	Mar CAHN

PROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL
PROCAINAMIDE HYDROCHLORIDE

@	IDT AUSTRALIA LTD	375MG	A089220	001	Jul 01, 1986	May CAHN
---	-------------------	-------	---------	-----	--------------	----------

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION
PROCHLORPERAZINE EDISYLATE

>A>	AP	AMPHASTAR PHARMS INC	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Jun CAHN
>D>	AP	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A040540	001	May 28, 2004	Jun CAHN
	AP		EQ 5MG BASE/ML	A040540	001	May 28, 2004	Apr CAHN

PROGESTERONE

CAPSULE;ORAL
PROGESTERONE

AB	BIONPHARMA INC	100MG	A200900	001	Aug 16, 2013	Jan CAHN	
AB		200MG	A200900	002	Aug 16, 2013	Jan CAHN	
>D>	AB	ABBVIE INC	100MG	N019781	001	May 14, 1998	Jun CAHN
>D>	AB	+	200MG	N019781	002	Oct 15, 1999	Jun CAHN
>D>		@	300MG	N019781	003	Oct 15, 1999	Jun CAHN
>A>	AB	VIRTUS PHARMS	100MG	N019781	001	May 14, 1998	Jun CAHN
>A>	AB	+	200MG	N019781	002	Oct 15, 1999	Jun CAHN
>A>		@	300MG	N019781	003	Oct 15, 1999	Jun CAHN

GEL;VAGINAL
CRINONE

+	ALLERGAN SALES LLC	4%	N020701	001	Jul 31, 1997	Apr CAHN
+		8%	N020701	002	Jul 31, 1997	Apr CAHN

INJECTABLE;INJECTION
PROGESTERONE

AO	+	ALLERGAN SALES LLC	50MG/ML	N017362	002		Apr CAHN
----	---	--------------------	---------	---------	-----	--	----------

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETHAZINE HYDROCHLORIDE

AA	NOSTRUM LABS INC	6.25MG/5ML	A040891	001	Mar 13, 2009	Feb CAHN
----	------------------	------------	---------	-----	--------------	----------

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

@	IMPAX LABS	12.5MG	A040724	001	Feb 12, 2008	Mar DISC
@		25MG	A040724	002	Feb 12, 2008	Mar DISC
@		50MG	A040791	001	May 20, 2008	Mar DISC
@	SUN PHARM INDS	12.5MG	A084555	001		Mar CAHN
@		25MG	A084554	001		Mar CAHN
@		50MG	A084557	001		Jan CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
PROPAFENONE HYDROCHLORIDE

AB	MYLAN PHARMS INC	225MG	A203803	001	Apr 29, 2016	Apr NEWA
AB		325MG	A203803	002	Apr 29, 2016	Apr NEWA
AB		425MG	A203803	003	Apr 29, 2016	Apr NEWA

TABLET;ORAL

PROPafenONE HYDROCHLORIDE

AB	ORION CORP ORION	150MG	A202445	001	May 11, 2016	Apr	NEWA
AB		225MG	A202445	002	May 11, 2016	Apr	NEWA
AB		300MG	A202445	003	May 11, 2016	Apr	NEWA
AB	SUN PHARM INDS	150MG	A075998	001	Nov 29, 2001	Mar	CAHN
AB		225MG	A075998	002	Nov 29, 2001	Mar	CAHN
AB		300MG	A075998	003	Nov 29, 2001	Mar	CAHN

PROPRANOLOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
INDERAL LA

AB	ANI PHARMS INC	60MG	N018553	004	Mar 18, 1987	Apr	CAHN
AB		80MG	N018553	002	Apr 19, 1983	Apr	CAHN
AB		120MG	N018553	003	Apr 19, 1983	Apr	CAHN
AB	+	160MG	N018553	001	Apr 19, 1983	Apr	CAHN

PROPRANOLOL HYDROCHLORIDE

>D>	@ UPSHER SMITH	60MG	A078311	001	Mar 06, 2009	Jun	CMFD
>A> BX		60MG	A078311	001	Mar 06, 2009	Jun	CMFD
	@	60MG	A078311	001	Mar 06, 2009	May	DISC
BX		60MG	A078311	001	Mar 06, 2009	Mar	CTEC
>D>	@	80MG	A078311	002	Mar 06, 2009	Jun	CMFD
>A> BX		80MG	A078311	002	Mar 06, 2009	Jun	CMFD
	@	80MG	A078311	002	Mar 06, 2009	May	DISC
BX		80MG	A078311	002	Mar 06, 2009	Mar	CTEC
>D>	@	120MG	A078311	003	Mar 06, 2009	Jun	CMFD
>A> BX		120MG	A078311	003	Mar 06, 2009	Jun	CMFD
	@	120MG	A078311	003	Mar 06, 2009	May	DISC
BX		120MG	A078311	003	Mar 06, 2009	Mar	CTEC
>D>	@	160MG	A078311	004	Mar 06, 2009	Jun	CMFD
>A> BX		160MG	A078311	004	Mar 06, 2009	Jun	CMFD
	@	160MG	A078311	004	Mar 06, 2009	May	DISC
BX		160MG	A078311	004	Mar 06, 2009	Mar	CTEC

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

>A> AP	AMPHASTAR PHARMS INC	1MG/ML	A075792	001	Aug 29, 2000	Jun	CAHN
>D> AP	EUROHLTH INTL SARL	1MG/ML	A075792	001	Aug 29, 2000	Jun	CAHN
AP		1MG/ML	A075792	001	Aug 29, 2000	Apr	CAHN
	@ SANDOZ	1MG/ML	A076400	001	Feb 26, 2003	Mar	DISC

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

>D>	@ MUTUAL PHARM	60MG	A070321	001	Sep 24, 1986	Jun	CAHN
	@ SUN PHARM INDS	10MG	A070319	001	Oct 22, 1985	Mar	CAHN
	@	20MG	A070320	001	Oct 22, 1985	Mar	CAHN
	@	40MG	A070103	001	Oct 22, 1985	Mar	CAHN
>A>	@	60MG	A070321	001	Sep 24, 1986	Jun	CAHN
	@	80MG	A070322	001	Aug 04, 1986	Mar	CAHN

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

>A>	@ HIKMA INTL PHARMS	50MG	A080154	001		Jun	CAHN
	@ SUN PHARM INDS	50MG	A083982	001		Mar	CAHN
>D>	@ WEST WARD	50MG	A080154	001		Jun	CAHN

PYRIDOSTIGMINE BROMIDETABLET, EXTENDED RELEASE;ORAL
PYRIDOSTIGMINE BROMIDE

AB	ALVOGEN MALTA	180MG	A204737	001	Jun 26, 2015	Jan	CAHN
----	---------------	-------	---------	-----	--------------	-----	------

QUAZEPAM

TABLET;ORAL

DORAL

	@ CUTIS HEALTH LLC	7.5MG	N018708	003	Feb 26, 1987	Mar	CAHN
+		15MG	N018708	001	Dec 27, 1985	Apr	CMFD
	@	15MG	N018708	001	Dec 27, 1985	Mar	CAHN

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

	@	ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013	Apr	DISC
	@		EQ 50MG BASE	A201762	002	Feb 27, 2013	Apr	DISC
	@		EQ 100MG BASE	A201762	003	Feb 27, 2013	Apr	DISC
	@		EQ 150MG BASE	A201762	004	Feb 27, 2013	Apr	DISC
	@		EQ 200MG BASE	A201762	005	Feb 27, 2013	Apr	DISC
	@		EQ 300MG BASE	A201762	006	Feb 27, 2013	Apr	DISC
	@		EQ 400MG BASE	A201762	007	Feb 27, 2013	Apr	DISC
AB		MACLEODS PHARMS LTD	EQ 25MG BASE	A203359	001	May 17, 2016	May	NEWA
AB			EQ 50MG BASE	A203359	002	May 17, 2016	May	NEWA
AB			EQ 100MG BASE	A203359	003	May 17, 2016	May	NEWA
AB			EQ 200MG BASE	A203359	004	May 17, 2016	May	NEWA
AB			EQ 300MG BASE	A203359	005	May 17, 2016	May	NEWA
AB			EQ 400MG BASE	A203359	006	May 17, 2016	May	NEWA
AB		UNICHEM LABS LTD	EQ 25MG BASE	A202674	001	Mar 08, 2016	Feb	NEWA
AB			EQ 50MG BASE	A202674	002	Mar 08, 2016	Feb	NEWA
AB			EQ 100MG BASE	A202674	003	Mar 08, 2016	Feb	NEWA
AB			EQ 200MG BASE	A202674	004	Mar 08, 2016	Feb	NEWA
AB			EQ 300MG BASE	A202674	005	Mar 08, 2016	Feb	NEWA
AB			EQ 400MG BASE	A202674	006	Mar 08, 2016	Feb	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

	@	ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005	Jan	DISC
	@		EQ 10MG BASE	A076049	002	Jan 14, 2005	Jan	DISC
	@		EQ 20MG BASE	A076049	003	Jan 14, 2005	Jan	DISC
	@		EQ 40MG BASE	A076049	004	Jan 14, 2005	Jan	DISC

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

	@	AUROLIFE PHARMA LLC	324MG	A089894	001	Dec 15, 1988	Mar	CAHN
BX	+	SUN PHARM INDS	324MG	A089338	001	Feb 11, 1987	Mar	CAHN

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

>D>	@	MUTUAL PHARM	100MG	A081029	001	Apr 14, 1989	Jun	CAHN
>A>	@	SUN PHARM INDS	100MG	A081029	001	Apr 14, 1989	Jun	CAHN
AB			200MG	A081030	001	Apr 14, 1989	Mar	CAHN
AB			300MG	A081031	001	Apr 14, 1989	Mar	CAHN

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN

>D>	AB	+	MUTUAL PHARM CO INC	324MG	N021799	001	Aug 12, 2005	Jun	CAHN
>A>	AB	+	SUN PHARM INDS	324MG	N021799	001	Aug 12, 2005	Jun	CAHN

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

>D>			EISAI INC	5MG	N204736	001	Mar 26, 2013	Jun	CAHN
>D>	+			10MG	N204736	002	Mar 26, 2013	Jun	CAHN
>A>			FSC THERAP	5MG	N204736	001	Mar 26, 2013	Jun	CAHN
>A>	+			10MG	N204736	002	Mar 26, 2013	Jun	CAHN

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

RALOXIFENE HYDROCHLORIDE

AB		AMNEAL PHARMS	60MG	A208206	001	Apr 08, 2016	Mar	NEWA
AB		GLENMARK PHARMS LTD	60MG	A204491	001	Mar 22, 2016	Mar	NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

AP		MYLAN LABS LTD	EQ 25MG BASE/ML	A079076	001	Jun 09, 2016	May	NEWA
AP		ZYDUS PHARMS USA INC	EQ 25MG BASE/ML	A091534	001	Feb 22, 2013	May	CPOT

INJECTABLE; INJECTION

ZANTAC

AP	+	IGI LABS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan CAHN
		ZANTAC IN PLASTIC CONTAINER					
	@	IGI LABS INC	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Jan CAHN
	@		EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Jan CAHN

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA		NOSTRUM LABS INC	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Mar CAHN
	@	WOCKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009	Apr DISC
	@		EQ 15MG BASE/ML	A079212	001	Feb 23, 2009	Apr DISC

RASAGILINE MESYLATE

TABLET; ORAL

RASAGILINE MESYLATE

AB		ORCHID HLTHCARE	EQ 0.5MG BASE	A201970	001	Mar 15, 2016	Feb NEWA
AB			EQ 1MG BASE	A201970	002	Mar 15, 2016	Feb NEWA

RESERPINE

TABLET; ORAL

RESERPINE

	@	HIKMA INTL PHARMS	0.1MG	A080975	001		Feb CAHN
	@		0.25MG	A080975	002		Feb CAHN
	@		1MG	A080975	003		Feb CAHN

RETAPAMULIN

OINTMENT; TOPICAL

ALTABAX

	+	AQUA PHARMS LLC	1%	N022055	001	Apr 12, 2007	Jan CAHN
--	---	-----------------	----	---------	-----	--------------	----------

RIBOFLAVIN 5'-PHOSPHATE SODIUM

SOLUTION/DROPS; OPHTHALMIC

PHOTREXA

	+	AVEDRO INC	0.146%	N203324	001	Apr 15, 2016	Apr NEWA
		PHOTREXA VISCOUS IN DEXTRAN 20%					
>A>	+	AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Jun CMS1
		PHOTREXA VISCOUS IN DEXTROSE 20%					
>D>	+	AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Jun CMS1
	+		0.146%	N203324	002	Apr 15, 2016	Apr NEWA

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

AP		EUROHLTH INTL SARL	600MG/VIAL	A064217	001	Oct 29, 1999	Apr CAHN
AP		HIKMA PHARMS	600MG/VIAL	A205039	001	Mar 03, 2016	Feb NEWA
AP		WATSON PHARMS INC	600MG/VIAL	A206736	001	Jan 19, 2016	Jan NEWA

RILUZOLE

TABLET; ORAL

RILUZOLE

AB		ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	Mar NEWA
----	--	----------------	------	---------	-----	--------------	----------

>D> RIMEXOLONE

SUSPENSION/DROPS; OPHTHALMIC

VEXOL

>D>	+	ALCON	1%	N020474	001	Dec 30, 1994	Jun DISC
>A>	@		1%	N020474	001	Dec 30, 1994	Jun DISC

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB		APIL	5MG	N020835	002	Apr 14, 2000	Jan CAHN
AB			30MG	N020835	001	Mar 27, 1998	Jan CAHN
AB	+		35MG	N020835	003	May 25, 2002	Jan CAHN
	@		75MG	N020835	004	Apr 16, 2007	Jan CAHN
AB	+		150MG	N020835	005	Apr 22, 2008	Jan CAHN

TABLET, DELAYED RELEASE; ORAL

ATELVIA

AB	+	APIL	35MG	N022560	001	Oct 08, 2010	Jan CAHN
----	---	------	------	---------	-----	--------------	----------

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

@ WOCKHARDT

1MG/ML

A078744 001 Oct 08, 2009 Apr DISC

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

RIVASTIGMINE

AB ALVOGEN MALTA

4.6MG/24HR

A204403 001 Sep 03, 2015 Jan CAHN

AB

9.5MG/24HR

A204403 002 Sep 03, 2015 Jan CAHN

AB

13.3MG/24HR

A204403 003 Aug 31, 2015 Jan CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

EXELON

AB + NOVARTIS

EQ 6MG BASE

N020823 006 Apr 21, 2000 Jan CRLD

RIVASTIGMINE TARTRATE

AB AUROBINDO PHARMA LTD

EQ 1.5MG BASE

A204572 001 Mar 25, 2016 Mar NEWA

AB

EQ 3MG BASE

A204572 002 Mar 25, 2016 Mar NEWA

AB

EQ 4.5MG BASE

A204572 003 Mar 25, 2016 Mar NEWA

AB

EQ 6MG BASE

A204572 004 Mar 25, 2016 Mar NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB ALKEM LABS LTD

EQ 5MG BASE

A203269 001 Feb 18, 2016 Feb NEWA

AB

EQ 10MG BASE

A203269 002 Feb 18, 2016 Feb NEWA

AB NOSTRUM LABS INC

EQ 5MG BASE

A202047 001 Dec 31, 2012 Jan CAHN

AB

EQ 10MG BASE

A202047 002 Dec 31, 2012 Jan CAHN

ROPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

ROPIVACAINE HYDROCHLORIDE

AP AKORN INC

5MG/ML

A203955 001 Apr 11, 2016 Mar NEWA

SOLUTION;INJECTION

NAROPIN

@ FRESENIUS KABI USA

50MG/10ML (5MG/ML)

N020533 013 May 01, 1998 May DISC

50MG/10ML (5MG/ML)

N020533 013 May 01, 1998 May NEWA

AP

20MG/10ML (2MG/ML)

N020533 001 May 01, 1998 May CMS1

AP

20MG/10ML (2MG/ML)

N020533 001 Sep 24, 1996 Mar CDFR

AP

40MG/20ML (2MG/ML)

N020533 002 Sep 24, 1996 Mar NEWA

@

75MG/10ML (7.5MG/ML)

N020533 012 Sep 24, 1996 Apr DISC

75MG/10ML (7.5MG/ML)

N020533 012 Sep 24, 1996 Apr NEWA

>D>

100MG/20ML (5MG/ML)

N020533 003 May 01, 1998 Jun CFTG

>A> AP

100MG/20ML (5MG/ML)

N020533 003 May 01, 1998 Jun CFTG

100MG/20ML (5MG/ML)

N020533 003 May 01, 1998 May CMS1

100MG/20ML (5MG/ML)

N020533 003 Sep 24, 1996 Mar CDFR

AP

100MG/10ML (10MG/ML)

N020533 005 Sep 24, 1996 Mar NEWA

AP

150MG/20ML (7.5MG/ML)

N020533 004 Sep 24, 1996 Mar CDFR

AP

150MG/30ML (5MG/ML)

N020533 008 Sep 24, 1996 Mar NEWA

>D>

200MG/100ML (2MG/ML)

N020533 006 Sep 24, 1996 Jun CFTG

>A> AP

200MG/100ML (2MG/ML)

N020533 006 Sep 24, 1996 Jun CFTG

200MG/100ML (2MG/ML)

N020533 006 Sep 24, 1996 Mar NEWA

AP

+

200MG/20ML (10MG/ML)

N020533 011 Sep 24, 1996 Mar NEWA

400MG/200ML (2MG/ML)

N020533 007 Sep 24, 1996 Mar NEWA

500MG/100ML (5MG/ML)

N020533 009 Jan 04, 2011 Apr CMS1

500MG/100ML (5MG/ML)

N020533 009 Sep 24, 1996 Mar NEWA

1GM/200ML (5MG/ML)

N020533 010 Jan 04, 2011 Apr CMS1

1GM/200ML (5MG/ML)

N020533 010 Sep 24, 1996 Mar NEWA

ROPIVACAINE HYDROCHLORIDE

>A> AP

AUROBINDO PHARMA LTD

40MG/20ML (2MG/ML)

A205612 001 Jul 13, 2016 Jun NEWA

>A> AP

100MG/20ML (5MG/ML)

A205612 003 Jul 13, 2016 Jun NEWA

>A> AP

100MG/10ML (10MG/ML)

A205612 006 Jul 13, 2016 Jun NEWA

>A> AP

150MG/30ML (5MG/ML)

A205612 004 Jul 13, 2016 Jun NEWA

>A> AP

150MG/20ML (7.5MG/ML)

A205612 005 Jul 13, 2016 Jun NEWA

>A> AP

200MG/100ML (2MG/ML)

A205612 002 Jul 13, 2016 Jun NEWA

>A> AP

200MG/20ML (10MG/ML)

A205612 007 Jul 13, 2016 Jun NEWA

AP

HOSPIRA

20MG/10ML (2MG/ML)

A090194 001 Sep 23, 2014 Mar CDFR

AP

40MG/20ML (2MG/ML)

A090194 005 Sep 23, 2014 Mar NEWA

AP

100MG/10ML (10MG/ML)

A090194 004 Sep 23, 2014 Mar CDFR

AP

150MG/30ML (5MG/ML)

A090194 002 Sep 23, 2014 Mar CDFR

AP

150MG/20ML (7.5MG/ML)

A090194 003 Sep 23, 2014 Mar CDFR

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

AP		200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	Mar	NEWA
AP	NAVINTA LLC	150MG/30ML (5MG/ML)	A078601	002	Jul 17, 2014	Mar	CDFR
AP		200MG/20ML (10MG/ML)	A078601	003	Jul 17, 2014	Mar	CDFR
AP	SAGENT STRIDES	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014	Mar	CDFR
AP		150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Mar	CDFR
AP		150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014	Mar	CDFR
AP		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Mar	CDFR

ROSUVASTATIN CALCIUM

TABLET; ORAL

CRESTOR

AB	IPR	5MG	N021366	002	Aug 12, 2003	Apr	CFTG
AB		10MG	N021366	003	Aug 12, 2003	Apr	CFTG
AB		20MG	N021366	004	Aug 12, 2003	Apr	CFTG
AB	+	40MG	N021366	005	Aug 12, 2003	Apr	CFTG

ROSUVASTATIN CALCIUM

AB	WATSON LABS INC	5MG	A079167	001	Apr 29, 2016	Apr	NEWA
AB		10MG	A079167	002	Apr 29, 2016	Apr	NEWA
AB		20MG	A079167	003	Apr 29, 2016	Apr	NEWA
AB		40MG	A079167	004	Apr 29, 2016	Apr	NEWA

RUFINAMIDE

TABLET; ORAL

BANZEL

AB	EISAI INC	200MG	N021911	002	Nov 14, 2008	May	CFTG
AB	+	400MG	N021911	003	Nov 14, 2008	May	CFTG

RUFINAMIDE

AB	GLENMARK PHARMS LTD	200MG	A205075	001	May 16, 2016	May	NEWA
AB		400MG	A205075	002	May 16, 2016	May	NEWA
AB	MYLAN PHARMS INC	200MG	A205095	001	May 16, 2016	May	NEWA
AB		400MG	A205095	002	May 16, 2016	May	NEWA
AB	ROXANE	200MG	A204988	001	May 16, 2016	May	NEWA
AB		400MG	A204988	002	May 16, 2016	May	NEWA

SCOPOLAMINEFILM, EXTENDED RELEASE; TRANSDERMAL
TRANSDERM SCOP

AB	+	GLAXOSMITHKLINE CON	1MG/72HR	N017874	001		May	CAHN
----	---	---------------------	----------	---------	-----	--	-----	------

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

@ SUN PHARM INDS EQ 25MG BASE
 @ EQ 50MG BASE
 @ EQ 100MG BASE

A077818	001	Feb 06, 2007	Mar	CAHN
A077818	002	Feb 06, 2007	Mar	CAHN
A077818	003	Feb 06, 2007	Mar	CAHN

SILDENAFIL CITRATE

TABLET; ORAL

SILDENAFIL CITRATE

>A> AB	ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr	DISC
	RUBICON RES PVT LTD	EQ 20MG BASE	A204883	001	Jun 20, 2016	Jun	NEWA
	@ TEVA	EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb	DISC
		EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb	NEWA
	@	EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb	DISC
		EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb	NEWA
	@	EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb	DISC
		EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb	NEWA

SILODOSIN

CAPSULE; ORAL

RAPAFLO

+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Apr	CAHN
		8MG	N022206	002	Oct 08, 2008	Apr	CAHN

SIMVASTATIN

SUSPENSION; ORAL

SIMVASTATIN

+	ROSEMONT PHARMS LTD	20MG/5ML	N206679	001	Apr 21, 2016	Apr	NEWA
		40MG/5ML	N206679	002	Apr 21, 2016	Apr	NEWA

TABLET;ORAL
SIMVASTATIN

@	SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Feb DISC
@		10MG	A076285	002	Dec 20, 2006	Feb DISC
@		20MG	A076285	003	Dec 20, 2006	Feb DISC
@		40MG	A076285	004	Dec 20, 2006	Feb DISC
@		80MG	A076285	005	Jun 23, 2006	Feb DISC

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;IV (INFUSION)
AMMONUL

AP	+	MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Feb CFTG
AP		SODIUM PHENYLACETATE AND SODIUM BENZOATE					
AP		AILEX PHARMS PVT LTD	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Feb NEWA

SODIUM BICARBONATE

INJECTABLE;INJECTION
SODIUM BICARBONATE

		HOSPIRA INC	0.5MEQ/ML	A202981	001	Mar 04, 2016	Feb NEWA
--	--	-------------	-----------	---------	-----	--------------	----------

SODIUM CHLORIDE

INJECTABLE;INJECTION
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		JUBILANT HOLLISTRSTR	9MG/ML	A203352	001	May 18, 2016	May NEWA
----	--	----------------------	--------	---------	-----	--------------	----------

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

AP		KREITCHMAN PET CTR	10-200mCi/ML	A203936	001	May 19, 2016	May NEWA
AP		ZEVACOR PHARMA INC	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb CAHN

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

		JUBILANT DRAXIMAGE	0.009-0.1mCi	N021305	006	May 19, 2005	Mar CMS1
	@		2-200mCi	N021305	004	Nov 18, 2004	Mar CMS1

SODIUM PHENYLBUTYRATE

POWDER;ORAL

BUPHENYL

AB	+	HORIZON PHARMA INC	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Mar CAHN
>A>	AB	SODIUM PHENYLBUTYRATE					
		PAR PHARM	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Jun NEWA
		TABLET;ORAL					
		BUPHENYL					
AB	+	HORIZON PHARMA INC	500MG	N020572	001	May 13, 1996	Mar CAHN
		SODIUM PHENYLBUTYRATE					
AB		PAR PHARM	500MG	A204395	001	Apr 15, 2016	Apr NEWA

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA		BELCHER PHARMS LLC	454GM/BOT	A205727	001	Feb 23, 2016	Feb NEWA
AA		INVATECH PHARMA	454GM/BOT	A206815	001	Feb 18, 2016	Feb NEWA

>A> SOFOBUVIR; VELPATASVIR

>A> TABLET;ORAL

>A> EPCLUSA

>A>	+	GILEAD SCIENCES INC	400MG;100MG	N208341	001	Jun 28, 2016	Jun NEWA
-----	---	---------------------	-------------	---------	-----	--------------	----------

SOTALOL HYDROCHLORIDE

TABLET;ORAL

SOTALOL HYDROCHLORIDE

@	IMPAX PHARMS	80MG	A075663	001	Nov 07, 2000	Mar DISC
@		120MG	A075663	002	Nov 07, 2000	Mar DISC
@		160MG	A075663	003	Nov 07, 2000	Mar DISC
@		240MG	A075663	004	Nov 07, 2000	Mar DISC
@	SUN PHARM INDS	80MG	A075515	001	Oct 15, 2001	Mar CAHN
@		80MG	A076576	001	Apr 08, 2004	Mar CAHN
@		120MG	A075515	004	Oct 15, 2001	Mar CAHN
@		120MG	A076576	002	Apr 08, 2004	Mar CAHN
@		160MG	A075515	002	Oct 15, 2001	Mar CAHN

TABLET; ORAL

SOTALOL HYDROCHLORIDE

@ 160MG
@ 240MG

A076576 003 Apr 08, 2004 Mar CAHN
A075515 003 Oct 15, 2001 Mar CAHN

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

AB SUN PHARM INDS 25MG
AB 50MG
AB 100MG

A089424 001 Jul 23, 1986 Mar CAHN
A089424 002 Aug 11, 1999 Mar CAHN
A089424 003 Aug 11, 1999 Mar CAHN

SUCRALFATE

TABLET; ORAL

SUCRALFATE

AB MYLAN IRELAND LTD 1GM

A074415 001 Jun 08, 1998 Jan CAHN

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS

BRIDION

ORGANON SUB MERCK EQ 200MG BASE/2ML (EQ 100MG
BASE/ML)
+ EQ 500MG BASE/5ML (EQ 100MG
BASE/ML)

N022225 002 Dec 15, 2015 Jan CPOT
N022225 001 Dec 15, 2015 Jan CPOT

SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

@ AUROLIFE PHARMA LLC 500MG

A085844 001 Feb CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

BACTRIM

>D> @ MUTUAL PHARM 200MG/5ML; 40MG/5ML
>A> @ SUN PHARM INDS 200MG/5ML; 40MG/5ML
BACTRIM PEDIATRIC
>D> @ MUTUAL PHARM 200MG/5ML; 40MG/5ML
>A> @ SUN PHARM INDS 200MG/5ML; 40MG/5ML

N017560 001 Jun CAHN
N017560 001 Jun CAHN
N017560 002 Jun CAHN
N017560 002 Jun CAHN

TABLET; ORAL

BACTRIM

AB SUN PHARM INDS 400MG; 80MG
BACTRIM DS
AB + SUN PHARM INDS 800MG; 160MG
SULFAMETHOXAZOLE AND TRIMETHOPRIM
AB SUN PHARM INDS 800MG; 160MG

N017377 001 Mar CAHN
N017377 002 Mar CAHN
A071017 001 Aug 25, 1986 Mar CAHN

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

@ SUN PHARM INDS 500MG

A089590 001 Oct 19, 1987 Mar CAHN

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

@ AUROLIFE PHARMA LLC 500MG

A085628 001 Feb CAHN

SULINDAC

TABLET; ORAL

SULINDAC

AB SUN PHARM INDS 150MG
AB 200MG

A072050 001 Apr 17, 1991 Mar CAHN
A072051 001 Apr 17, 1991 Mar CAHN

SUMATRIPTAN

SPRAY; NASAL

IMITREX

AB + GLAXOSMITHKLINE 5MG/SPRAY
AB + 20MG/SPRAY

N020626 001 Aug 26, 1997 Feb CFTG
N020626 003 Aug 26, 1997 Feb CFTG

SUMATRIPTAN

AB LANNETT 5MG/SPRAY
AB 20MG/SPRAY

A204841 001 Feb 19, 2016 Feb NEWA
A204841 002 Feb 19, 2016 Feb NEWA

SUMATRIPTAN SUCCINATEINJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

>D>	AP	BEDFORD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001	Feb 06, 2009	Jun CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001	Feb 06, 2009	Jun CAHN
		POWDER; INHALATION ONZETRA XSAIL					
	+	AVANIR PHARMS	EQ 11MG BASE	N206099	001	Jan 27, 2016	Jan NEWA
		SOLUTION;SUBCUTANEOUS ZEMBRACE SYMTOUCH					
		DR REDDYS LABS LTD	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jan NEWA

TACROLIMUSOINTMENT;TOPICAL
PROTOPIC

>D>	AB	+	ASTELLAS	0.03%	N050777	001	Dec 08, 2000	Jun CAHN
>D>	AB	+		0.1%	N050777	002	Dec 08, 2000	Jun CAHN
>A>	AB	+	LEO PHARMA AS	0.03%	N050777	001	Dec 08, 2000	Jun CAHN
>A>	AB	+		0.1%	N050777	002	Dec 08, 2000	Jun CAHN

TAMOXIFEN CITRATESOLUTION;ORAL
SOLTAMOX

MIDATECH PHARMA US EQ 10MG BASE/5ML

N021807 001 Oct 29, 2005 Jan CAHN

TABLET;ORAL

TAMOXIFEN CITRATE

@ ACTAVIS LABS FL INC EQ 10MG BASE

A076179 001 Feb 20, 2003 Jan DISC

@ EQ 20MG BASE

A076179 002 Feb 20, 2003 Jan DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION;INTRAVENOUS
ULTRA-TECHNEKOW FM+ MALLINKRODT NUCLEAR 1-19 CI/GENERATOR
@ 0.25-3 CI/GENERATORN017243 003 Feb 18, 2014 Jan CAHN
N017243 002 Jan CAHNTEGASEROD MALEATETABLET;ORAL
ZELNORM

@ US WORLDMEDS LLC EQ 2MG BASE

N021200 001 Jul 24, 2002 Jan CAHN

@ EQ 6MG BASE

N021200 002 Jul 24, 2002 Jan CAHN

TELITHROMYCIN

TABLET;ORAL

KETEK

@ SANOFI AVENTIS US 300MG

N021144 002 Feb 09, 2005 Mar DISC

@ 400MG

N021144 001 Apr 01, 2004 Mar DISC

TELMISARTAN

TABLET;ORAL

TELMISARTAN

AB HETERO LABS LTD V 20MG

A205901 001 Apr 22, 2016 Apr NEWA

AB 40MG

A205901 002 Apr 22, 2016 Apr NEWA

AB 80MG

A205901 003 Apr 22, 2016 Apr NEWA

TEMAZEPAMCAPSULE;ORAL
TEMAZEPAM

AB AMNEAL PHARMS 7.5MG

A203482 001 May 23, 2016 May NEWA

AB 15MG

A203482 002 May 23, 2016 May NEWA

AB 22.5MG

A203482 003 May 23, 2016 May NEWA

AB 30MG

A203482 004 May 23, 2016 May NEWA

AB SUN PHARM INDS 7.5MG

A078581 001 Sep 08, 2009 Mar CAHN

@ 15MG

A071174 001 Jul 10, 1986 Mar CAHN

AB 22.5MG

A071175 002 Sep 14, 2009 Mar CAHN

@ 30MG

A071175 001 Jul 10, 1986 Mar CAHN

TEMOZOLOMIDECAPSULE;ORAL
TEMOZOLOMIDE

AB	IDT AUSTRALIA LTD	5MG	A206413	001	Apr 12, 2016	Mar	NEWA
AB		20MG	A206413	002	Apr 12, 2016	Mar	NEWA
AB		100MG	A206413	003	Apr 12, 2016	Mar	NEWA
AB		140MG	A206413	004	Apr 12, 2016	Mar	NEWA
AB		180MG	A206413	005	Apr 12, 2016	Mar	NEWA
AB		250MG	A206413	006	Apr 12, 2016	Mar	NEWA
AB	KREMERS URBAN PHARMS	5MG	A203898	001	Feb 10, 2016	Jan	NEWA
AB		20MG	A203898	002	Feb 10, 2016	Jan	NEWA
AB		100MG	A203898	003	Feb 10, 2016	Jan	NEWA
AB		140MG	A203898	004	Feb 10, 2016	Jan	NEWA
AB		180MG	A203898	005	Feb 10, 2016	Jan	NEWA
AB		250MG	A203898	006	Feb 10, 2016	Jan	NEWA
AB	LOTUS PHARM CO LTD	5MG	A206309	001	Apr 27, 2016	Apr	NEWA
AB		20MG	A206309	002	Apr 27, 2016	Apr	NEWA
AB		100MG	A206309	003	Apr 27, 2016	Apr	NEWA
AB		140MG	A206309	004	Apr 27, 2016	Apr	NEWA
AB		180MG	A206309	005	Apr 27, 2016	Apr	NEWA
AB		250MG	A206309	006	Apr 27, 2016	Apr	NEWA
>A> AB	MYLAN PHARMS INC	5MG	A205227	001	Jun 29, 2016	Jun	NEWA
>A> AB		20MG	A205227	002	Jun 29, 2016	Jun	NEWA
>A> AB		100MG	A205227	003	Jun 29, 2016	Jun	NEWA
>A> AB		140MG	A205227	004	Jun 29, 2016	Jun	NEWA
>A> AB		180MG	A205227	005	Jun 29, 2016	Jun	NEWA
>A> AB		250MG	A205227	006	Jun 29, 2016	Jun	NEWA

TERBUTALINE SULFATEINJECTABLE;INJECTION
TERBUTALINE SULFATE

>A> AP	+	AMPHASTAR PHARMS INC	1MG/ML	A076770	001	Apr 23, 2004	Jun	CAHN
>D> AP	+	EUROHLTH INTL SARL	1MG/ML	A076770	001	Apr 23, 2004	Jun	CAHN
AP	+		1MG/ML	A076770	001	Apr 23, 2004	Apr	CAHN

TABLET;ORAL

TERBUTALINE SULFATE

@ IMPAX LABS

2.5MG

A075877 001 Jun 26, 2001 Mar DISC

@

5MG

A075877 002 Jun 26, 2001 Mar DISC

LANNETT

2.5MG

A077152 001 Mar 25, 2005 Mar CTEC

5MG

A077152 002 Mar 25, 2005 Mar CTEC

TESTOSTERONEFILM, EXTENDED RELEASE;TRANSDERMAL
ANDRODERM

+ ALLERGAN SALES LLC

2MG/24HR

N020489 003 Oct 20, 2011 Mar CAHN

@

2.5MG/24HR

N020489 001 Sep 29, 1995 Mar CAHN

+

4MG/24HR

N020489 004 Oct 20, 2011 Mar CAHN

@

5MG/24HR

N020489 002 May 02, 1997 Mar CAHN

PELLET;IMPLANTATION

TESTOPEL

+ AUXILIUM PHARMS INC

75MG

A080911 001 Mar CAHN

TABLET, EXTENDED RELEASE;BUCCAL

STRIANT

+ AUXILIUM PHARMS INC

30MG

N021543 001 Jun 19, 2003 Mar CAHN

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

TESTOSTERONE CYPIONATE

>D> AO BEDFORD 100MG/ML

A090387 001 Jul 15, 2010 Jun CAHN

>D> AO 200MG/ML

A090387 002 Jul 15, 2010 Jun CAHN

>A> AO EUROHLTH INTL SARL 100MG/ML

A090387 001 Jul 15, 2010 Jun CAHN

>A> AO 200MG/ML

A090387 002 Jul 15, 2010 Jun CAHN

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

AB HETERO LABS LTD V 12.5MG

A204574 001 Feb 03, 2016 Jan NEWA

AB 25MG

A204574 002 Feb 03, 2016 Jan NEWA

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC
TETRACAINE HYDROCHLORIDE

+ ALCON RES LTD 0.5%

N208135 001 Feb 29, 2016 Feb NEWA

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

TETRACYCLINE HYDROCHLORIDE

AB CHARTWELL CIENCA 250MG

A062752 001 Aug 12, 1988 Apr CMFD

AB 500MG

A062752 002 Aug 12, 1988 Apr CMFD

@ SUN PHARM INDS 250MG

A060736 001 Mar CAHN

@ 500MG

A060736 002 Mar CAHN

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL

THEO-24

+ AUXILIUM PHARMS INC 400MG

A081034 001 Feb 28, 1992 Mar CAHN

SOLUTION, ELIXIR;ORAL

ELIXOPHYLLIN

+ NOSTRUM LABS INC 80MG/15ML

A085186 001 Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

THEOCHRON

AB NOSTRUM LABS INC 100MG

A088320 001 Feb 21, 1985 Jan CAHN

AB 200MG

A088321 001 Feb 21, 1985 Jan CAHN

@ 300MG

A087400 002 Jan 11, 1983 Jan CAHN

THEOPHYLLINE

AB MYLAN IRELAND LTD 400MG

A040560 003 Apr 21, 2006 Jan CAHN

AB + 600MG

A040560 002 Apr 21, 2006 Jan CAHN

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

AB SUN PHARM INDS 10MG

A089953 004 Aug 01, 1986 Mar CAHN

@ 15MG

A088461 001 Nov 18, 1983 Mar CAHN

AB 25MG

A089953 003 Aug 01, 1986 Mar CAHN

AB 50MG

A089953 002 Aug 01, 1986 Mar CAHN

AB 100MG

A089953 001 Oct 07, 1988 Mar CAHN

@ 150MG

A088737 001 Sep 26, 1984 Mar CAHN

@ 200MG

A088738 001 Oct 16, 1984 Mar CAHN

THIOTHIXENE

CAPSULE;ORAL

THIOTHIXENE

@ SANDOZ 1MG

A071610 001 Jun 24, 1987 Mar DISC

@ 2MG

A071570 001 Jun 24, 1987 Mar DISC

@ 5MG

A071529 001 Jun 24, 1987 Mar DISC

@ 10MG

A071530 001 Jun 24, 1987 Mar DISC

TINIDAZOLE

TABLET;ORAL

TINIDAZOLE

BX UNIQUE PHARM LABS 250MG

A202489 001 Oct 09, 2013 Apr CTEC

BX 500MG

A202489 002 Oct 09, 2013 Apr CTEC

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

>A> AP CLARIS EQ 40MG BASE/ML

A206965 001 Jul 01, 2016 Jun NEWA

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL

XELJANZ XR

+ PFIZER INC EQ 11MG BASE

N208246 001 Feb 23, 2016 Feb NEWA

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

@ SUN PHARM INDS 100MG

A071357 001 Jul 16, 1987 Mar CAHN

@ 250MG

A071358 001 Jul 16, 1987 Mar CAHN

@ 500MG

A071359 001 Jul 16, 1987 Mar CAHN

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

@ SUN PHARM INDS

EQ 400MG BASE

A073311 001 Nov 27, 1991 Mar CAHN

TABLET; ORAL

TOLMETIN SODIUM

AB SUN PHARM INDS

EQ 200MG BASE

A073310 001 Nov 27, 1991 Mar CAHN

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

@ ACTAVIS TOTOWA

25MG

A078637 001 Feb 27, 2013 Apr DISC

AB 25MG

A078637 001 Feb 27, 2013 Jan CAHN

@ 50MG

A078637 002 Feb 27, 2013 Apr DISC

AB 50MG

A078637 002 Feb 27, 2013 Jan CAHN

@ 100MG

A078637 003 Feb 27, 2013 Apr DISC

AB 100MG

A078637 003 Feb 27, 2013 Jan CAHN

@ 200MG

A078637 004 Feb 27, 2013 Apr DISC

AB 200MG

A078637 004 Feb 27, 2013 Jan CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB ACI HEALTHCARE LTD 50MG

A202075 001 Nov 28, 2011 Mar CAHN

AB SUN PHARM INDS 50MG

A076100 001 Jun 20, 2002 Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

ULTRAM ER

AB1 + VALEANT PHARMS 100MG

N021692 001 Sep 08, 2005 Mar CAHN

AB1 200MG

N021692 002 Sep 08, 2005 Mar CAHN

AB1 300MG

N021692 003 Sep 08, 2005 Mar CAHN

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP AKORN 100MG/ML

A206634 001 Jun 09, 2016 May NEWA

AP AUROBINDO PHARMA LTD 100MG/ML

A205035 001 Jan 14, 2016 Jan NEWA

AP NORTH CREEK PHARMS 100MG/ML

A202755 001 Feb 25, 2016 Feb NEWA

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 50MG

A072484 001 Apr 30, 1990 Feb CAHN

AB SUN PHARM INDS 50MG

A073137 002 Mar 24, 1993 Mar CAHN

AB 100MG

A073137 001 Mar 24, 1993 Mar CAHN

AB 150MG

A073137 003 Dec 22, 1995 Mar CAHN

TRETINOIN

CREAM; TOPICAL

TRETINOIN

AB ELAN PHARMA INTL LTD 0.025%

A075264 001 Dec 24, 1998 Feb CAHN

AB1 0.05%

A075265 001 Dec 24, 1998 Feb CAHN

AB 0.1%

A075213 001 Dec 24, 1998 Feb CAHN

GEL; TOPICAL

TRETINOIN

AB ELAN PHARMA INTL LTD 0.01%

A075589 001 Jun 11, 2002 Feb CAHN

AB 0.025%

A075529 001 Feb 22, 2000 Feb CAHN

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

>A> AT TELIGENT PHARMA INC 0.025%

A204608 001 Jul 07, 2016 Jun NEWA

>A> AT 0.1%

A204606 001 Jul 07, 2016 Jun NEWA

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT TELIGENT PHARMA INC 0.1%

A205373 001 May 13, 2016 May NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB	SUN PHARM INDS	300MG	A076570	001	Aug 28, 2003	Mar CAHN
----	----------------	-------	---------	-----	--------------	----------

TRIMETHOPRIM

TABLET;ORAL

TRIMETHOPRIM

>D>	@ MUTUAL PHARM	100MG	A070494	001	Jan 22, 1986	Jun CAHN
>A>	@ SUN PHARM INDS	100MG	A070494	001	Jan 22, 1986	Jun CAHN
	@	200MG	A070495	001	Sep 24, 1986	Mar CAHN

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION;ORAL

PRIMSOL

>A>	+	AYTU BIOSCIENCE INC	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jun CAHN
>D>	@	AYTU PHARMS	EQ 25MG BASE/5ML	\$074374	001	Jun 23, 1995	Jun CMS2
>A>	@		EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Jun CMS2
	@		EQ 25MG BASE/5ML	A074374	001	Jun 23, 1995	Jan CAHN
>D>	+		EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jun CAHN
	+		EQ 50MG BASE/5ML	1074973	001	Jan 24, 2000	Jan CAHN

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

TRIMIPRAMINE MALEATE

AB	CROSSMEDIKA SA	EQ 25MG BASE	A208127	001	Apr 15, 2016	Apr NEWA
AB		EQ 50MG BASE	A208127	002	Apr 15, 2016	Apr NEWA
AB		EQ 100MG BASE	A208127	003	Apr 15, 2016	Apr NEWA

TRIPTORELIN PAMOATE

INJECTABLE;INTRAMUSCULAR

TRELSTAR

+	ALLERGAN SALES LLC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Apr CAHN
+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Apr CAHN
+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Apr CAHN

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROSPIUM CHLORIDE

@	SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr DISC
---	------------	------	---------	-----	--------------	----------

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS;OPHTHALMIC

RESCULA

@	R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000	Mar DISC
@	SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000	Mar CAHN

URSODIOL

CAPSULE;ORAL

ACTIGALL

AB	@ ALLERGAN SALES LLC	150MG	N019594	001	Dec 31, 1987	Mar CAHN
AB	+	300MG	N019594	002	Dec 31, 1987	Mar CAHN

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 450MG BASE	A204750	001	Mar 31, 2016	Mar NEWA
AB	HETERO LABS LTD V	EQ 450MG BASE	A205166	001	Mar 18, 2016	Mar NEWA

VALPROATE SODIUM

INJECTABLE;INJECTION

VALPROATE SODIUM

>A>	AP	AMPHASTAR PHARMS INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Jun CAHN
>D>	AP	EUROHLTH INTL SARL	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Jun CAHN
	AP		EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Apr CAHN

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

AB	BIONPHARMA INC	250MG	A073484	001	Jun 29, 1993	Jan CAHN
----	----------------	-------	---------	-----	--------------	----------

SYRUP;ORAL

VALPROIC ACID

AA	NOSTRUM LABS INC	250MG/5ML	A090517	001	May 28, 2010	Mar CAHN
----	------------------	-----------	---------	-----	--------------	----------

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	AMNEAL PHARMS CO	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	May CAHN
AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	May CAHN
AP	AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A205780	001	Mar 31, 2016	Mar NEWA
AP		EQ 1GM BASE/VIAL	A205780	002	Mar 31, 2016	Mar NEWA
AP		EQ 5GM BASE/VIAL	A205779	001	Mar 29, 2016	Mar NEWA
AP		EQ 10GM BASE/VIAL	A205779	002	Mar 29, 2016	Mar NEWA
AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A205694	001	Jan 21, 2016	Jan NEWA
AP		EQ 1GM BASE/VIAL	A205694	002	Jan 21, 2016	Jan NEWA

VANDETANIB

TABLET;ORAL

CAPRELSA

>A>	GENZYME CORP	100MG	N022405	001	Apr 06, 2011	Jun CAHN
>A>	+	300MG	N022405	002	Apr 06, 2011	Jun CAHN
>D>	IPR PHARMS INC	100MG	N022405	001	Apr 06, 2011	Jun CAHN
>D>	+	300MG	N022405	002	Apr 06, 2011	Jun CAHN

VECURONIUM BROMIDE

INJECTABLE;INJECTION

VECURONIUM BROMIDE

AP	EUROHLTH INTL SARL	10MG/VIAL	A075549	001	Jun 13, 2000	Apr CAHN
AP		20MG/VIAL	A075549	002	Jun 13, 2000	Apr CAHN
AP	GLAND PHARMA LTD	10MG/VIAL	A205390	001	May 26, 2016	May NEWA
AP		20MG/VIAL	A205390	002	May 26, 2016	May NEWA
AP	SAGENT PHARMS	10MG/VIAL	A078274	001	Dec 29, 2008	Jan CAHN
AP		20MG/VIAL	A078274	002	Dec 29, 2008	Jan CAHN

VENETOCLAX

TABLET;ORAL

VENCLEXTA

ABBVIE INC

		10MG	N208573	001	Apr 11, 2016	Apr NEWA
		50MG	N208573	002	Apr 11, 2016	Apr NEWA
+		100MG	N208573	003	Apr 11, 2016	Apr NEWA

VERAPAMIL HYDROCHLORIDE

SOLUTION;INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP	EXELA PHARMA SCS LLC	5MG/2ML (2.5MG/ML)	N018925	001	Mar 30, 1984	Apr CMFD
----	----------------------	--------------------	---------	-----	--------------	----------

TABLET;ORAL

VERAPAMIL HYDROCHLORIDE

>D>	@ MUTUAL PHARM	80MG	A071489	002	Jan 13, 1988	Jun CAHN
>D>	@	120MG	A071489	001	Jan 13, 1988	Jun CAHN
>A>	@ SUN PHARM INDS	80MG	A071489	002	Jan 13, 1988	Jun CAHN
>A>	@	120MG	A071489	001	Jan 13, 1988	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

@ PFIZER

		180MG	N019152	002	Dec 15, 1989	Feb DISC
--	--	-------	---------	-----	--------------	----------

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

AP	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Apr CAHN
----	--------------------	-----------------	---------	-----	--------------	----------

VORICONAZOLE

FOR SUSPENSION;ORAL

VORICONAZOLE

AB	AMNEAL PHARMS	200MG/5ML	A205034	001	Apr 13, 2016	Mar NEWA
AB	NOVEL LABS INC	200MG/5ML	A206799	001	May 31, 2016	May NEWA

INJECTABLE;IV (INFUSION)

VORICONAZOLE

AP	ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016	Mar NEWA
	TABLET;ORAL					
	VORICONAZOLE					
AB	AJANTA PHARMA LTD	50MG	A206181	001	May 24, 2016	May NEWA
AB		200MG	A206181	002	May 24, 2016	May NEWA
AB	APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	May NEWA
AB		200MG	A206762	002	May 24, 2016	May NEWA
AB	AUROBINDO PHARMA LTD	50MG	A206837	001	Jan 22, 2016	Jan NEWA
AB		200MG	A206837	002	Jan 22, 2016	Jan NEWA
AB	NOVEL LABS INC	50MG	A207371	001	May 24, 2016	May NEWA
AB		200MG	A207371	002	May 24, 2016	May NEWA
AB	ZYDUS PHARMS USA INC	50MG	A206747	001	May 24, 2016	May NEWA
AB		200MG	A206747	002	May 24, 2016	May NEWA

VORTIOXETINE HYDROBROMIDE

TABLET;ORAL

>D>	BRINTELLIX					
>D>	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Jun CTNA
>D>		EQ 10MG BASE	N204447	002	Sep 30, 2013	Jun CTNA
>D>		EQ 15MG BASE	N204447	003	Sep 30, 2013	Jun CTNA
>D>	+	EQ 20MG BASE	N204447	004	Sep 30, 2013	Jun CTNA
>A>	TRINTELLIX					
>A>	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Jun CTNA
>A>		EQ 10MG BASE	N204447	002	Sep 30, 2013	Jun CTNA
>A>		EQ 15MG BASE	N204447	003	Sep 30, 2013	Jun CTNA
>A>	+	EQ 20MG BASE	N204447	004	Sep 30, 2013	Jun CTNA

XENON XE-133

GAS;INHALATION

XENON XE 133

	LANTHEUS MEDCL	20mCi/VIAL	N017284	002		Feb CTEC
	MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982	Feb CMFD
		20mCi/VIAL	N018327	002	Mar 09, 1982	Feb CMFD

ZOLMITRIPTAN

TABLET;ORAL

ZOLMITRIPTAN

AB	AJANTA PHARMA LTD	2.5MG	A204041	001	May 20, 2016	May NEWA
AB		5MG	A204041	002	May 20, 2016	May NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A207021	001	May 11, 2016	Apr NEWA
AB		5MG	A207021	002	May 11, 2016	Apr NEWA

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

@	SUN PHARM INDS	5MG	A077288	001	Apr 23, 2007	Mar CAHN
@		10MG	A077288	002	Apr 23, 2007	Mar CAHN

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

AB	SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003	Feb CAHN
AB		50MG	N020789	002	Aug 22, 2003	Feb CAHN
AB	+	100MG	N020789	001	Mar 27, 2000	Feb CAHN
	ZONISAMIDE					
AB	BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan CAHN
	@	SUN PHARM INDS	A077635	001	Dec 22, 2005	Mar CAHN
	@	50MG	A077635	002	Dec 22, 2005	Mar CAHN
	@	100MG	A077635	003	Dec 22, 2005	Mar CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

EXCEDRIN (MIGRAINE)

+ GLAXOSMITHKLINE CONS 250MG; 250MG; 65MG	N020802	001	Jan 14, 1998	Feb	CAHN
---	---------	-----	--------------	-----	------

BUDESONIDE

SPRAY, METERED; NASAL

BUDESONIDE

APOTEX INC 0.032MG/SPRAY	A078949	002	Nov 20, 2015	Apr	NEWA
--------------------------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BIONPHARMA INC 5MG	N022429	001	Jul 23, 2009	Jan	CAHN
--------------------	---------	-----	--------------	-----	------

+ 10MG	N022429	004	Jul 23, 2009	Jan	CAHN
--------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BIONPHARMA INC 5MG	N022429	003	Jul 23, 2009	Jan	CAHN
--------------------	---------	-----	--------------	-----	------

+ 10MG	N022429	002	Jul 23, 2009	Jan	CAHN
--------	---------	-----	--------------	-----	------

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@ CYPRESS PHARM 5MG/5ML	A090300	001	Oct 10, 2008	Apr	DISC
-------------------------	---------	-----	--------------	-----	------

NOSTRUM LABS INC 5MG/5ML	A091327	001	Oct 17, 2011	Mar	CAHN
--------------------------	---------	-----	--------------	-----	------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ CYPRESS PHARM 5MG/5ML	A090300	002	Oct 10, 2008	Apr	DISC
-------------------------	---------	-----	--------------	-----	------

NOSTRUM LABS INC 5MG/5ML	A091327	002	Oct 17, 2011	Mar	CAHN
--------------------------	---------	-----	--------------	-----	------

TABLET, CHEWABLE; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

NOVEL LABS INC 5MG	A206793	001	Mar 08, 2016	Feb	NEWA
--------------------	---------	-----	--------------	-----	------

10MG	A206793	002	Mar 08, 2016	Feb	NEWA
------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL

CHLORHEXIDINE GLUCONATE

>D>	BECTON DICKINSON 4%	A072525	001	Oct 24, 1989	Jun	CRLD
-----	---------------------	---------	-----	--------------	-----	------

>A>	+ 4%	A072525	001	Oct 24, 1989	Jun	CRLD
-----	------	---------	-----	--------------	-----	------

>D>	PHARMASEAL SCRUB CARE
-----	-----------------------

>D>	+ CAREFUSION 4%	N019793	001	Dec 02, 1988	Jun	DISC
-----	-----------------	---------	-----	--------------	-----	------

>A>	@ 4%	N019793	001	Dec 02, 1988	Jun	DISC
-----	------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP ONE-STEP

+ BECTON DICKINSON CO 2%; 70% (3ML)	N020832	001	Jul 14, 2000	May	CAHN
-------------------------------------	---------	-----	--------------	-----	------

+ 2%; 70% (10.5ML)	N020832	004	Aug 20, 2003	May	CAHN
--------------------	---------	-----	--------------	-----	------

+ 2%; 70% (26ML)	N020832	006	Nov 21, 2006	May	CAHN
------------------	---------	-----	--------------	-----	------

CHLORAPREP ONE-STEP FREPP

+ BECTON DICKINSON CO 2%; 70% (1.5ML)	N020832	003	Apr 26, 2002	May	CAHN
---------------------------------------	---------	-----	--------------	-----	------

CHLORAPREP WITH TINT

+ BECTON DICKINSON CO 2%; 70% (26ML)	N020832	002	May 03, 2005	May	CAHN
--------------------------------------	---------	-----	--------------	-----	------

+ 2%; 70% (10.5ML)	N020832	005	Apr 03, 2006	May	CAHN
--------------------	---------	-----	--------------	-----	------

+ 2%; 70% (3ML)	N020832	007	Oct 10, 2006	May	CAHN
-----------------	---------	-----	--------------	-----	------

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ BECTON DICKINSON CO 2%; 70% (0.67ML)	N021555	001	Oct 07, 2002	May	CAHN
--	---------	-----	--------------	-----	------

CHLORAPREP SINGLE SWABSTICK

+ BECTON DICKINSON CO 2%; 70% (1.75ML)	N021555	002	May 10, 2005	May	CAHN
--	---------	-----	--------------	-----	------

CHLORAPREP TRIPLE SWABSTICK

+ BECTON DICKINSON CO 2%; 70% (5.25ML)	N021555	003	Jun 10, 2009	May	CAHN
--	---------	-----	--------------	-----	------

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

@ AUROLIFE PHARMA LLC 12MG	A070797	001	Aug 12, 1988	Feb	CAHN
----------------------------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BIONPHARMA INC

25MG;EQ 200MG FREE ACID AND
POTASSIUM SALT

A090397 001 Nov 22, 2010 Jan CAHN

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

AUROBINDO PHARMA LTD

10MG
20MGA206531 001 Apr 26, 2016 Apr NEWA
A206531 002 Apr 26, 2016 Apr NEWAFLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

ROXANE

0.05MG/SPRAY

A207957 001 May 26, 2016 May NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

BIONPHARMA INC

EQ 200MG FREE ACID AND POTASSIUM
SALT

A078682 001 Mar 24, 2009 Jan CAHN

>A>

PURACAP PHARM LLC

EQ 200MG FREE ACID AND POTASSIUM
SALT

A206568 001 Jun 21, 2016 Jun NEWA

MIDOL LIQUID GELS

+ BIONPHARMA INC

200MG

N021472 001 Oct 18, 2002 Jan CAHN

TABLET;ORAL

IBUPROFEN

STRIDES PHARMA

200MG
200MGA079129 001 Mar 28, 2011 May CAHN
A091355 001 Apr 04, 2011 May CAHN

@ SUN PHARM INDS

200MG

A070493 001 Dec 24, 1985 Mar CAHN

@

200MG

A070908 001 Sep 26, 1986 Mar CAHN

@

200MG

A071462 001 Oct 02, 1986 Mar CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

MYLAN PHARMS INC

15MG

A203187 001 Jun 01, 2016 May NEWA

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

>A>

LANSOPRAZOLE

>A>

DEXCEL PHARMA

15MG

N208025 001 Jun 07, 2016 Jun NEWA

LEVONORGESTREL

TABLET;ORAL

HER STYLE

NOVAST LABS LTD

1.5MG

A207976 001 Mar 11, 2016 Feb NEWA

LEVONORGESTREL

GLENMARK PHARMS LTD

1.5MG

A207044 001 Mar 25, 2016 Mar NEWA

+ PERRIGO R AND D

0.75MG

A090740 001 Dec 30, 2010 Apr CRLD

@ WATSON LABS

0.75MG

A078665 001 Aug 28, 2009 Apr DISC

PLAN B

@ TEVA BRANDED PHARM

0.75MG

N021045 002 Aug 24, 2006 Apr DISC

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BIONPHARMA INC

1MG

N021855 001 Aug 04, 2005 Jan CAHN

+

2MG

N021855 002 Aug 04, 2005 Jan CAHN

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MONISTAT 3 COMBINATION PACK

+ MEDTECH PRODUCTS

2%,200MG

N020670 002 Apr 16, 1996 Mar CMS1

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+ BIONPHARMA INC

EQ 200MG BASE

N021920 001 Feb 17, 2006 Mar CAHN

TABLET;ORAL

NAPROXEN SODIUM

AUROBINDO PHARMA LTD

EQ 200MG BASE

A205497 001 Mar 18, 2016 Mar NEWA

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

ACTAVIS LABS NY INC EQ 2MG BASE
EQ 4MG BASEA204794 001 May 10, 2016 Apr NEWA
A204833 001 Feb 26, 2016 Feb NEWAOXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+ ALLERGAN SALES LLC 3.9MG/24HR

N202211 001 Jan 25, 2013 Jan CAHN

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

MISSION PHARMACAL CO 65MG/ML

A206211 001 Mar 24, 2016 Mar NEWA

TABLET;ORAL

THYRO-BLOCK

@ MEDA PHARMS 130MG

N018307 001 May CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

STRIDES PHARMA EQ 75MG BASE

A201745 001 Feb 29, 2012 May CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 06 JUNE 2016

NO JUNE 2016 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551 001	9242986	Dec 08, 2029	DS DP			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	>A> 6028222	Aug 05, 2017	DP		>A> PED	Jan 11, 2017
	>A> 6028222*PED	Feb 05, 2018				
	>A> 6992218	Jun 06, 2021	DP			
	>A> 6992218*PED	Dec 06, 2021				
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	9327028	Jul 21, 2031	U-1839			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9333195	Jul 07, 2020	DP U-1263			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8809305	Dec 23, 2022	U-1078			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	8426586	Oct 10, 2029	DS		I-730	Apr 15, 2019
	RE43431	Jan 22, 2022	DS		ODE	Apr 15, 2023
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	8978966	Jan 13, 2032	DP		NPP	Apr 28, 2019
	9216260	Jun 28, 2031	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	>A> 9365514	Mar 04, 2032	DP		ODE	Dec 11, 2022
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002					M-177	Apr 05, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006					M-177	Apr 05, 2019
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001					NP	May 10, 2019
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	9326945	Feb 24, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	9326945	Feb 24, 2031	DP			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 001 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 002 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 003 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 004 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 005 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 006 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 002 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 003 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 001					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 002					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 003					PC	Nov 28, 2016
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032	U-1731			
	9226892	Sep 29, 2032	U-1732			
	9226892	Sep 29, 2032	U-1733			
>A>	9351984	Dec 19, 2021	DP			
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Apr 27, 2025	DS DP U-155			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001					>A> I-738	Jun 22, 2019
<u>AXITINIB - INLYTA</u>						
N 202324 001	6534524	Apr 29, 2025	DS DP			
<u>AXITINIB - INLYTA</u>						
N 202324 002	6534524	Apr 29, 2025	DS DP			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	9265725	Dec 08, 2027	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	9259428	Jun 13, 2023	U-644			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9169238	Feb 04, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9169238	Feb 04, 2030	DP			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	9192616	Aug 02, 2026	U-1229			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9265831	Jan 28, 2031	DP			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	>A> 9364485	Aug 31, 2030	DP U-1858		NDF	Feb 05, 2019
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	9241918	Mar 16, 2025	DP U-1814			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9216183	Jan 15, 2023	U-1487			
	9226931	Jan 15, 2023	U-1799			
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001	>A> RE43298	Dec 22, 2024	DS DP U-1128			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001	8778999	Sep 03, 2029	DP U-1834		NP	Apr 08, 2019
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9192576	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001					M-178 NPP	Apr 29, 2019 Apr 29, 2019
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9320716	Jun 09, 2020	DP U-1325			
<u>BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE</u>						
N 204442 001					NP	May 26, 2019
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	9259421	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	9248123	Jan 13, 2032	U-1808			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024	U-1220		NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	>A> 6582727	Aug 22, 2020	DP		>A> NP	Jun 17, 2019
	>A> 8207149	Apr 25, 2028	U-1871			
	>A> 8361488	Jul 19, 2028	DP			
	>A> 8426391	Aug 27, 2028	DP U-1872			
	>A> 8778373	Apr 25, 2028	U-1873			
	>A> 8906410	Feb 02, 2027	DP			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					I-733	May 20, 2019
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					I-733	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					I-735	May 20, 2019
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	9295687	Jul 10, 2035	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	>A> 7417042	Jul 20, 2026	DS DP		I-722	Jan 21, 2019
	>A> 8129346	Apr 14, 2025	U-1260		I-723	Jan 21, 2019
<u>CEFIXIME - SUPRAX</u>						
N 202091 001	9233112	Dec 14, 2028	DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001					NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002					NPP	May 27, 2019
					NPP	May 27, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9320740	Mar 14, 2034	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	9309229	Jan 18, 2032	DS DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					NCE	Mar 17, 2020
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					NCE	Mar 17, 2020
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9233068	Dec 11, 2029	DP		NP	Dec 10, 2018
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251 001	8932610	Mar 24, 2030	DP U-1578		NC	Apr 29, 2019
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	9345714	Sep 13, 2022	DP U-1578			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7803788	Feb 02, 2022		U-257		
	9296769	Aug 15, 2032	DS DP U-257			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001					ODE	Nov 10, 2022
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE	Mar 11, 2023
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE	Mar 11, 2023
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001	>A> 9375410	Nov 14, 2023	U-1088			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	9248191	Aug 27, 2024	U-1479			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9233077	Jun 17, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9233077	Jun 17, 2034	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	9233956	May 04, 2029	U-1811		M-170	Nov 20, 2018
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001					D-161	Feb 05, 2019
					D-162	Feb 05, 2019
					I-726	Feb 05, 2019
					I-727	Feb 05, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAKLINZA - DACLATASVIR DIHYDROCHLORIDE</u>						
N 206843 001					D-161 D-162 I-726 I-727	Feb 05, 2019 Feb 05, 2019 Feb 05, 2019 Feb 05, 2019
<u>DAKLINZA - DACLATASVIR DIHYDROCHLORIDE</u>						
N 206843 002					D-161 D-162 I-726 I-727	Feb 05, 2019 Feb 05, 2019 Feb 05, 2019 Feb 05, 2019
<u>DALVANCE - DALBAVANCIN HYDROCHLORIDE</u>						
N 021883 001					D-154	Jan 20, 2019
<u>ACZONE - DAPSONE</u>						
N 207154 001	5863560	Sep 11, 2016	DP		NS	Feb 24, 2019
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
	9161926	Nov 18, 2033	DP			
<u>(COPACKAGED) - VIEKIRA PAK - RITONAVIR; PARITAPREVIR; OMBITASVIR; DASABUVIR SODIUM</u>						
N 206619 001	8492386	Sep 04, 2032	U-1840		D-163	Apr 22, 2019
	8685984	Sep 04, 2032	U-1840			
<u>JADENU - DEFERASIROX</u>						
N 206910 001	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>JADENU - DEFERASIROX</u>						
N 206910 002	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>JADENU - DEFERASIROX</u>						
N 206910 003	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFITELIO - DEFIBROTIDE SODIUM</u>						
N 208114 001					NCE ODE	Mar 30, 2021 Mar 30, 2023
<u>OZURDEX - DEXAMETHASONE</u>						
N 022315 001	9283178	Oct 20, 2020	U-1205			
<u>TOBRADEX ST - DEXAMETHASONE; TOBRAMYCIN</u>						
N 050818 001	8450287	Dec 19, 2027	DP			
<u>DEXILANT - DEXLANSOPRAZOLE</u>						
N 022287 001	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
<u>DEXILANT - DEXLANSOPRAZOLE</u>						
N 022287 002	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
<u>SOLUTAB - DEXLANSOPRAZOLE - DEXILANT</u>						
N 208056 001	6238994	May 17, 2019	DP			
	6238994*PED	Nov 17, 2019				
	6462058	Jun 15, 2020	DS DP	U-950		
	6462058	Jun 15, 2020	DS DP	U-951		
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP	U-950		
	6664276	Jan 30, 2023	DS DP	U-951		
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020		U-950		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9220784	Oct 17, 2027	U-1488			
	>A> 9339551	Oct 17, 2027	U-1488			
	>A> 9339552	Oct 17, 2027	DP U-1488			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9308195	Sep 30, 2033	DP			
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 001				>A> PC		Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 002				>A> PC		Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 003				>A> PC		Dec 04, 2016
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 002	>A> 8129385	Oct 05, 2027	DS DP			
	>A> 9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 003	>A> 8129385	Oct 05, 2027	DS DP			
	>A> 9242986	Dec 08, 2029	DS DP			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	9241946	Apr 05, 2022	U-1063			
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 003					PC	Nov 19, 2016
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 005					PC	Nov 15, 2016
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 007	>A> 6958161	Dec 15, 2022	DP U-918			
	>A> 8715724	Feb 03, 2028	DP			
	>A> 9295652	Oct 23, 2034	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 008	>A> 6958161	Dec 15, 2022	DP U-918			
	>A> 8715724	Feb 03, 2028	DP			
	>A> 9295652	Oct 23, 2034	DP U-918			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9302009	Oct 24, 2030	DP			
<u>ELBASVIR; GRAZOPREVR - ZEPATIER</u>						
N 208261 001	7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
	8871759	May 04, 2031	DS DP U-1813			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	8551957	Oct 19, 2029	DP U-1651		M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	8551957	Oct 19, 2029	DP U-1651		M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	7407955	May 02, 2025	DS DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	7407955	May 02, 2025	DS DP			
	>A> 8673927	May 04, 2027	DP U-1652			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	5814639	Sep 29, 2015	DS DP		NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Aug 09, 2022	DS DP U-257			
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	5814639	Sep 29, 2015	DS DP	Y	NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
	9295657	Mar 13, 2035	U-1830			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9295657	Mar 13, 2035	U-1829			
<u>EPINEPHRINE HYDROCHLORIDE - EPINEPHRINE</u>						
N 205029 001	9283197	Aug 15, 2034	DP U-1828			
	9283197	Aug 15, 2034	DP U-1829			
	9283197	Aug 15, 2034	DP U-1830			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6469182	Jun 16, 2019	U-1096		I-721	Jan 28, 2019
	6469182	Jun 16, 2019	U-1812		ODE	Jan 28, 2023
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001					D-164	May 20, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002					D-164	May 20, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003					D-164	May 20, 2019
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER</u>						
N 205703 001	>A> 6310094	Jan 12, 2021	DP			
	>A> 6310094*PED	Jul 12, 2021				
	>A> 6528540	Jan 12, 2021	DP			
	>A> 6528540*PED	Jul 12, 2021				
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	>A> 6310094	Jan 12, 2021	DP			
	>A> 6310094*PED	Jul 12, 2021				
	>A> 6528540	Jan 12, 2021	DP			
	>A> 6528540*PED	Jul 12, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9220698	Mar 10, 2031	U-1781			
	>A> 9345695	May 31, 2022	DP			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	>A> 9345695	May 31, 2022	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	U-1368		I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022	U-1396			
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	5424286	Dec 01, 2016	U-1108			
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
	8216180	Jan 12, 2028	DP	Y		
	8329648	Aug 18, 2026	U-1313			
	8431685	Apr 13, 2025	DP U-412			
	8439864	Mar 25, 2028	DP	Y		
	8461105	Apr 13, 2025	DP U-412			
	8906851	Aug 18, 2026	U-1313			
	9238076	Apr 15, 2024	DP U-412			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	9314447	May 31, 2033	DP U-1447			
	9314447	May 31, 2033	DP U-1448			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9241935	Jan 25, 2027	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001 >A>	9364656	Sep 30, 2031	U-736			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	8586551	Jul 15, 2023	DS DP			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001 >A>	5808146	Nov 09, 2016	DS		NCE	May 27, 2021
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	9320862	Nov 06, 2024	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	9333310	Oct 02, 2027	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-1841		NP	Apr 25, 2019
	8703806	May 28, 2030	U-1841			
	8808713	May 28, 2030	DP U-1841			
	8815258	Mar 17, 2031	U-1841			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					D-155	Feb 01, 2019
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001 >A>	6774122	Jan 09, 2021	U-596		I-725	Feb 19, 2019
>A>	6774122	Jan 09, 2021	U-1826			
>A>	6774122*PED	Jul 09, 2021				
>A>	7456160	Jan 09, 2021	U-596			
>A>	7456160	Jan 09, 2021	U-1826			
>A>	7456160*PED	Jul 09, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	8329680	Jan 09, 2021	U-596			
	8329680	Jan 09, 2021	U-1826			
	8329680*PED	Jul 09, 2021				
>A>	8466139	Jan 09, 2021	U-596			
>A>	8466139	Jan 09, 2021	U-1826			
>A>	8466139*PED	Jul 09, 2021				
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-731	Apr 27, 2019
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006	5980864	Nov 09, 2021	DS DP U-1119			
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 001					PC	Jul 27, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 002					PC	Apr 25, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 003					PC	Apr 25, 2016
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Jul 28, 2018	DS DP U-1378			
	9254278	Mar 09, 2032	U-1816			
	9326966	Mar 09, 2032	U-1816			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	6582678	Apr 24, 2018	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	6582678	Apr 24, 2018	DP			
	6878721	Feb 25, 2025	DS DP U-1773			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001					NP	Nov 06, 2018
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9289391	Oct 30, 2021	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9296753	Oct 30, 2033	DS DP		D-165 I-729 I-736 I-737 ODE ODE	May 06, 2019 Mar 04, 2019 May 06, 2019 May 06, 2019 Mar 04, 2023 May 06, 2023
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9295639	Sep 30, 2029	U-1756			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001					NCE	Jul 26, 2017
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003					M-180	May 26, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007					M-180	May 26, 2019
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 001					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 002					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	7544799	Jul 16, 2018	DS DP		Y	
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	7544799	Jul 16, 2018	DS DP		Y	
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168			
<u>INGENOL MEBUTATE - PICATO</u>						
N 020833 001	7410656	Oct 10, 2020	U-1222			
<u>INGENOL MEBUTATE - PICATO</u>						
N 020833 002	7410656	Oct 10, 2020	U-1222			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	9265893	Sep 23, 2032	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	9265893	Sep 23, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	9265893	Sep 23, 2032	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
>A>	9345750	May 18, 2031	DP U-1855			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780 004	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
>A>	9358352	Feb 15, 2031	DP U-1861			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
>A>	9358352	Feb 15, 2031	DP U-1861			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
>A>	9358352	Feb 15, 2031	DP U-1861			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	9339497	Jun 12, 2033	U-1848		ODE	Oct 22, 2022
>A>	9364473	Jun 12, 2033	U-1856			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	9216969	Nov 08, 2026	DS DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	9216167	May 28, 2024	U-1800			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001	9278101	Jul 30, 2023	U-1518			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001	>A> 9339504	Jul 02, 2028	DP U-1596			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002 >A>	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003 >A>	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004 >A>	9339504	Jul 02, 2028	DP U-1596			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	9284342	Sep 13, 2030	DS DP U-1470		D-158 D-159 D-160	Feb 12, 2019 Feb 12, 2019 Feb 12, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001					I-734	May 13, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002					I-734	May 13, 2019
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029	U-1801			
	8283369	Nov 26, 2028	U-1802			
	8283369	Nov 26, 2028	U-1804			
	8357713	Nov 26, 2028	DP U-1801			
	8357713	Nov 26, 2028	DP U-1802			
	8357713	Nov 26, 2028	DP U-1803			
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029	U-1803			
	9216179	Aug 02, 2030	U-1806			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9283282	Oct 28, 2018	DS DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002 >A>	9339489	Mar 14, 2034	DP U-1850			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003 >A>	9339489	Mar 14, 2034	DP U-1850			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004 >A>	9339489	Mar 14, 2034	DP U-1850			
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001 >A>	9358338	Apr 27, 2035	U-1870			
	>A> 9370622	Sep 28, 2035	U-1870			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	7407955	May 02, 2025	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	>A> 6303661	Apr 24, 2017	U-802			
	>A> 6340475	Sep 19, 2016	DP U-1852			
	>A> 6488962	Jun 20, 2020	DP			
	>A> 6635280	Sep 19, 2016	DP			
	>A> 6890898	Feb 02, 2019	U-803			
	>A> 7078381	Feb 02, 2019	U-803			
	>A> 7407955	May 02, 2025	DS DP			
	>A> 7459428	Feb 02, 2019	U-803			
	>A> 8119648	Aug 12, 2023	U-802			
	>A> 8178541	Aug 12, 2023	DP U-1853			
	>A> 8673927	May 04, 2027	U-1503			
	>A> 8846695	Jun 04, 2030	U-1503			
	>A> 8883805	Nov 26, 2025	DP			
	>A> 9155705	May 21, 2030	DP			
	>A> 9173859	May 04, 2027	DP U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	>A> 6303661	Apr 24, 2017	U-802			
	>A> 6340475	Sep 19, 2016	DP U-1852			
	>A> 6488962	Jun 20, 2020	DP			
	>A> 6635280	Sep 19, 2016	DP			
	>A> 6890898	Feb 02, 2019	U-803			
	>A> 7078381	Feb 02, 2019	U-803			
	>A> 7407955	May 02, 2025	DS DP			
	>A> 7459428	Feb 02, 2019	U-803			
	>A> 8119648	Aug 12, 2023	U-802			
	>A> 8178541	Aug 12, 2023	DP U-1853			
	>A> 8673927	May 04, 2027	U-1503			
	>A> 8846695	Jun 04, 2030	U-1503			
	>A> 8883805	Nov 26, 2025	DP			
	>A> 9155705	May 21, 2030	DP			
	>A> 9173859	May 04, 2027	DP U-1503			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9265893	Sep 23, 2032	DP		M-176	Apr 22, 2019
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	>A> 9364470	Mar 07, 2025	U-1851			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	>A> 9364470	Mar 07, 2025	U-1851			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	>A> 9364470	Mar 07, 2025	U-1851			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
	>A> 9364470	Mar 07, 2025	U-1851			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
>A>	9364470	Mar 07, 2025	U-1851			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
>A>	9364470	Mar 07, 2025	U-1851			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001 >A>	9370629	May 20, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jul 05, 2017	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9259423	May 23, 2031	U-1822			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	9265762	May 29, 2027	DP U-1820			
<u>MEGESTROL ACETATE - MEGESTROL ACETATE</u>						
A 203139 001					PC	Jan 24, 2016
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	8410077	Mar 13, 2029	DP		ODE	Mar 10, 2023
	9200088	Mar 13, 2029	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	9233184	Aug 01, 2027	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	9233184	Aug 01, 2027	DP			
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 001					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 002					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	9320714	Feb 03, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	9339472	Oct 14, 2025	DP		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1097			
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	7326708	Nov 24, 2026	DS DP U-1227			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP			
	8945063	Mar 19, 2030	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP			
	8945063	Mar 19, 2030	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP			
	8945063	Mar 19, 2030	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					ODE	Apr 08, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9278105	May 12, 2031	U-282			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023	U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023	U-1527			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 001	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 002	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 003	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 004	7955619	Aug 12, 2028	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9238108	Jan 22, 2027	DP			
	9278182	Feb 01, 2026	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON</u>						
N 206302 001	>A> 7803838	Aug 29, 2026	DP		>A> NC	Jun 03, 2019
	>A> 7838552	Oct 04, 2027	U-185			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	>A> 9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	>A> 9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	>A> 9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	>A> 9364564	Dec 26, 2027	DP			
<u>NITISINONE - ORFADIN</u>						
N 206356 001	9301932	Feb 02, 2033	DP U-1836			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
<u>NITROGLYCERIN - GONITRO</u>						
N 208424 001	>A> 9101592	Mar 11, 2032	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	>A> 7138390	Nov 16, 2022	DS DP		>A> NCE	May 27, 2021
	>A> 8058267	Feb 21, 2022	U-1854		>A> ODE	May 27, 2023
	>A> 8377916	Feb 21, 2022	U-1854			
	>A> 9238673	Jun 17, 2033	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	>A> 7138390	Nov 16, 2022	DS DP		>A> NCE	May 27, 2021
	>A> 8058267	Feb 21, 2022	U-1854		>A> ODE	May 27, 2023
	>A> 8377916	Feb 21, 2022	U-1854			
	>A> 9238673	Jun 17, 2033	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001					M-173	Mar 18, 2019
<u>OMEGA-3-ACID ETHYL ESTERS TYPE A - OMTRYG</u>						
N 204977 001					NCE	Apr 23, 2019
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2017	DP		NCE	May 05, 2019
	5948818	May 13, 2017	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 001	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
	6428810	Nov 03, 2019	DP U-1817			
<u>OMEPRazole MAGNESIUM - PRILOSEC</u>						
N 022056 002	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 15, 2016	U-588			
	6489346	Jul 15, 2016	DP U-588		Y	
	6645988	Jul 15, 2016	DP		Y	
	6699885	Jul 15, 2016	U-588		Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-588			
	RE45198	Jul 15, 2016	U-588			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 15, 2016	U-623			
	5840737	Jul 15, 2016	U-624			
	6489346	Jul 15, 2016	DP U-623		Y	
	6489346	Jul 15, 2016	DP U-624		Y	
	6645988	Jul 15, 2016	DP		Y	
	6699885	Jul 15, 2016	U-623		Y	
	6699885	Jul 15, 2016	U-624		Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
	RE45198	Jul 15, 2016	U-623			
	RE45198	Jul 15, 2016	U-624			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	7399772	Jul 15, 2016	U-588			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 002	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001					ODE	Nov 13, 2022
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002					ODE	Nov 13, 2022
<u>OSPemIFENE - OSPHENA</u>						
N 203505 001	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	9351975	Apr 13, 2027	DP			
>A>	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	9351975	Apr 13, 2027	DP			
>A>	9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	9351975	Apr 13, 2027	DP			
>A>	9370525	Apr 13, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	9259388	Nov 06, 2029	U-1644			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001					NP	Apr 26, 2019
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002					NP	Apr 26, 2019
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003					NP	Apr 26, 2019
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004					NP	Apr 26, 2019
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005					NP	Apr 26, 2019
<u>OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE</u>						
N 208032 001					>A> NC	Jun 29, 2019
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 001	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 002	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 003	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 004	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	7598271	May 04, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
	8772497	May 16, 2026	DS			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001					NPP	Mar 18, 2019
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	6756393	Mar 06, 2021	DS DP		NCE	Apr 29, 2021
	6815458	Mar 06, 2021	DS DP U-1843			
	7115634	Oct 06, 2021	DS DP			
	7601740	Jun 17, 2027	DS DP			
	7659285	Aug 24, 2026	U-1844			
	7732615	Jun 03, 2028	DS DP			
	7858789	Dec 13, 2020	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8110574	Dec 13, 2020	DS DP			
	8618130	Jan 15, 2024	U-1845			
	8921393	Jan 15, 2024	U-1846			
	9296694	Mar 06, 2021	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	>A> 9358297	Jun 24, 2031	DP U-1454			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 004					PC	May 18, 2016
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 006					>A> PC	Jan 01, 2017
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	5288726	Apr 14, 2017	DS DP U-991			
	5288726*PED	Oct 14, 2017				
	8404703	Jan 02, 2023	U-1381			
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	5288726	Apr 14, 2017	DS DP U-991			
	5288726*PED	Oct 14, 2017				
	8404703	Jan 02, 2023	U-1381			
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023	U-1381			
	8569325*PED	Jul 02, 2023				
<u>PROPOFOL - PROPOFOL</u>						
A 205307 001					PC	Feb 24, 2016
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	9289446	Jun 22, 2019	DP U-116			
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324 001					>A> NP ODE	Apr 15, 2019 Apr 15, 2023
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%</u>						
N 203324 002					>A> NP ODE	Apr 15, 2019 Apr 15, 2023

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	9271968	Feb 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	9271968	Feb 27, 2026	DP			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6858618	Dec 17, 2021	U-618		I-732	May 27, 2019
	6858618	Dec 17, 2021	U-1032		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005					ODE	May 27, 2023
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	9216178	Nov 01, 2032	DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	9095509	Dec 06, 2030	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	9095509	Dec 06, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001 >A>	9353103	Jul 28, 2026	U-1467		M-171 M-179	Feb 26, 2019 May 20, 2019
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	7326708	Nov 24, 2026	DS DP U-802			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001					>A> NCE	Jun 28, 2021
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001					I-728	Mar 31, 2019
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	9272137	Sep 07, 2027	DP			
	9327114	Oct 08, 2032	DP U-1328			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	6715485	Mar 03, 2020	DP			
	7975690	Aug 18, 2025	DP U-1809			
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023	U-1809			
	8550073	Oct 22, 2029	DP			
	8555877	Mar 03, 2020	DP			
	8590530	Sep 15, 2025	DP U-1809			
	8875704	Apr 07, 2028	DP U-1809			
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9108015	Sep 15, 2025	DP			
	9119932	Apr 23, 2024	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	5886035	Dec 18, 2022	DS DP U-778			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	9289586	Feb 26, 2027	U-1390			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9295675	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9295675	Feb 11, 2034	DP U-1531			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171			
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	>A> 7250419	Dec 02, 2019	DS DP U-1171			
	>A> 7250419	Dec 02, 2019	DS DP U-1860			
	>A> 7250419	Dec 02, 2019	DS DP U-1864			
	>A> 7250419	Dec 02, 2019	DS DP U-1865			
	>A> 7250419	Dec 02, 2019	DS DP U-1866			
	>A> 7250419	Dec 02, 2019	DS DP U-1867			
	>A> 7265124	Jul 09, 2021	DS DP U-1171			
	>A> 7265124	Jul 09, 2021	DS DP U-1860			
	>A> 7265124	Jul 09, 2021	DS DP U-1868			
	>A> 7265124	Jul 09, 2021	DS DP U-1869			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	>A> 6525060	Dec 02, 2019	DS DP U-1171			
	>A> 6525060	Dec 02, 2019	DS DP U-1683			
	>A> 6525060	Dec 02, 2019	DS DP U-1860			
	>A> 6525060	Dec 02, 2019	DS DP U-1862			
	>A> 7250419	Dec 02, 2019	DS DP U-1171			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	>A> 7250419	Dec 02, 2019	DS DP U-1860			
	>A> 7250419	Dec 02, 2019	DS DP U-1864			
	>A> 7250419	Dec 02, 2019	DS DP U-1865			
	>A> 7250419	Dec 02, 2019	DS DP U-1866			
	>A> 7250419	Dec 02, 2019	DS DP U-1867			
	>A> 7265124	Jul 09, 2021	DS DP U-1171			
	>A> 7265124	Jul 09, 2021	DS DP U-1860			
	>A> 7265124	Jul 09, 2021	DS DP U-1868			
	>A> 7265124	Jul 09, 2021	DS DP U-1869			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9254328	Mar 13, 2026	DP			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	6770660	Jun 01, 2023	U-1444			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	6956027	Mar 25, 2023	DS		NCE	Nov 06, 2017
	6956041	Dec 08, 2020	DP			
	7091208	Dec 08, 2020	U-247			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	9283233	Apr 13, 2030	U-1821			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	9333310	Oct 02, 2027	DP		M-172	Feb 24, 2019
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	9333310	Oct 02, 2027	DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001					ODE	Dec 11, 2022
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001 >A>	RE42353	Jun 27, 2022	DS DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002 >A>	RE42353	Jun 27, 2022	DS DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001 >A>	9375478	Jan 30, 2035	U-1857			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	8546399	Jun 27, 2031	DS DP		NCE	Apr 11, 2021
	9174982	May 26, 2030	U-1835		ODE	Apr 11, 2023
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9278961	Dec 15, 2028	U-1825			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9227946	Jun 15, 2027	U-1668			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 001					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 002					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	May 13, 2030	U-674			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196 001	8236285	Aug 07, 2032	DS DP U-70			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>